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Eukaryotic cells employ multiple posttranscriptional mechanisms to fine tune gene 
expression programs in response to external signals.  Regulation of messenger RNA and 
microRNA by RNA-binding proteins is critical to the control of this process.  Hence, 
disruptions of RNA regulatory processes result in neurologic diseases, cancer, and 
immunologic disorders among other complications.  Posttranscriptional control of RNA 
is particularly important for precise cytokine expression in T cells during adaptive 
immune responses.   
We have studied human lymphocyte activation as a model for correlating changes in 
RNA regulation with dynamic cellular state changes and stress responses.  We 
hypothesize that RNA-binding proteins such as Argonaute (Ago) and HuR play critical 
roles in shaping the dynamic immune response in T cells.  We have previously 
demonstrated the ability to map Ago-microRNA binding sites using high-throughput 
sequencing of RNA isolated by cross-linking immunoprecipitation (HITS-CLIP) 
{Chi:2009ht}.  Here we used HITS-CLIP to define genome-wide maps of both Ago and 
HuR RNA binding sites in freshly isolated primary human T cells in the resting state and 
after one hour of stimulation with anti-CD3 and anti-CD28 antibodies.  We also applied 
RNA sequencing and ribosomal profiling to these lymphocytes to establish their 
transcriptional and translational status.   
We observed different patterns of both Ago and HuR binding from HITS-CLIP in resting 
and activated T cells.  Comparing the Ago and HuR HITS-CLIP genome-wide maps 
suggests agonistic and antagonistic actions of these two proteins to confer microRNA-
mediated regulation of mRNA translation.  Furthermore, we overlaid these dynamic RNA 
binding-protein maps with ribosomal profiles of the target transcripts to investigate 
translational output as it relates to Ago and HuR regulation.  By comparing the changes 
in both RNA-binding maps with ribosomal profiling results from lymphocytes before and 
after one hour of T cell activation, we developed a combinatorial dynamic map for these 
two RNA-binding proteins.  Additionally, examining the function of Ago in T cells 
deficient in HuR helped us understand the relationship between these regulatory proteins 
in determining the resting and activated lymphocyte states.  Our results suggest that 
differences in protein-RNA interactions for Ago and HuR occur quickly after T cell 
activation and provide important insight into the specificity of how microRNA 
translational regulation mediates the immune response.  
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CHAPTER 1.  Introduction 
The adaptation to environmental signals is an essential component of cellular life.  In 
multicellular organisms, these pathways have evolved to include responses to both 
external stimuli and internal signals.  For example, in the immune system, lymphocytes 
need to modify their states quickly to respond to the presence of potentially harmful 
antigen, such as during the recognition of virally infected or malignant cells, and then 
back to quiescence so as not to damage normal tissue. 
The Inflammatory and Adaptive Immune Response 
The spread of a pathogen is first combatted by the inflammatory response of the innate 
immune system.  Macrophages and dendritic cells survey the host for antigen, such as in 
sites of infection and inflammation, and are triggered to ingest bacteria and infected cells 
due to their recognition of molecules shared by pathogens and distinguishable from the 
host.  These molecules also trigger the cells to become activated and secrete cytokines, 
including tumor necrosis factor (TNF), and chemokines to initiate inflammation 
(Janeway and Medzhitov 2002).  Clinically, inflammation is characterized by heat, 
redness, and swelling, which are caused by the cytokine induced increase in blood flow 
and leakage of fluid from the bloodstream into the site, and pain, due to the infiltration of 
white blood cells.  The inflammatory neutrophil and macrophage populations help to 
increase the flow of lymph to bring together antigen-presenting cells (APCs) with 
lymphocytes to activate the adaptive immune response (Barton 2008; Nathan 2002).   
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Among other inflammatory signals, local cells such as fibroblasts are stimulated by TNF 
to produce a wide array of cytokines and chemokines that help to propagate the 
inflammatory response and recruit white blood cells into the injured tissue. While only 
short exposure to TNF is necessary for the initiation of the NF-κB transcriptional 
program, which can account for much of the early response, a sustained stimulus can lead 
to the induction of three temporal classes of responses: transcripts that initiate expression 
within a half-hour and are quickly diminished, transcripts that accumulate over the first 
two hours and then are sustained, and transcripts that increase more gradually.  These 
responses are highly regulated temporally to ensure the proper initiation of the 
inflammatory cascade.  While the induction of these signals is transcriptionally controlled, 
the fate and regulation of the transcripts is defined largely post-transcriptionally (Bradley 
2008; Hao and Baltimore 2009; Hoffmann 2002; Tian 2005). 
When a dendritic cell ingests a pathogen, it becomes activated to mature into an APC that 
is able to stimulate pathogen-specific lymphocytes in the lymph node.  These activated 
APCs secrete cytokines that help to shape both the innate and adaptive immune responses.  
Lymphocytes circulate in the host’s bloodstream in a fairly quiescent state until they 
encounter antigen and co-stimulatory molecules in the context of an APC.  Such an 
encounter triggers proliferation and differentiation of lymphocytes into primed effector 
cells that can reject the infectious agent. These initiating interactions of the adaptive 
immune response occur in the peripheral lymphoid organs such as the lymph nodes, 
spleen and mucosal lymphoid tissues (Banchereau and Steinman 1998).   
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While antibodies can recognize pathogens circulating in the blood and in extracellular 
spaces, the cytotoxic T lymphocytes of the adaptive immune system are needed to 
identify intracellular bacterial pathogens, parasites, viruses, and tumor antigens.  Foreign 
proteins and tumor antigens are processed and presented as peptide fragments on major 
histocompatibility complex (MHC) molecules to T cells, which can kill the offensive 
cells.  MHC I molecules generally capture and present peptides from the cytosol of the 
cell.  MHC II molecules present exogenous peptide to cluster of differentiation four 
(CD4) T cells that can function as “helper” cells to orchestrate T cell responses, antibody 
responses, or to down regulate adaptive immune responses as suppressor cells.  During 
lymphocyte maturation each T cell develops a unique antigen receptor, or T cell Receptor 
(TCR), which recognizes a specific antigenic peptide held by an MHC molecule.  Thus 
the genotype of the MHC restricts the antigen specificity of the T cell.  Lymphocytes are 
selected during differentiation for deletion or tolerance of lymphocytes expressing TCRs 
specific for self-antigen (Rock and Goldberg 1999).   
Cytotoxic T cells typically express the cluster of differentiation eight (CD8) co-receptor 
on their surfaces which binds MHC class I.  The TCR and CD8 molecules can bind to the 
same MHC complex simultaneously, which greatly enhances the resulting activation 
signal (J.-H. Wang and Reinherz 2002).  Other co-stimulatory interactions may also be 
necessary to stimulate a productive immune response such as with the B7 proteins, which 
stimulate T cells via the cluster of differentiation twenty-eight (CD28) molecule (Jenkins 
et al. 1991).  Upon engagement of cognate peptide-MHC complexes, the Src family 
kinases LCK and FYN are recruited to the TCR and phosphorylate tyrosine substrates in 
the cytoplasmic tails of the receptor’s subunits in immunoreceptor tyrosine-based 
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activation motifs (ITAMs).  These phosphorylated receptor molecules recruit and then 
activate a second tyrosine kinase, ZAP-70.  The FYN adaptor protein also associates with 
FYB, also called SLAP or ADAP, which aids in the proliferative response and cytokine 
production by helping to stabilize the interaction of the TCR with APCs through integrin 
clustering and adhesion (Griffiths et al. 2001; Peterson et al. 2001).   
Activation of ZAP-70 in turn leads to the phosphorylation of adaptor proteins LAT and 
SLP-76 that recruit other proteins that stimulate the Ras pathway, the mobilization of 
calcium, and the reorganization of the cytoskeleton of the T cell.  One protein that is 
recruited to the membrane is phospholipase Cγ1 (PLCG1) which hydrolyzes 
phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol 1,4,5-trisphosphate (IP3) and 
diacylglycerol (DAG).  IP3 interrogates receptors on the endoplasmic reticulum to release 
Ca2+ into the cytoplasm, triggering a cascade of calcium dependent signaling leading to 
the activation of NFAT and its regulated transcriptional control of interleukin-2 (IL-2) 
and other cytokines (Weiss and Littman 1994).  DAG in turn activates numerous protein 
targets including protein kinase C (PKC) family members and Ras guanyl-nucleotide-
releasing protein (RasGRP).  These help to activate Ras signaling which eventually leads 
to the activation of mitogen-activated protein (MAP) kinases.  This results in the 
phosphorylation and activation the transcription factor AP-1, which induces both FOS 
and JUN transcription among others changes.  PKCs also are involved in activating the 
NFκB transcription factor which contributes to the induction of pro-inflammatory 
cytokines (Cantrell 2002; Jordan, Singer, and Koretzky 2003; Weiss and Littman 1994).   
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The addition of co-stimulatory CD28 signaling to CD3 stimulation leads to higher 
expression and stabilization key inflammatory molecules such as IL-2, interferon gamma 
(IFNG), TNF, and granulocyte-macrophage colony stimulating factor (GM-CSF) 
(Lindstein et al. 1989; Thompson et al. 1989).  Although it has also been reported that the 
primary differential effect of CD28 engagement may be related to an increase in NFAT 
signaling in the lymphocyte (Diehn et al. 2002).  CD28 binding, in addition to TCR 
binding, stimulates transcription of the EGR family, Nuclear Receptor Subfamily, and 
CD69 (Kaye 2000; Shao et al. 1997).  The interaction between a T cell and peptide-MHC 
complex can be mimicked in culture by interrogation of the TCR complex via anti-CD3 
antibodies and co-stimulation with anti-CD28 antibodies.  By using beads coated with 
both of these antibodies (CD3/CD28 beads), the signals are distributed on a surface 
comparable to the size of an APC and the lymphocyte can encounter both signals 
simultaneously.   
Interferon gamma (IFNG) production after T cell stimulation can directly inhibit viral 
replication and also help kill intracellular pathogens by initiating starvation programs in 
their host cells.  Additionally, IFNG signals for the increased production and expression 
of major histocompatibility complex I (MHC I) and other components of antigen 
processing machinery to increase the presentation of viral components to the immune 
system for potential recognition and attack.  IFNG synergizes with TNF to activate and 
recruit macrophages to the site of infection or injury to aid in the clearance and killing of 
infected material, and in antigen presentation (Boehm et al. 1997; Rock and Goldberg 
1999).  IFNG mediates its antiviral and immune modulatory effects through Janus 
Tyrosine Kinase (JAK) signaling.  Homodimers of IFNG bind to two interferon gamma 
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receptor (IFNGR) 1 molecules that have intracellular domains associated with JAK1.  
Binding of IFNG leads to the joining of each IFNGR1 subunit with one of IFNGR2 that 
is associated with JAK2.  This brings together the active IFNG receptor complex made 
up of two of each receptor and two of each JAK.  The JAK1 and JAK2 molecules are 
auto- and trans-phosphorylated creating a docking site for signal transducers and 
activators of transcription (STAT) 1.  A homodimer of STAT1 forms after 
phosphotyrosine activation by the JAKs.  This STAT1 homodimer translocates to the 
nuclease and binds to gamma-activated sequence (GAS) elements to induce transcription 
(Horvath 2000; Levy and Darnell 2002; Shuai and Liu 2003; Stark and Darnell 2012; 
Stark et al. 1998). 
With the initiation of an inflammatory and adaptive immune response, it is clear that a 
variety of signaling pathways lead to a vast induction of transcription.  While these 
transcriptional changes help to characterize the inflammatory response, they do not 
complete the regulatory picture.  When lymphocytes encounter antigen, they are required 
to respond very quickly.  Thus, it is logical that T cells not rely solely on transcriptional 
changes to alter protein expression.  RNA-binding proteins can help to regulate 
translation by affecting mRNA stability, localization, inclusion in stress granules, and 
access to ribosomes, among other processes.  RNA-binding proteins in T cells regulate 
rapid changes in the production of cytokines, among other proteins.  The induction of 
cytokine production needs immediate control to ensure the production of an effective 
immune response to antigen, but also a transient response to protect surrounding healthy 
cells from destruction.  RNA-binding proteins can ensure this by helping to induce 
translation, or targeting transcripts for degradation or translational repression (Anderson 
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2008).  To better understand lymphocyte responses, and as a surrogate system for 
examining the dynamic control of mRNA, we have undertaken to study the post-
transcriptional regulation of T cell activation.   
Lymphocytes as a Model System for Studying Basic Cellular Function, Immune 
Responses, and Disease 
The elaborate transcriptional and translational regulation of T cell activation, and the 
connection of these processes with the general mechanisms of the integrated stress 
response make T cells a perfect system for the study of the dynamic control of RNA 
regulation.  Working with T cells, we can study a purified cell population rather than a 
tissue made up of many cellular components without significant manipulation, as 
compared to the dissociation of a tissue.  Furthermore, we can work with normal human 
cells without the requirement for invasive procedures or post-mortem collection of tissue.  
Although CD8 T cells can have varied responses such as cytotoxic responses, immune 
tolerance, and anergy, they are more uniform than CD4 lymphocytes phenotypes that 
have various transcriptional profiles and cytokine secretion depending on their committed 
lineage. 
In this work, we studied the regulation of CD8 lymphocytes directly ex vivo from normal 
human donors.  Therefore, they represent true biologic samples and do not have the 
biases of cells that have been transformed or otherwise propagated in culture systems.  
Also, each donor sample represents a true replicate.  While the donors were all normal 
adults, they represent different genetic background and ages which gives much more 
biologic complexity than multiple plates of cell lines or even genetically identical mice.  
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Thus, processes and events that we find consistent between donor samples are more 
likely to represent general mechanisms of control.  Also, by pairing these studies with the 
mouse system we can take advantage of genetic models and utilize the power of 
conservation to rapidly dissect findings from the human system. 
The in vitro activation and manipulation of lymphocytes can mimic in vivo biologic 
interactions of T cells with APCs.  Here we focused on broad T cell activation by 
CD3/CD28 stimulation to maximize our response and best recapitulate a general stress 
response, but this could also be done in an antigen-specific manner to study even more 
specific cell populations and responses.  Because lymphocyte activation is important for 
the control of many disease states including inflammation, infection, tumor biology, and 
autoimmunity, we think that studying lymphocyte stimulation is generally applicable and 
biologically meaningful.  Much of the signaling and regulatory mechanisms studied in 
lymphocytes should be pertinent to other cellular systems, especially regarding general 
regulation of the stress response.  Nevertheless, because of the connection between the 
translational regulation of cytokine production and the balance between stimulatory and 
anergic responses, we hypothesize that understanding the basic regulatory control of T 
cell activation could be especially informative in the understanding of tumor immunity 
and autoimmunity. 
Paraneoplastic Neurologic Degeneration 
Paraneoplastic disorders refer to symptoms resulting from the presence of a tumor at a 
site remote from the neoplasm and can be caused by hormone and cytokine secretion by 
the tumor cells or by an immune response to the tumor.  In some cases, tumor cells 
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express proteins that are normally restricted to the brain, termed onconeural antigens.  
Because the antigens are normally restricted to the nervous system, the ectopic 
expression in the tumor makes them vulnerable to immune system surveillance, much 
like foreign antigens, and can help to elicit a strong tumor immune response that correlate 
with positive outcomes in subsequent cancer treatment. Unfortunately, the anti-tumor 
immune reaction can lead to severe autoimmune disease mediated by these onconeural 
proteins, leading to neurologic degeneration.  Paraneoplastic neurologic degeneration 
(PND) disorders represent some of the best-known clinical cases of spontaneous tumor 
immunity, especially with identified antigenic targets of the immune system.  
Interestingly, the onconeural antigens in multiple PNDs are RNA-binding proteins (R. B. 
Darnell 1996; R. B. Darnell and Posner 2003a; 2003b; 2006). 
While patients are often diagnosed with a PND based on the presence of onconeural-
specific antibodies, their role in disease progression is unclear as disease models utilizing 
onconeural autoantibodies have failed to initiate disease (Sakai et al. 1995).  Antibodies 
often mediate responses to extracellular antigens, while PND antigens are often expressed 
intracellularly (Okano and Darnell 1997).  CD8 T cells are often key effectors of tumor 
immunity due to their ability to recognize the unusual protein repertoires often expressed 
in malignant cells.  PND patients often have activated T cells in their cerebral spinal fluid 
and previous lab members have identified onconeural antigen-specific CD8 lymphocytes 
in PND patients, including the discovery of CD8 T cells that display unusual cytokine 
expression phenotypes (Albert et al. 1998; Albert, Austin, and Darnell 2000; Roberts et al. 
2009).  Studies in mice have suggested that in normal animals there is immune tolerance 
to onconeural antigens (DeLuca et al. 2009) and Blachère et al., unpublished.  The 
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mechanisms mediating tolerance to these neuronal proteins are unknown and the critical 
method by which this tolerance is broken in PND patients leading to both tumor 
immunity and neuronal autoimmunity is not yet understood.  By studying the basic 
regulatory processes mediating T cell activation, we hope to uncover insight into the 
control of the powerful tumor immunity and devastating autoimmunity displayed by 
these patients.   
RNA Regulation in the Immune Response 
T cell Activation and Rapid Cellular Stress Responses 
When cells encounter various biologic stresses such as heat shock, amino acid starvation, 
oxidative stress, or viral infection, a common integrated stress response (ISR) pathway is 
induced to protect the cell from damage and adapt to the environmental changes.  One 
main functional outcome of this pathway is the control of the translational status of 
mRNA in the cells to modulate the priority of which transcripts are made into protein 
during the period of new cellular demands.  While different cellular cascades help to 
initiate these different responses, many converge upon the phosphorylation of serine 51 
of the alpha subunit of the eukaryotic initiation factor two (EIF2A).  Serine 51 
phosphorylation blocks EIF2A from helping establish active initiation complexes at the 
ribosome, which decreases translation. Changes in translational control with the induction 
of the ISR are also accompanied by alterations in gene expression to help the cells adapt, 
including the induction of regulators of EIF2A phosphorylation such as GADD34 
(PPP1R15A) (Harding et al. 2002; 2003; Murphy 2006).  Unlike GADD34, constitutive 
repressor of EIF2A phosphorylation (CReP or PPP1R15B) is constitutively expressed, 
10
but both can help dephosphorylate EIF2A blocking it from activating the ISR (Jousse et 
al. 2003).  In addition to changes in transcription and translation, an activated ISR can 
also affect the localization of mRNA.  mRNA present in the cell can be sequestered in 
stress granules and p-bodies, although the presence of the latter is not depended on 
EIF2A phosphorylation, to harbor latent transcripts or target them for degradation 
(Anderson 2008; Brengues, Teixeira, and Parker 2005; Harding et al. 2002; Kedersha and 
Anderson 2002; Murphy 2006; Scheu et al. 2006; Sheth and Parker 2006).  RNA-binding 
proteins, such as Argonaute (Ago) and HuR to be discussed later, can rapidly shuttle in 
and out of stress granules, presumably in conjunction with bound mRNAs, to mediate 
translational silencing and potentially degradation (Bhattacharyya, Habermacher, Martine, 
Closs, and Filipowicz 2006a; 2006b; Leung and Sharp 2007; 2010). 
The dissociation between the transcription of cytokine mRNA and synthesis of the 
protein during CD4 T cell differentiation has been linked to a pathway resembling ISR 
(Scheu et al. 2006).  Also, in a mouse model of immune tolerance, the production of 
cytokine mRNA was disconnected from the generation of effector proteins in T cells 
specific for self but not foreign antigens (Villarino et al. 2011).  T cell activation in 
hypoxic conditions has also been shown to increase the secretion of IFNG without 
increased levels of the IFNG transcript (Roman et al. 2010).  Although these may not be 
direct representations of the classical ISR pathway, the translational control of cytokine 
expression and their localization to stress granules makes T cell activation an intriguing 
system to study the regulation of these pathways and applicable to many general cellular 
dynamic responses. 
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RNA-Binding Proteins in Immune Cells 
These observations raise the general issue of how gene regulation is manifest in the 
dynamics of the immune response.  Hao and Baltimore analyzed the inflammatory 
response by determining the transcriptional profiles of macrophages at various time 
points after the stimulation with TNF.  They described that the response could be grouped 
into three sets of genes: ones that peaked in expression at half an hour after activation, 
after two hours of activation, or increased steadily with stimulation and peaked at 12 
hours after activation.  They concluded that transcription and mRNA turnover are 
important to the control of inflammation (Hao and Baltimore 2009).  Another level of 
regulation, not excluded by these observations, is translational regulation.  One 
predominant advantage of this point of regulatory control is in the potential for even more 
rapid responses of immune cells in response to stimuli. 
As immune cells survey the host for antigen, they are required to adapt quickly to 
changes within their host.  For example, when a lymphocyte encounters antigen, it needs 
to quickly initiate an inflammatory response including the production of cytokines.  This 
response needs to be carefully controlled and transient so that it does not damage the 
surrounding tissue.  Thus, it is logical that much of lymphocyte protein expression be 
regulated at the translational level.  For instance, by harboring latent cytokine transcripts 
in cytoplasmic granules, RNA-binding proteins can compete for interactions with their 
targets.  These proteins work in combination to modulate a cytokine mRNA’s stability 
and access to ribosomes, which can be quickly accomplished without the need for new 
transcription to initiate a response (Anderson 2008; 2010).   
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AU-rich elements (ARE) are usually found in the 3’UTR of transcripts and are found in 
many mRNAs encoding immediate-early and early response genes, including cytokines, 
proliferative factors, and other functional groups that drive inflammation (Gruber et al. 
2011).  These cis-regulatory elements were first identified as binding sites for RNA-
binding proteins nearly twenty-five years ago (Malter 1989).  Since then it has been 
elucidated that many RNA-binding proteins act at these sites to both positively and 
negatively regulate mRNA turnover, changes in subcellular localization, and access to 
translational machinery in response to cellular stresses.  ARE-binding proteins such as 
HuR (ELAVL1), TIA1/TIAR, and tristetraprolin (TTP), have been shown to have critical 
inflammatory functions, such as in the regulation of cytokine mRNA (Meisner and 
Filipowicz 2010).  
For example, all of these factors have been shown to interact with ARE in the TNF 
3’UTR in mediating the immune response.  HuR deficient T cells in mice displayed 
increased levels of Tnf mRNA and analyses of myeloid-restricted HuR over-expression 
showed translational suppression of inflammatory mRNAs, including Tnf (Katsanou et al. 
2005; Papadaki et al. 2009).  TIA-1 and TIAR recruit target mRNAs to stress granules in 
response to different stimuli to block their translation (Kedersha et al. 1999).  
Macrophages from mice lacking either Tia-1 or Tiar and stimulated with LPS produced 
increased levels of TNF protein without altering its transcript abundance or half-life 
(Kedersha et al. 1999; Piecyk et al. 2000).  Mice deficient in Ttp spontaneously develop 
severe autoimmune disorders due to the over expression of TNF protein and other 
inflammatory factors which are normally targets of deadenylation and mRNA decay due 
to TTP destabilization (Blackshear 2002; Lai et al. 1999; Taylor et al. 1996). 
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HuR Regulation of RNA 
HuR, also known as HuA or ELAVl1, is a ubiquitously expressed RNA-binding protein 
that is closely related to the neuronal proteins HuB, HuC, and HuD (Ma et al. 1996; 
Okano and Darnell 1997).  The neuronal isoforms are targets of the immune system in 
both lung cancer cells and the nervous system in a PND known as the Hu Syndrome.  
This is an interesting connection between RNA regulation and the pathology of PND and 
we speculate that HuR could be critical to controlling the immune response of T cell 
phenotypes that are altered in the targeting of its neuronal homologues.  Hu proteins 
contain three RNA recognition motifs.  These proteins were identified as binding to U-
rich sequences and many U-rich and ARE binding motifs have been identified (Ma et al. 
1996; Myer, Fan, and Steitz 1997). 
HuR was shown to actively shuttle between the nucleus and cytoplasm in response to 
different stress conditions including the activation of immune cells (Meisner and 
Filipowicz 2010).  This export of HuR into the cytoplasm is critical for its regulatory 
control of certain target transcripts (X. C. Fan and Steitz 1998b; Peng et al. 1998). The 
shuttling is mediated by two different pathways, one which utilizes the HuR nuclear 
localization signal and is dependent on CRM1, and the second uses transportin molecules 
(X. C. Fan and Steitz 1998a; Gallouzi, Brennan, and Steitz 2001; Rebane, Aab, and Steitz 
2004).  HuR also associates with stress granules in response to cellular stress (Gallouzi et 
al. 2000).  In response to cellular stimuli, signaling cascades can lead to posttranslational 
modifications of HuR which may mediate its subcellular localization or influence its 
RNA binding (Abdelmohsen et al. 2007; Doller, Pfeilschifter, and Eberhardt 2008).  The 
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levels of HuR protein have also been shown to be regulated in response to T cell 
stimulation and other stress responses by multiple pathways including auto-regulation 
and control by microRNAs (Abdelmohsen et al. 2008; Akool et al. 2003; Atasoy et al. 
1998; X. Guo, Wu, and Hartley 2009; Jeyaraj et al. 2010; Papadaki et al. 2009; Sakai et al. 
2003).  
HuR has been demonstrated to regulate targeted transcripts by cooperative and 
competitive interactions with other RNA-binding proteins often by interfering with ARE-
mediated decay of mRNA by other RNA-binding proteins (Anderson 2008; Brennan and 
Steitz 2001; Casolaro et al. 2008; X. C. Fan and Steitz 1998b; Myer, Fan, and Steitz 
1997).  Although much work studying HuR has focused on transcript stability, HuR has 
also been linked to dynamic control of translation (Katsanou, Dimitriou, and 
Kontoyiannis 2006; Kawai et al. 2006; Lal et al. 2004; Mazan-Mamczarz et al. 2003; 
Sureban et al. 2007).  Still, much of the research investigating the targets and effects of 
HuR binding has been studied in vitro with reporter constructs or by over expressing HuR, 
in potentially biased screens for regulation and non-physiologic conditions.   
HuR Regulation in T cells 
As introduced in the previous section, HuR has been shown to help regulate many 
cellular processes including the stress response and immune pathways.  The effects of 
HuR binding vary by mRNA target, most often involving regulation of stability and 
translation.  HuR has been implicated in both inducing and suppressing inflammatory 
responses.   
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In T cells, HuR has been shown to regulate CD3ζ, CD40L, Fas, IFNG, IL-4, IL-13, and 
TNF (Brennan and Steitz 2001; Izquierdo 2008; Katsanou et al. 2005; Moulton et al. 
2008; Myer, Fan, and Steitz 1997; J. G. Wang et al. 2006; Yarovinsky et al. 2006).  
During lymphocyte activation, HuR promotes the stabilization of cytokine transcripts by 
binding to AU-rich elements (ARE) in the 3’ untranslated region (3’UTR).  By 
interacting both cooperatively and competitively with other RNA-binding proteins, these 
associations can promote or inhibit translation of cytokines to determine the fate of the 
transcript (Anderson 2008; Casolaro et al. 2008; X. C. Fan and Steitz 1998b; Myer, Fan, 
and Steitz 1997).  HuR levels have also shown to be up-regulated following T cell 
activation (Atasoy et al. 1998; Papadaki et al. 2009; Sakai et al. 2003). 
Mice deficient in HuR are not viable, while post-natal conditional ablation of HuR causes 
gastroentological inflammation, along with depletion of hematopoietic lineages and death 
within the first two weeks of life (Ghosh et al. 2009; Katsanou et al. 2009).  Animals 
lacking HuR only in their T cells proceed throughout development.  Still, these mice have 
altered lymphocyte phenotypes.  HuR deficient T cells show altered maturation and do 
not exit the thymus at normal rates due to diminished chemotactic responses to cytokines 
that have been shown to alter HuR subcellular localization.  Upon CD3/CD28 stimulation, 
T cells lacking HuR showed a reduced proliferative response and a decreased apoptotic 
response.  HuR deficient cells displayed increased levels of Tnf mRNA (Papadaki et al. 
2009).   
While the role of HuR in regulating cytokines has been pervasive, the majority of the 
work has been done in cell culture systems that do not necessarily represent physiologic 
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conditions.  Furthermore, much of work studying the association of HuR with targets, 
including during T cell activation, has been studied without crosslinking, which may lead 
to the identification of false targets of regulation due to the potential association of RNA-
binding proteins with transcripts after cell lysis for immunoprecipitation (Mili and Steitz 
2004; Mukherjee et al. 2009).  Genome-wide HuR binding sites have been mapped using 
photoactivatable ribonucleoside crosslinking and immunoprecipitation (PAR-CLIP) 
approach, but its requirement for incorporating a photo-activatable nucleotide analog into 
RNA limits its use to in vitro systems that may not represent biologically meaningful 
binding sites or dynamic changes in response to stress (Lebedeva et al. 2011; Mukherjee 
et al. 2011).  Thus, more stringent analysis of genome-wide targets is necessary in 
biologically relevant samples and in dynamic cellular responses. 
Ago Regulation and microRNAs  
MicroRNAs are small ~22-nucleotide RNAs that help direct Ago binding to mRNA to 
regulate target deadenylation, decay and translational status in diverse biologic processes 
such as proliferation, differentiation, and stress responses.  The majority of microRNA 
genes in mammals are found in regions of the genome that were previously thought to be 
intergenic, although a number of microRNA are transcribed within the introns of coding 
genes.  MicroRNAs are also found in genomic clusters that suggest joint transcriptional 
regulation.  In all cases, the microRNAs are thought to begin as longer RNA molecules 
than their characteristic evolutionarily conserved stem loops.  Generally, after the initial 
message known as the primary microRNA is transcribed, the first step in processing is 
the cleavage of the ~60-70 nucleotide stem loop from the rest of the message, by the 
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RNase III enzyme Drosha, to form the precursor microRNA. This cleavage event 
resolves one end of the mature microRNA duplex.  The precursor microRNA is then 
actively exported from the nucleus by Ran-GTP and Exportin-5.  The second cleavage is 
completed by another RNase III endonuclease Dicer at a fixed distance from the Drosha 
cleavage site.  These cleavage products become incorporated into Ago proteins as single-
stranded RNA molecules in ribonucleoprotein complexes, known as the RNA-induced 
silencing complex (RISC) (Ambros 2004; Bartel 2004). 
MicroRNAs can mediate post-transcriptional regulation by targeting transcripts for 
mRNA cleavage and degradation or by modulating translation of their targets.  These 
endpoints are decided by the complementarity of the microRNA sequence to the target 
and by the interaction of the Ago-microRNA complex with other RNA-binding proteins 
in response to cellular signaling and multiple stress responses (Bartel 2004; 2009; Leung 
and Sharp 2007; 2010).  Thus, Ago regulation can be dynamically controlled.  For 
example, the localization of Ago to stress granules is microRNA dependent and can be 
transient, with evidence that Ago can shuttle in and out of a stress granule in less than a 
minute (Leung, Calabrese, and Sharp 2006). Another example of rapid regulatory control 
involving microRNAs is in the light adaptation response of the retina where levels of 
microRNA were shown to change rapidly by decay and increased transcription to impact 
mRNA control (Krol et al. 2010).  These and other regulatory systems, such as in 
interactions with other RNA-binding proteins, allow for rapid responses to external 
stimuli to influence the final stages of gene expression within a cell.   
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Some studies have indicated that microRNAs mediate repression of protein expression 
predominantly by decreasing target transcript levels (Baek et al. 2008; H. Guo et al. 
2010; Hendrickson et al. 2009).  Others have reported that translational control precedes 
corresponding changes in mRNA expression (Bazzini, Lee, and Giraldez 2012; Selbach 
et al. 2008).  The mechanisms mediating Ago-mediated mRNA control are also varied 
including microRNA dependent deadenylation of transcripts leading to the degradation of 
target transcripts unrelated to translational control, or the inhibition of protein synthesis 
before or after the initiation of translation (Mathonnet et al. 2007; Olsen and Ambros 
1999; Pillai et al. 2005; L. Wu, Fan, and Belasco 2006).  While most studies of 
microRNA mediated translational control have focused on repression of translation, it has 
also been reported that Ago binding helps to mediate translational activation of some 
target mRNAs in certain biologic conditions (Henke et al. 2008; Jopling et al. 2005; 
Vasudevan and Steitz 2007; Vasudevan, Tong, and Steitz 2007; 2008; Ørom, Nielsen, 
and Lund 2008).  In summary, Ago-microRNA regulation of targets has been linked to 
repression and enhancement of translation with and without changes in target abundance 
by influencing many mechanisms of translational control. 
Ago Regulation in T cells 
Ago regulation and microRNAs have been shown to be critical to the development of a 
healthy immune system and normal inflammatory responses.  The differential abundance 
of microRNAs in distinct T cell lineages has been examined, but these studies have not 
considered the activation state of the lymphocytes or the mRNA regulation of Ago in 
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parallel (Landgraf et al. 2007; Monticelli et al. 2005; Salaun et al. 2011; H. Wu et al. 
2007).   
The Dicer enzyme is critical for generation of microRNAs by cleaving double stranded 
precursors.  Mice lacking Dicer in the T cell lineage showed greatly impaired T cell 
differentiation, particularly for the development of CD8 T cells (Cobb 2005; Muljo et al. 
2005).  Furthermore, CD8 T cells conditionally deficient in Dicer after maturation were 
shown to have a heightened response to T cell activation.  Lymphocytes stimulated in 
vitro showed quicker surface expression of CD69 and this activation marker persisted 
longer than in wild type T cells after the termination of the TCR stimulus.  The T cells 
also showed quicker initiation of proliferation as seen by progression into the cell cycle.  
After in vitro stimulation of wild type T cells, microRNA-130/301, thought to be 
regulating CD69 expression, were increased as compared to resting cells (Zhang and 
Bevan 2010).  Conditional deletion of Dicer in response to T cell activation with viral 
challenge led to a faulty expansion of antigen-specific T cells and poor viral clearance (T. 
Wu et al. 2012).  Deletion of Ago2 in the bone marrow resulted in aberrant generation of 
B cells and cells of the erythroid lineage (O'Carroll et al. 2007).   
T cell Differentiation and Responses Impacted by the Overexpression or Deletion of 
microRNAs in Mice 
Regulatory T cells deficient in mir-146a showed a deficiency in their ability to control 
IFNG production themselves or in CD4 and CD8 cells due to loss of suppression of 
STAT1.  This selective cytokine deregulation differed from Dicer deficient regulatory T 
cells that showed decreased suppression of multiple cytokines and general loss of 
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suppressive capacity (Liston et al. 2008; Lu et al. 2010).  Macrophages from mice with a 
genetic deletion of miR-146a show an exaggerated response with intra-peritoneal 
lipopolysaccharide challenge, with elevated levels of serum TNF and decreased survival 
rate.  The mice develop spontaneous autoimmunity with age, displaying enlarged spleens 
and lymph nodes, inflammation in peripheral organs, increased serum levels of IL-6, and 
expression of activation markers on T cells.  This autoimmunity resulted in a decreased 
survival rate and the appearance of spontaneous tumors in secondary lymphoid organs 
(Boldin et al. 2011).   
Mice lacking miR-155 showed deficiencies in both T and B cells.  For example, CD4 T 
cells showed reduced expression of IFNG upon stimulation (Rodriguez et al. 2007; Thai 
et al. 2007).  Additionally, mir-155 is necessary for the heightened responses of 
regulatory T cells to IL-2 even though most suppressor functions are maintained in its 
absence (Lu et al. 2009).  Ago CLIP binding maps in WT and miR-155 deficient mouse 
regulatory CD4 T cells were recently published and help to establish that roughly forty 
percent of miR-155 binding sites do not display canonical seed matches (Loeb et al. 
2012).  These studies examine a different subset of T cells than is the focus of the work 
described here, but suggest a need to understand other mechanisms of transcript targeting 
for Ago binding aside from seed match pairing in lymphocytes.  
Hematopoietic stem cells from the bone marrow were transduced with retrovirus to 
ectopically express miR-181a.  When these cells reconstituted the bone marrow of sub-
lethally irradiated hosts, while the percentage of mature B cells nearly doubled, the 
number of CD8 T cells was reduced more than ten-fold.  Only small alterations were 
21
observed in the CD4 T cell and myeloid compartments (Chen et al. 2004).  miR-181a is 
highly expressed early in T cell development and decreases with maturation.  CD4 T cells 
overexpressing miR-181a showed increased intracellular calcium fluctuations and IL-2 
production with antigen stimulation, and required less peptide present on APCs to reach 
their maximal response, demonstrating that they were more sensitive to TCR stimulation.  
The opposite effect was seen in T cells with reduced miR-181a expression. These 
responses were shown to be mediated in part by the regulation of CD28 expression, but 
also by downstream components of the TCR signaling pathway (Li et al. 2007).  Liu et al. 
utilized the increase in the development of double positive cells with overexpression of 
miR-181a-1 in vitro as a screen for functional microRNA activity.  Sequential 
mutagenesis of the miR-181 stem loop demonstrated that while sequences in the mature 
microRNA were important for T cell development, the regulation of distinct miR-181 
family members was dictated by their pre-microRNA loop sequences (G. Liu et al. 2008).  
Although the absolute expression levels of miR-181 are lower in double positive cells 
than other stages of development, it represents a larger percentage of the microRNA pool 
in these cells and this mediates the regulatory control of targets such as CD69 to regulate 
T cell development (Neilson et al. 2007). 
Many studies have focused on the role of the miR-17-92 cluster in B cells due to its 
overexpression in human B cell lymphomas.  This is due to transcriptional up-regulation 
of the cluster by c-MYC.  The oncogenic capacity of these microRNAs is greatly due to 
the targeting effects of miR-19a and miR-19b (Mu et al. 2009).  Mice deficient in the 
miR-17-92 cluster die shortly after birth.  Wild type mice reconstituted with miR-17-92 
deficient bone marrow showed drastic reductions in total lymphocyte counts due to 
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impaired B cell development, while the T cell compartment appeared grossly unaffected 
(Ventura et al. 2008).  miR-17-92 is highly expressed during lymphocyte development 
and is decreased in mature cell populations including CD4 and CD8 single positive cells.  
Overexpression of miR-17-92 in lymphocytes led to lymphoproliferative disease, 
autoimmunity, and death.  Interestingly, CD4 T cells overexpressing miR-17-92 
proliferated with CD3 stimulation at similar levels to control CD4 T cells stimulated with 
both CD3 and CD28 indicating that the aberrant microRNA expression may have 
functionally mimicked CD28 co-stimulation (Xiao et al. 2008).  miR-17-92 expression is 
temporally regulated with T cell activation and is needed for expansion of CD8 T cells 
after antigen encounter (T. Wu et al. 2012).  By examining mice with T cells deficient for 
the miR-17-92 cluster, these microRNAs were shown to promote Th1 responses and 
suppression of tumor growth in melanoma challenged mice.  Furthermore, miR-19b was 
demonstrated to rescue the production of IFNG in CD3/CD28 stimulated deficient cells 
with retroviral transduction of that microRNA (Jiang et al. 2011). 
The Combinatorial Control of Ago and HuR  
As reviewed above, HuR and Ago both positively and negatively regulate gene 
expression by transcriptional and translational control and are both critical to the 
regulation of healthy immune responses.  We have previously demonstrated the ability to 
use high-throughput sequencing crosslinking immunoprecipitation (HITS-CLIP) to 
establish a precise and genome-wide map of Ago-microRNA-mRNA ternary interactions.   
Interestingly, this map showed that Ago binds to mRNA targets at very specific sites, on 
average only 2.6 regions per Ago regulated transcript.  This specificity is hard to explain 
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solely by the reliance of a microRNA-mRNA interaction determined by a microRNA 
seed sequence of as few as six nucleotides of complementarity.  Furthermore, Ago-
mRNA binding sites did not appear to have a general sequence preference, suggesting 
that additional RNA-binding proteins may be required to determine mRNA accessibility 
to Ago (Chi et al. 2009).  Many Ago binding sites have also been identified without 
exactly matching canonical microRNA seed sequences.  While some of these regulatory 
sites represent microRNA mediated targeting through non-classical seed pairings, some 
cannot be explained by microRNA direction alone (Chi et al. 2009; Chi, Hannon, and 
Darnell 2012; Leung et al. 2011; Loeb et al. 2012).  
3’UTRs are abundant in both microRNA binding sites and ARE.  This creates a 
concentrated region for the possible combinatorial control of target mRNAs by Ago and 
other RNA-binding proteins.  Ago and microRNA are important in the regulation of AU-
rich elements (ARE) through their interactions with other RNA-binding proteins such as 
HuR (Meisner and Filipowicz 2010).  Accordingly, a recent systematic analysis indicated 
that the efficacy of miRNA mediated silencing was attenuated by the presence of AREs 
near predicted miRNA target sites, suggesting that ARE-binding proteins may globally 
influence recruitment of Ago-miRNA complexes (Jacobsen et al. 2010).  Much work 
studying the interactions of Ago and HuR have focused on specific target transcripts.  
While these may be informative for the specific examples, the differences in the outcome 
of their combinatorial control indicate the need for more systematic study of their co-
regulation.   
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For example, CAT-1 protein levels increase in response to stress without a corresponding 
change in transcription.  In normal cellular conditions, miR-122 mediates the subcellular 
localization of the CAT-1 mRNA to P-bodies.  Upon activation of a stress response, HuR 
was demonstrated to bind to the 3’UTR of CAT-1 via ARE and reverse its microRNA-
mediated repression.  Binding by HuR led to the exit of CAT-1 from P-bodies and its 
association with active polysomes, resulting in an increase in CAT-1 translation.  The 
mechanism mediating the interaction between Ago and HuR on the CAT-1 mRNA is 
unknown, but because the target sequence sites for each protein are not directly adjacent, 
the authors speculate that the proximity of their interaction may be enhanced by the RNA 
secondary structure, possibly bringing the sites closer together than indicated by their 
sequence, or by HuR oligomerization along the 3’UTR to disrupt Ago-miR-122 binding 
(Bhattacharyya, Habermacher, Martine, Closs, and Filipowicz 2006a; 2006b).   
Conversely, HuR was shown to be necessary for the microRNA let-7 mediated repression 
of c-Myc.  HuR associated with c-Myc in RNA-immunoprecipitation experiments.  By 
diminishing levels of HuR in Hela cells by siRNA or overexpressing recombinant HuR 
protein, HuR was observed to negatively correlate with c-Myc mRNA and protein levels 
suggesting repression of c-Myc by HuR.  Using synthesized biotinylated mRNA 
fragments and chimeric GFP-reporter constructs, specific regions of the 3’UTR were 
identified as mediating the interaction between HuR and c-Myc.  Let-7 was predicted to 
bind a region adjacent to the proposed HuR binding site.  Decreasing functional let-7 
with antagomiRs, or increasing its levels by transfection of synthesized precursor duplex 
RNA, increased or decreased c-Myc expression respectively.  HuR was shown to be 
necessary for Ago2-let-7 binding to the c-Myc 3’UTR and the co-immunoprecipitation of 
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HuR with Ago was RNA dependent, although this immunoprecipitation did not utilize 
crosslinking and the interaction could have been formed after cell lysis (Kim et al. 2009).  
It is possible that the opposite affects of Ago and HuR interaction for this transcript are 
due to differences in the proximity of the binding sites for each protein, cell lines, cellular 
states, or that the interactions are more complex than only the involvement of these two 
regulators. 
Although myeloid cell proliferation, survival, and differentiation were maintain in mice 
deficient in HuR in the myeloid compartment, steady state mRNA and microRNA levels 
were disrupted in these cells.  The angiogenic pathway was implicated as being regulated 
by HuR expression and the strength of ARE in the 3’UTR correlated with the down 
regulation of these potential targets.  In searching for regulated mRNA with ARE 
adjacent to putative microRNA binding sites, the Vegf-a mRNA was recognized as 
having reduced levels of both transcript and protein in the knock out cells, containing a 
previously identified binding site of HuR from PAR-CLIP, and a bioinformatics 
predicted ARE-adjacent site for miR-200b which was increased in the HuR deficient 
macrophages.  Vegf-a mRNA was shown to immunoprecipitate with both Ago and HuR.  
In reporter systems, the intact miR-200b site was necessary to mediate reduction of 
luciferase expression with miR-200b transfection and concurrent HuR knockdown further 
mediated this repression.  An antagomiR blocking miR-200b only de-repressed Vegf-a 
reporters if HuR was present and more Vegf-a mRNA was shown to associate with Ago2 
in the absence of HuR.  In a mouse tumor challenge, although wild type and myeloid 
HuR knock out mice had similar myeloid invasion of the tumor microenvironment, the 
tumors displayed defects in their vasculature and angiogenesis, and tumor growth was 
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attenuated due to tumor cell apoptosis.  Morpholino knock down of elavl1 zebrafish or 
miR-200b mimic injection resulted in severe vascular development in the subintestinal 
vein (SIV), while elavl1 mRNA rescued the defects from miR-200b overexpression.  
Interestingly, using a suboptimal dose of either intervention resulted in fairly normal 
vasculature, but when both were applied simultaneously, the majority of zebrafish had 
defective SIV, supporting the antagonistic role of Ago and HuR in regulating vegfaa that 
had been demonstrated in vitro (Chang et al. 2012). 
Utilizing in vitro systems and reporter constructs, Ago-miR-19 demonstrated repression 
of RhoB in an HuR dependent manner.  This repression was relieved during UV-
irradiation of keratinocytes leading to the apoptosis of these stressed cells (Glorian et al. 
2011).  In other cell culture studies using reporter constructs and recombinant protein 
expression, HuR binding sites were shown to be necessary to mitigate Ago-let-7 
mediated cleavage of IL-1B mRNA.  The transfection of oligonucleotides specific for the 
intervening sequences between the microRNA and HuR binding sites blocked Ago 
repression of this transcript suggesting that oligomerization of HuR may be necessary for 
its interaction in suppressing Ago cleavage (Kundu et al. 2012). 
Previous Studies Using CLIP to Explore Co-Regulation of Ago and HuR Targets 
Recent studies using Ago and HuR CLIP experiments have investigated the potential co-
regulation of mRNA by these RNA-binding proteins on a genome-wide scale.  HuR 
binding sites were recently identified in unstressed HeLa cells using PAR-CLIP.  The 
largest group of target sites was found in the 3’UTRs of transcripts, but around a third of 
binding sites were in intronic regions of the message.  These target sequences were 
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highly evolutionarily conserved.  In comparing HuR binding sites with Ago regulation 
identified by PAR-CLIP in HEK293 cells, a preference for binding in areas of Ago 
targeting was not observed.  With knockdown of HuR in the HeLa cells, miR-7 was 
shown to have increased expression levels that inversely correlated with the levels of 
HuR.  HuR binding sites in the intron and surrounding exons containing the microRNA 
sequence were proposed to influence the levels of this microRNA, although no direct 
mechanism was explored (Lebedeva et al. 2011). 
HuR PAR-CLIP was also done in HEK293 cells with epitope-tagged protein.  
Reproducible binding sites, determined by the crosslinking index of each sequenced tag, 
were found predominantly in the introns and 3’UTRs of target mRNAs, suggesting that 
pre-mRNA processing may be related to target stability.  The authors suggest that the 
PAR-CLIP data reflects both stable and transient HuR-mRNA interactions and that 
targets identified by immunoprecipitation without crosslinking may reflect more stable 
binding events as evidenced by HuR knockdown leading to a more profound affect on 
identified targets’ mRNA stability in targets identified in the RIP-chip method.  In 
comparing data from Ago PAR-CLIP from the same cell line with HuR PAR-CLIP 
binding sites, significant overlapping patterns of regulation were observed for the two 
proteins, suggesting the potential for competition of these proteins for effective binding 
to targets and subsequent regulation.  Still, the mRNA level changes seen with HuR 
knockdown could be explained with or without the presence of overlapping or adjacent 
microRNA binding sites.  The authors suggest that this indicates a model of HuR using 
physical competition for access to binding sites to mitigate microRNA-mediated 
repression (Mukherjee et al. 2011). 
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Accordingly, previous CLIP experiments comparing Ago and HuR regulation have been 
completed in steady state cell culture systems and may not represent their binding 
patterns in biologic systems or in dynamic cellular state changes.  While PAR-CLIP has 
been demonstrated to produce reliable binding site information for Ago and HuR proteins 
in addition to the HITS-CLIP methods, the necessity for incorporating a photo-activatable 
nucleotide analog into cells for PAR-CLIP analysis limits its utility in the study of 
biologic systems (Kishore et al. 2011).  In only one of the two described studies, Ago and 
HuR binding maps were compared from the same type of cell line, nevertheless, they 
were not the same biologic samples and in one case used an epitope tagged version of 
HuR for immunoprecipitation in the HEK293 cells, which would not have been present in 
the previous Ago studies to which they compare their results (Mukherjee et al. 2011).  
Therefore, studying the dynamic regulation of Ago and HuR within a biologically 
meaningful context is critical to the understanding of these important RNA regulators. 
Perspectives 
The adaptive immune response has been studied in great mechanistic detail and many of 
the molecular processes involved T cell activation have been resolved.  However, the 
regulatory mechanisms mediating these complex systems in the context of rapid cellular 
stress responses and disease are still not largely understood.  Lymphocytes are required to 
respond quickly to rapid changes they confront within their host.  When a T cell 
encounters its cognate antigen, cytokine production must be carefully regulated to 
instigate immediate induction of the inflammatory response, but also be transient to 
ensure the protection of surrounding tissue.  Therefore, although nascent transcription is 
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large component of this response, it is logical that much of protein expression be 
controlled at a post-transcriptional level.  The Ago and HuR RNA-binding proteins have 
been shown to be critical for normal lymphocyte development and the regulation of their 
phenotypes.  While their mRNA targets and binding sites has been vastly explored in the 
literature, analysis of their regulation in biologic settings is limited.  For these reasons, 
we have undertaken to study the role of Ago and HuR regulation during CD8 T cell 
activation by CD3 and CD28 stimulation in normal human donor CD8 lymphocytes.  We 
accomplished this by overlaying genome-wide HITS-CLIP binding maps, for Ago and 
HuR, with translational profiles of the cells as they relate to transcriptional abundance.  
Using these dynamic regulatory maps, we gain insight into the mechanisms governing T 
cell stimulation. 
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CHAPTER 2.  Experimental Procedures 
Peripheral Blood Isolation 
Blood cells were collected by peripheral blood draw or leukapheresis under a Rockefeller 
University IRB-approved protocol with informed consent.  PBMC were isolated by 
density gradient centrifugation over Ficoll-Hypaque (Pharmacia). 
Cell Culture 
Cells were maintained at 37°C in 5% CO2.  Human T cells were maintained T cell Media 
(AIM V Medium (Invitrogen) supplemented with 1% pooled human sera).  Mouse T cells 
and other non-adherent cells were maintained in R10 medium (RPMI 1640 medium 
(Mediatech) supplemented with 10% FBS (Hyclone), 2mM Glutamax (Gibco), sodim 
pyruvate, non-essential amino acids, 15 mM Hepes buffer, 50 μM β-mercaptoethanol, 
and gentimycin).  Ascites cells were maintained in Growth Medium (equal volumes 
MCDB105 medium (Sigma) and M199 medium (Invitrogen) supplemented with 10% 
FBS, and penicillin-streptomycin_.  All adherent cell lines mentioned were maintained in 
D10 medium (DMEM high glucose (Mediatech) containing all of the same supplements 
as R10).   
Negative Selection of CD8 T cells 
Human PBMC were incubated with a cocktail of biotin-conjugated antibodies specific for 
markers on non-CD8 T cells from a CD8+ T cell Isolation Kit and then bound by anti-
biotin magnetic beads supplemented with anti-CD19, anti-CD56, anti-CD4 and anti-
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CD14 MACS beads (Miltenyi Biotech).  Cells were washed and run through two 
magnetic columns collecting the flow through to isolate cells not bound by antibody. 
Positive Selection of CD8 T cells 
Human PBMC were incubated with anti-CD56 MACS beads (Miltenyi).  These cells 
washed and then were depleted by running the cells through two successive magnetic 
columns collecting the flow through to isolate cells not bound by CD56 antibody.  The 
cells were then incubated with anti-CD8 MACS beads (Miltenyi), were washed, and 
loaded onto a magnetic column to isolate antibody bound cells.  After washing the 
column, the positive cells were eluted by plunging the column.  This selection process 
was repeated on a second column to ensure cell purity.  Mouse positive selection uses the 
same protocol without the CD56 depletion.  To rest human T cells, cells were 
resuspended at 2x106/ml and 5-10 ml was put in a 50 ml conical tube (Denville 
Scientific) with loose caps at 37°C overnight.  After the resting period, cells were 
harvested and filtered through a 70 µm cell strainer to remove dead cells and any debris 
and the cells were collected by centrifugation. 
CD3/CD28 Stimulation 
T cells were plated at ~18x106/ml in R10 medium with 25 µl/106 T cells washed 
CD3/CD28 mouse or human T-Activator Dynabeads (Invitrogen).  Cultures were agitated 
every 12 minutes to aid in the dispersal of stimulatory beads to each T cell.  After one 
hour, cells were harvested and processed for future analysis. 
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Flow Cytometry Surface Staining 
All surface antibodies were purchased from BD Biosciences.  Cell surface expression of 
markers were measured using fluorescently-conjugated antibodies according to the 
manufacturer’s instructions.  Cells were resuspended in 100 µl FACS buffer: PBS 
supplemented with 1% PHS, 1% FBS (HyClone), and for mouse cells 5% goat serum.  
Mouse cells were then Fc blocked for 10 minutes using 1 µg of anti-CD16/CD32 
(FcγRII/III).  For both human and mouse cells, 1 µg of each antibody was added directly 
to the cells.  Human cells were incubated for 10 minutes at room temperature in the dark 
and mouse cells were incubated for 15 minutes at 4°C.  Cells were washed twice with 
FACS buffer and collected immediately on a BD FACScaliber machine and analyzed 
using Flowjo software (Treestar).  
Reverse Transcription and Quantitative PCR Analysis 
Total RNA was extracted from CD8 T cells using an RNeasy Mini Kit  with on-column 
DNAse treatment (Qiagen) and eluted in 20 µl of RT-grade H2O.  RNA was then reverse 
transcribed using the iScript cDNA Synthesis Kit (BioRad) as per manufacturer’s 
instructions.  cDNA was amplified by qPCR using iTaq SYBR Green Supermix with 
ROX (Biorad) on an iQ5 Multicolor Real-Time PCR Detection System (Biorad) using a 
58°C annealing temperature and both melt curves and -RT controls were performed.  
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Primers 
Human IFNG   
Forward: TCAGCTCTGCATCGTTTTGGGTTC 
Reverse: TCCGCTACATCTGAATGACCTGCAT 
Human TNF 
Forward:  CTGCCTGCTGCACTTTGGAGTGAT 
Reverse:  TGGGCCAGAGGGCTGATTAGAG 
Mouse Ifng 
Forward: CAGCAACAGCAAGGCGAAAAAGG 
Reverse: TTTCCGCTTCCTGAGGCTGGAT 
Mouse Gapdh 
Forward: TGAACGGGAAGCTCACTGGCAT 
Reverse: TCAGATGCCTGCTTCACCACCT 
Western Blot 
T cells were lysed in PXL by three cycles of freezing and thawing.  DNA was removed 
from lysate by DNase treatment at 37°C for 5 minutes.  Samples were spun at 14,000rpm 
for 10 minutes at 4°C and the supernatant was harvested to a new tube.  NuPAGE loading 
sample buffer and reducing agent (Invitrogen) were added to 1x concentrations in the 
lysate and samples were heated for 15 minutes at 70°C.  Lysate was run on a 8% (Ago) or 
10% (HuR) NuPAGE Bis-Tris gel (Invitrogen) in MOPS Buffer and transferred to 
Protran BA85 nitrocellulose (Whatman) or Immobilon-FL PVDF (Millipore) by standard 
methods.  For nitrocellulose membranes, membranes were blocked for 1hr at room 
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temperature in 5% non-fat dry milk (Carnation) in PBS followed by addition of primary 
antibody for 1 hour at room temperature or overnight at 4°C. Blots were washed 3x10 
minutes with Western blot wash buffer (23mM Tris, pH 8.0, 190mM NaCl, 0.1% w/v 
BSA, 1 mM EDTA, 0.5% Triton X-100, 0.02% SDS) after each antibody incubation.  
HRP-conjugated secondary antibodies (Jackson Immunochemicals) were used at 
1:10,000 dilution in 5% milk/PBS for 1 hr at RT, washed as before, and HRP signal was 
detected by Enhanced ChemiLuminescence (Western Lightning detection kit, Perkin 
Elmer) and detected on film (Kodak MR).  For Immobilon-FL membranes, membranes 
were blocked for 1 hour at room temperature in Odyssey Blocking Buffer (LI-COR) 
followed by the addition of primary antibody in LI-COR Antibody Buffer (50 mM Tris-
HCl, pH 7.5, 150 mM NaCl, 0.1% Tween-20, 2% BSA and 0.02% Sodium Azide), for 1 
hour at room temperature or overnight at 4°C.  Blots were washed 4x5 minutes in TBST 
after each antibody incubation.  Fluorescently-conjugated secondary antibody (Goat anti-
mouse IgG IRDye, 827-08364, LI-COR) was used at 1:30,000 Dilution in LI-COR 
Antibody Buffer for 45 minutes rocking at room temperature shielded from light by foil.  
The blots were washed 3 times as before and then once with TBS without tween.  
Fluorescent signal was detected on the Odyssey LI-COR machine. 
Ago and HuR HITS-CLIP  
Bead Preparations for Immunoprecipitation 
Protein A beads were vortexed and an aliquot was washed 3x in PBS with 0.02% Tween-
20.  Beads were pre-coated with rabbit anti-mouse IgG (Jackson ImmunoResearch, 315-
005-008 at 2.3 mg/ml) as a bridging antibody (1 µl antibody per 2 µl beads for HuR or 1 
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µl antibody per 8 µl beads for Ago) for 35 minutes rotating at room temperature.  Beads 
were washed 3x in PBS with 0.02% Tween-20.  HuR or Ago antibody was then loaded to 
the beads.  For HuR 1.7 µg/µl beads of 19F12 or 3A2 was added (Santa Cruz, (Gallouzi 
et al. 2000; Wang et al. 2000)).  For Ago, 3 µl of 2A8 ascites (provided by Dr. Zissimos 
Mourelatos (Nelson et al. 2007)) is added per 400 µl beads.  For irrelevant antibody 
controls, equivalent amounts of 7G1-1 antibody was added (Memorial Sloan-Kettering 
Cancer Center Monoclonal Antibody Core Facility, (Brown et al. 2001)).  For Ago CLIP 
with Protein G beads, beads are washed in the same way, but no bridging antibody is 
needed and 3 µl 2A8 is added per 200 µl beads.  Beads were rotated for 2 hours at 4°C to 
bind antibody.  Generally, for HuR CLIP, we used roughly 20 µl of beads per 10 million 
CD8 T cells, and for Ago CLIP, 40 µl beads per 10 million CD8 T cells.  After 
incubation with the antibodies for immunoprecipitation, the beads were washed once in 
PBS with 0.02% Tween-20 and three times in lysis buffer containing complete protease 
inhibitor mini EDTA free tablets (1 tablet/10 ml buffer) (Roche).   
T cell Lysate Preparation 
T cells were UV crosslinked as indicated on a bed of ice three times at 200 mJ/cm2 (254 
nm UV light) in a minimal volume of PBS with swirling between each irradiation, using 
a Stratalinker 2400 (Stratagene).  Lymphocyte lysate was prepared by adding a volume of 
1 ml PXL lysis buffer (1X PBS [tissue culture grade; no Mg2+, no Ca2+, GIBCO], 0.1% 
SDS, 0.5% Na-DOC, 0.5% NP-40) with complete protease inhibitor and the buffer was 
pipet multiple times to mix and resuspend cells in the buffer.  T cells were rested on ice 
for ten minutes with vortexing 15 seconds every 2 minutes to ensure complete lysis.  The 
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lysate was then DNase treated with RQ1 RNase-free DNase (Promega) for 5 minutes 
shaking in the Thermomixer R at 37°C.  5 µl of a 1:100 (high) or 1:10,1000 (low) RNase 
A solution was added to each sample as indicated and the lysate was incubated in the 
Thermomixer R for 5 minutes shaking at 37°C.  The lysate was spun at 14,000 rpm for 30 
minutes at 4°C to clear the lysate and the supernatant was harvested to a new tube for 
immunoprecipitation. 
Samples were then rotated with primary antibody-loaded beads at 4°C for 2 hours. 
Following IP beads were washed sequentially (1 ml washes) twice with 1X PXL lysis 
buffer, twice with 5X PXL (5X PBS [tissue culture grade; no Mg2+, no Ca2+, GIBCO], 
0.1% SDS, 0.5% Na-DOC, 0.5% NP-40), twice with high stringency buffer (15 mM Tris-
HCl, pH 7.5, 5 mM EDTA, 2.5 mM EGTA, 1% Triton X-100, 1% Na-deoxycholate 
(DOC), 0.1% SDS, 120 mM NaCl, 25 mM KCl), high salt buffer (15 mM Tris-HCl, pH 
7.5, 5 mM EDTA, 2.5 mM EGTA, 1% Triton X- 100, 1% Na-DOC, 0.1% SDS, 1 M 
NaCl) and twice with low salt buffer (15 mM Tris- HCl, pH 7.5, 5 mM EDTA) followed 
by two washes with NT-2 buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM MgCl2, 
and 0.05% NP-40) and two washes with PNK buffer (50mM Tris-HCl, pH 7.5, 10 mM 
MgCl2, 0.5% NP-40). After each capture on the magnet beads, the beads were 
resuspended by end-over-end rotation.  Throughout the washes tubes were treated in a 
random order to diminish the chance of artifacts. Throughout the CLIP protocol 1.5 ml 
SlickSeal microfuge tubes (National Diagnostics) were used to reduce non-crosslinked 
RNA binding to tubes. 
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Dephosphorylation of RNA, 3’ Linker Ligation, and Rephosphorylatoin of 5’ end of RNA 
Tags 
Immunoprecipitations were treated with calf intestinal phosphatase to remove the 5’ 
phosphate from RNA crosslinked to Ago and HuR (RNA tags) so that the RNA could not 
circularize during ligation, an otherwise predominant competing intramolecular reaction.  
Beads were resuspended in 60 µl of 1X dephosphorylation buffer and 3 units of CIAP 
(Roche) with RNAsin Plus RNase Inhibitor (Promega) and incubated in the Thermomixer 
R at 37°C for 20 min, programmed to shake at 1000rpm for 15 s every 2 min.  This was 
followed 1 ml washes, once with PNK Buffer, twice with PNK buffer with EGTA 
(10mM Tris pH 7.5, 20mM EGTA, 0.5% NP-40) and twice again with with PNK buffer 
(no EGTA).  
For Ago CLIP, to ligate a 32P-labeled RNA linker to the 3’ end of the RNA, the 
puromycin- blocked linker (L32, 5’-OH-GUGUCAGUCACUUCCAGCGG-3’-
puromycin, Dharmacon) was first labeled using T4 phosphonucleotide kinase (PNK, New 
England Biolabs, NEB).  50 pmol of L32 RNA, 15 µl 32P-γ-ATP, 1 µl RNAsin and 2 µl 
of T4 PNK in 1X PNK buffer were incubated at 37°C for 30 min, an additional 0.02 ml 1 
mM ATP to drive the reaction to complete and was incubated 5 min.  Radiolabeled linker 
was spun through a G-25 column (Amersham) to remove free ATP.  30 pmol of the 
labeled 3’RNA linker was added to a 60 µl T4 RNA ligase reaction (Fermentas), 
according to kit instructions, and on-bead ligation reactions were incubated at 16°C for 1 
hr in a thermomixer programmed to shake at 1000rpm for 15 sec every 4 min. After 1 hr, 
80 pmol of cold L32 RNA linker with 5’ phosphate was added to each tube and incubated 
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overnight.  For HuR CLIP, only the cold L32 RNA linker with 5’ phosphate was used for 
ligation overnight. 
Following linker ligation, the beads were washed three times with PNK buffer. To 
rephosphorylate the 5’ end of the RNA for 5’ linker ligation, 80 ul of T4 PNK mix (6 ul 
of 1 mM ATP, 4 ul T4 PNK enzyme [NEB], 1 ul RNasin in 1X T4 PNK buffer [NEB], 
total volume 80ul) was added to each tube and incubated at 37°C in the Thermomixer R 
for 20 min at 1000 rpm shaking for 15 sec every 4 min.  For HuR CLIP, this step was 
done in the presence of 32P-γ-ATP for 20 minutes and then 1 mM cold ATP was added to 
drive the reaction to completion for 5 additional minutes at 37°C.  Beads were washed 
three times with 1 ml PNK buffer. 
SDS-PAGE Separation of RNA-binding Protein:RNA Complexes 
After last PNK buffer wash, each tube of beads was resuspended in 30 ul NuPAGE 
loading buffer (LDS, Invitrogen) brought to 1x concentration with PNK buffer and 
containing reducing agent for Ago CLIP.  The beads were incubated in the Thermomixer 
R at 70°C for 10min shaking at 1000 rpm.  Supernatants were taken off the beads and run 
on Novex NuPAGE 10% Bis-Tris gels for HuR and 8% for Ago (Invitrogen) in MOPS 
running buffer (Invitrogen) for 2 hr at 175V and transferred to Protran BA85 
nitrocellulose (Whatman) using a Novex wet transfer apparatus (Invitrogen). After 
transfer, the nitrocellulose was quickly rinsed with RNase-free PBS, blotted with 
Kimwipes, wrapped in plastic wrap and exposed to Biomax MR film (Kodak). 
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Recovery of Complexes, Protease Digestion, and 5’ Linker Ligation 
Nitrocellulose membranes were aligned carefully with the exposed film and filter excised 
fro the low RNase immunoprecipitation lanes at a size directly above the overdigested 
band as indicated in Figure 4.3 and Figure 5.2 with a scalpel.  Each band of nitrocellulose 
membrane was further cut into smaller pieces and proteinase K treated (0.2 ml of a 1:5 
dilution of proteinase K (4 mg/ml, Roche) in PK buffer (100 mM Tris-Cl pH 7.5, 50 mM 
NaCl, 10 mM EDTA)) in the Thermomixer R at 37°C, shaking at 1100 rpm for 20 
minutes.  Then 0.2 ml of PK buffer with 7M urea solution was added and incubated for 
another 20 minutes at 37°C shaking at 1100 rpm. Finally, 0.4 ml of RNA phenol (pH 6.8, 
Applied Biosystems/Ambion) and 0.13 ml of 49:1 CHCl3:isoamyl alcohol were added 
and incubated at 37°C, shaking at 1100 rpm for additional 20 min.  Tubes were spun at 
20,000g in a desktop microcentrifuge at room temperature.  Glycogen (0.8 ul, Applied 
Biosystems/Ambion), 50 ul 3M NaOAc pH 5.2, and 1 ml of 1:1 ethanol:isopropanol were 
added to the aqueous phase in a fresh tube and RNA was precipitated overnight at -20°C.  
RNA was pelleted, washed twice with 75% ethanol.  The pellet dried and dissolved in 6 
ul RNase-free H2O. RNA ligation to add the 5’ linker (RL5D: 5’-OH-
AGGGAGGACGAUGCGGr(N)r(N)r(N)r(N)G3’-OH) was performed with 1 µl 10X T4 
RNA ligase buffer (Fermentas), 1 µl BSA (0.2 µg/µl), 1 µl ATP (10mM), 0.1 µl T4 RNA 
ligase (3U, Fermentas), and 20 pmol of RL5D RNA linker in a total volume of 10 µl in 
the Thermomixer R at 16°C for 5 hrs.  To the ligation reaction, 79 µl H2O, 11 µl 10X 
RQ1 DNase buffer, 5 µl RQ1 DNase (Promega) and 5 ul RNasin (Promega) were added 
and incubated at 37°C for 20 min.  300 µl H2O, 300 µl RNA phenol (Ambion) and 100 µl 
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CHCl3 were added, vortexed, spun and the aqueous layer taken.  RNA was precipitated 
with 50 ul 3M NaOAc pH 5.2, 0.5 µl glycogen (Ambion) and 1 ml 1:1 
ethanol:isopropanol overnight at -20°C. 
RT-PCR and High-Throughput Sequencing of PCR Products 
RNA was pelleted, washed, dried as before, and resuspended in 10 µl of RNase-free H2O.  
2 µl of resuspended RNA was used as a –RT control and was brought to the same volume.  
The RNA was mixed with 2 µl of primer P32 (3’ DNA primer 32, 5’- 
CTTCACTCACCTCGCAACCG-3’, Operon) at 5 pmol/µl, and 3 µl 3mM dNTPs, and 
incubated at 65°C for 5 min in the Thermomixer R, chilled, and spun briefly.  1 µl 0.1M 
DTT, 4 µl 5X SuperScript RT buffer, 1 µl RNasin, and 1 µl SuperScript III (Invitrogen) 
were added and incubated at 50°C for 45 minuntes, 55°C for 15 minutes, 90°C for 5 
mininutes and then moved onto ice.  PCR reactions were performed immediately with 27 
µl Accuprime Pfx Supermix (Invitrogen), 0.75 µl P51 (5’ DNA primer 51, 5’- 
AGGGAGGACGATGCGG-3’, Operon) at 20 pmol/µl, 0.75 µl P32 primer, 20 pmol/ul 
and 2 µl of the RT reaction, incubated at 95°C for 2 minutes and then cycled for 20-35 
cycles using a program of 95°C for 20 seconds, 58°C for 30 seconds, and 68°C for 30 
seconds.  A 10% denaturing polyacrylamide was poured and the entire PCR reaction was 
loaded along with 3 µl of Amplisize Molecular Ruler (Biorad).  To visualize DNA, the 
gel was immersed in a 1:10,000-fold dilution of SYBR Gold (Molecular Probes) in TBE 
for 10 minutes.  Routinely, aliquots of the reaction were removed at various cycle 
numbers and product excised from the lowest cycle number giving visible product.  
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Remaining RT reaction was then brought up to this minimal cycle number, gel purified 
and the products were pooled with the smaller reactions.  Acrylamide bands containing 
DNA of 60-100nts were excised and DNA purified by crushing in diffusion buffer (0.5M 
ammonium acetate, 10mM Mg acetate, 1mM EDTA, 0.1% SDS), incubating at 50°C for 
30 min at 1200 rpm, and filtering through Whatman GF/D filters in Nanosep columns 
(VWR). DNA was recovered from filtrate using Qiaquick gel purification buffers and 
columns (Qiagen) and eluted in 30 µl TE. An additional PCR reaction was performed 
using the following fusion primers to permit sequencing on the Illumina platform. 
SP5fusion: 
5’AATGATACGGCGACCACCGACTATGGATACTTAGTCAGGGAGGACGATGC
GG3’ 
SP3fusion: 
5’CAAGCAGAAGACGGCATACGACCGCTGGAAGTGACTGACAC3’ 
PCR amplification was performed using Accuprime Pfx (Invitrogen) and ranged between 
6 and 12 cycles. The product was then run on a 2% NuSieve agarose gel and purified 
using Qiaquick spin columns (Qiagen). A total of 10-30 µl of DNA (quantified using the 
Quant-IT kit (Invitrogen)) at 10 nM was submitted for sequencing. The sequencing of 
CLIP tags was performed using the sequencing primer SSP1 on an Illumina HiSeq. 
SSP1:  
5’CTATGGATACTTAGTCAGGGAGGACGATGCGG3’  
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Data analysis was done using the Galaxy platform (Hillman-Jackson et al. 2012) and 
using R Statistical Analysis Software (http://www.R-project.org). 
Preparation of samples for RNA Sequencing analysis 
RNA was prepared from CD8 T cells using the High Pure RNA extraction kit (Roche) as 
per manufacturer’s instructions and the standard Illumina TruSeq protocol was followed 
to prepare samples for high-throughput sequencing. 
Ribosomal Profiling and mRNA Sequencing 
T cell Lysate Preparation and Sucrose Gradients 
CD8 T cells were treated for 8 minutes with 100 µg/ml cycloheximide at 37°C.  Treated 
cells were harvested and collected by centrifugation.  Lysates were prepared in Lysis 
Buffer (10 mM Tirs-HCl, pH 7.4, 5 mM MgCl2, 100 mM KCl), which was supplemented 
freshly before lysis with 1% Triton X-100, 2 mM DTT, 100 µg/ml cycloheximide, 500 
U/ml RNasin Plus (Promega), and complete protease inhibitor mini EDTA free tablets (1 
tablet/10 ml buffer) (Roche).  The lysate in a volume of 600 µl was homogenized gently 
four times with a 26-gauge needle at 4°C.  The lysate was then clarified by centrifugation 
at 14,000 rpm for 10 minutes on a desktop microcentrifuge at 4°C.  The supernatant was 
collect and 6 µl 10 mM CaCl2 was added to a final concentration of 1 mM.  1000 U/ml 
micrococcal nuclease was added to T cell lysate and was incubated rotating at room 
temperature for 25 minutes.  9.6 µl 0.5 M EGTA was added and the lysate volume was 
adjusted to 1.1 ml with lysis buffer for layering on sucrose.   
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Equal volumes of supernatants were loaded onto a 10%–50% w/v linear density gradient 
of sucrose in Lysis Buffer without the added supplements and prepared using a Gradient 
Master 107 (BioComp), in 14x3x89 mm polyallomer ultracentrifuge tubes (Beckman 
331372). Gradients were centrifuged at 35,000 rpm for 3 hours at 4°C in a Beckman 
SW41 rotor and sixteen fractions of 0.72 ml volume were collected with continuous 
monitoring at 254 nm using an ISCO UA-6 UV detector. 
Isolation of Ribosomal Protected Fragment RNA 
The pooled material from sucrose fractions 6-8 was spun through Ultra-4 centrifugal 
filters with Ultracel-100 membranes (Amicon) at 1900g for 30 minutes at 4°C.  1.2 ml 
ice-cold Release Buffer (20 mM HEPES-KOH, 100 mM KCl, 1 mM EDTA, 2 mM DTT, 
20 U/ml SUPERaseIn (Ambion)) was added to the membrane and incubated on ice for 10 
minutes.  The filters were then spun again at 1900g for 15 minutes at 4°C with a new 15 
ml collection tube.  The filtrate was supplemented with SDS to 1% and treated with 
proteinase K (200 µg/ml) for 30 minutes at 42°C.  The RNA was extracted by acid 
phenol:chloroform (pH 4.5, Ambion) with 360 µl Phenol, 120 µl 49:1 CHCl3:isoamyl 
alcohol.  The samples were vortexed and the aqueous layer was separated by spinning at 
14,000 rpm in a desktop microcentrifuge for 10 minutes at room temperature.  The 
aqueous layer (~400 µl) was supplemented with 40 µl 3M NaOAc pH 5.5, 1 µl Glycogen, 
and 1 ml 100% EtOH.  The solution was inverted and left at -20°C overnight for the 
RNA to precipitate. 
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Isolation of Poly-A RNA and Partial Alkaline Hydrolysis 
Matching aliquots of CD8 T cells also treated with cycloheximide as described above 
were resuspended in 1 ml Trizol and the RNA was chloroform extracted with 200 µl 49:1 
CHCl3:isoamyl alcohol.  The solution was mixed and incubated for 3 minutes at room 
temperature followed by centrifugation at 14,000 rpm in a desktop microcentrifuge for 15 
minutes at room temperature.  The aqueous layer was transferred to a new tube and 
supplemented with 1 µl Glycogen and 500 µl Isopropanol.  The RNA was precipitated at 
-20°C for 2 hours.  The RNA was pelleted by centrifugation at 14,000 rpm in a desktop 
microcentrifuge for 20 minutes at 4°C.  RNA pellets were washed twice with 80% EtOH 
and then air dried for 10 minutes on the bench top.  RNA was resuspended in 30 µl H2O 
and heated at 65°C for 2 minutes and placed on ice.  The Dynabeads mRNA Purification 
Kit (Invitrogen) was used to select for poly-A RNA as per manufacturers instructions 
using (145 µl Oligo (dT)25 beads per RNA sample from 25x106 T cells).  Poly-A selected 
RNA was eluted from the beads in 75 µl PBS heated at 80°C for 2 minutes and 
transferred to a new tube.  3.75 µl 1M NaOH was added to the sample, mixed well and 
spun down.  It was then incubated at 37°C for 30 minutes to fragment RNA shaking 15 
seconds at 1250 rpm every 1.5 minutes in the Thermomixer R.  3.75 µl 1M HCl was 
added to quench the base and 0.825 µl 1M HEPES added to buffer the solution.  1 µl 
Glycogen was added followed by 1 ml 100% EtOH.  The solution was inverted and left at 
-20°C overnight for the RNA to precipitate. 
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PNK Treatment and Size Selection 
Both the ribosomal protected fragment (RPF) and alkaline hydrolyzed poly-A selected 
(mRNA) were pelleted by centrifugation at 14,000 rpm in a desktop microcentrifuge for 
20 minutes at 4°C.  RNA pellets were washed twice with 80% EtOH and then air dried 
for 10 minutes on the bench top.  RNA was resuspended in 30 µl H2O supplemented.  To 
rephosphorylate the 5’ end of the RNA, the RNA was treated with PNK (4 µl PNK 
enzyme, 2 µl SUPERasin, 4 µl PNK Buffer) for 1 hour at 37°C, 75°C for 10 minutes and 
then moved to ice.  20% polyacrylamide Urea gel was poured and the entire RNA sample 
was loaded along with microRNA marker (New England Biolabs, N2102S), low range 
ssRNA Ladder (New England Biolabs, N0364S), and RNA 32-mer oligonucleotide (also 
PNK treated to match running conditions of sample).  To visualize RNA, the gel was 
immersed in a 1:10,000-fold dilution of SYBR Gold (Molecular Probes) in TBE for 10 
minutes.  Gel fragments were cut from gel at ~35 nucleotides for RPFs and between ~35-
55 nucleotides for mRNA, as indicated in Figure 7.8.  400 µl RNA gel Extraction Buffer 
(300 mM NaOAc, 1 mM EDTA, 0.1 U/ml SUPERasin) was added to each gel slice 
which was crushed in buffer with the plunger of a 1 ml syringe.  Crushed slices were then 
frozen on dry ice for 30 minutes to help dissociation.  The crushed gel was then rotated in 
buffer overnight at 4°C after which the RNA solution was filtered through Whatman 
GF/D filters in Nanosep columns (VWR).  2 µl Glycogen was added and 1 ml EtOH was 
used to precipitate RNA at -20°C for at least 2 hours or overnight.   
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Poly-A Tailing Reaction 
Protein-G Dynabeads were prepared by washing three times in Antibody Binding Buffer 
(ABB) (1X PBS, pH 7.4 with 0.02% Tween-20).  Beads were resuspended in 225 µl/50 
µl beads ABB with 25 µl/50 µl beads Denhardt’s Solution (Sigma).  The beads were 
blocked rotating at room temperature for 45 minutes to 1 hour.  RNA was pelleted by 
centrifugation at 14,000 rpm in a desktop microcentrifuge for 20 minutes at 4°C.  RNA 
pellets were washed twice with 80% EtOH and then air dried for 10 minutes on the bench 
top.  6.25 µl H2O was added to RNA pellet and it was left on ice to go into solution aided 
by tapping of the tube and then the material was spun down.  RNA was denatured at 
65°C for 5 minutes and then placed immediately on ice.  RNA was added to a reaction 
poly-A tail reaction mixture of 1 µl 10X E-PAP Buffer (NEB), 1.5 µl 1 mM ATP, 1.5 µl 
RNAsin Plus (Promega), and 1 µl 3U/µl E-PAP (NEB) in a PCR tube.  The RNA was 
polyadenylated at 37°C for 10 minutes, 65°C  for 20 minutes, and then moved to ice.   
Reverse Transcription Reaction 
Protein-G Dynabeads blocking in ABB and Denhardt’s Solution were washed 3 times 
with ABB.  For 250 µl original bead volume, we added 100 µl ABB, 25 µl Denhardt’s 
Solution, 125 µl anti-BrdU antibody (Santa Cruz, sc-32323) and rotated at room 
temperature for a minimum of 45 minutes.  The poly-A tailed RNA was spun down and 
2.5 µl of each sample was pooled together for a final volume of 10 µl for –RT control.  
The RNA was supplemented with 1 µl H2O, 1 µl 0.752 M Tris, 1 µl each of dATP, dCTP, 
dGTP (8.2 mM, Invitrogen) and 1 µl Br-dUTP (8.2 mM, Sigma).  1 µl of 25 µM primers 
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was added to each tube (NV20T-RT1 for RPF samples and NV20T-RT 2 for mRNA 
samples) and 0.5 µl of each were added to the –RT control.   
NV20T-RT1: 
5’pGACATCGTNNNNNNGATCGTCGGACTGTAGAACTCT/idSp/CAAGCAGAAG
ACGGCATACGATTTTTTTTTTTTTTTTTTTTVN  
NV20T-RT2: 
5’pGCACTGTTNNNNNNGATCGTCGGACTGTAGAACTCT/idSp/CAAGCAGAAG 
ACGGCATACGATTTTTTTTTTTTTTTTTTTTVN  
The samples were quickly spun down and incubated at 75°C for 3 minutes.  A pre-
warmed mixture of 1 µl 82 mM DTT, 1 µl 10U/µl RNAsin Plus (Promega) and 1 µl 
Superscript III (or H2O for –RT control) were added to each sample and the reverse 
transcription reaction was incubated at 48°C for 45 minutes, 55°C for 15 minutes, 85°C 
for 5 minutes and then moved to ice. 
cDNA Purification: Immunoprecipitation I 
Protein-G Dynabeads labeled with anti-BrdU antibody were washed three times in IP 
Buffer (0.3x SSPE, 1mM EDTA, 0.5% Tween-20).  1 µl 2U/µl RNase H (Invitrogen) 
was added to each reverse transcription reaction and incubated at 37°C for 20 minutes to 
digest RNA and then placed on ice.  10 µl H2O was added to the reaction and then it was 
spun through a G-25 column (Amersham) to remove free nucleotides.  The flow through 
was adjusted to a final volume of 100 µl with H2O and then incubated at 70°C for 5 
minutes and at room temperature for 2 minutes.  25 µl of original slurry volume of 
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Protein-G beads in 100 µl IP Buffer was added to fresh tubes and the supernatant was 
removed.  cDNA was added to the beads and the beads were resuspended by tapping, 
trying to keep everything at the bottom of the tube.  Beads were rotated for 30 minutes at 
room temperature to immunoprecipitate the cDNA via the incorporated Br-dUTP.  The 
beads were then washed with 900 µl of each buffer for 3 minutes at room temperature.  
First, they were washed once with IP Buffer with Denhardt’s (4.5 ml IP Buffer/0.5 ml 
Denhardt’s), then twice with low salt buffer (15 mM Tris- HCl, pH 7.5, 5 mM EDTA) 
with 2% Denhardt’s, twice with high stringency buffer (15 mM Tris-HCl, pH 7.5, 5 mM 
EDTA, 2.5 mM EGTA, 1% Triton X-100, 1% Na-deoxycholate (DOC), 0.1% SDS, 120 
mM NaCl, 25 mM KCl) with 2% Denhardt’s, and twice with IP Buffer without 
Denhardt’s.  The last wash was completely removed from the beads and 50 µl 100 µM 
BrdU (Sigma) in IP Buffer was added to competitively elute the cDNA off of the beads.  
Beads were resuspended in solution by tapping and rotated for 30 minutes at room 
temperature.  The beads were placed on the magnet and the eluate was collected and spun 
through a G-25 column.  The flow through was adjusted to 150 µl total volume with H2O.  
This cDNA solution was stored overnight at 4°C. 
cDNA Purification: Immunoprecipitation II 
After leaving the samples overnight, the immunoprecipitation was repeated.  The cDNA 
solution was quickly vortexed and spun down.  It was incubated at 70°C for 5 minutes 
and at room temperature for 2 minutes.  25 µl of original slurry volume of Protein-G 
beads in 100 µl IP Buffer was added to fresh tubes and the supernatant was removed.  
cDNA was added to the beads and the beads were resuspended by tapping, trying to keep 
49
everything at the bottom of the tube.  Beads were rotated for 30 minutes at room 
temperature to immunoprecipitate the cDNA via the incorporated Br-dUTP.  The beads 
were then washed with 900 µl of each buffer for 3 minutes at room temperature.  First, 
they were washed once with IP Buffer with 10% Denhardt’s, twice with low salt buffer 
with 2% Denhardt’s, twice with high stringency buffer with 2% Denhardt’s, and twice 
with IP Buffer without Denhardt’s.  The last wash was completely removed from the 
beads. 
cDNA Circularization and Relinearization 
20 µl CircLigase reaction mixture (2 µl CircLigase 10X Reaction buffer, 4 µl 5 M 
Betaine, 1 µl 50 mM MnCl2, 0.5 µl (50U) CircLigase ssDNA Ligase II (Epicentre), and 
12.5 µl H2O) was added to the beads which were tapped into solution.  This reaction was 
incubated at 60°C for 1 hour in the Thermomixer R to circularize the cDNA.  The beads 
were collected and washed twice in low salt buffer with 2% Denhardt’s, twice with high 
stringency buffer with 2% Denhardt’s, and twice with APE1 wash buffer (50 mM 
Potassium Acetate, 20 mM Tris-Acetate, 10 mM Magnesium Acetate, pH 7.9).  The last 
wash was removed from the beads completely and the cDNA was relinearized using an 
APE1 cut site with 2 µl 10X Reaction Buffer (NEB4), 1.25 µl 10U/µl APE1 (NEB), and 
16.75 µl H2O.  This reaction was incubated for 1 hour at 37°C  in Thermomixer R 
shaking at 1300 rpm for 15 seconds every 30 seconds.  The beads were again washed 
twice in low salt buffer with 2% Denhardt’s, twice with high stringency buffer with 2% 
Denhardt’s, and twice in Phusion Wash Buffer (50 mM Tris pH 8.0).   
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PCR Amplification and High-Throughput Sequencing 
To amplify the cDNA, PCR was done with Phusion Polymerase.  First, 37.5 µl H2O, 10 
µl 5X Phusion HF Buffer, and 1 µl 10 mM dNTPs wre added to the beads.  This was 
incubated at 98°C  for one minute shaking at 1200 rpm in the Thermomixer R to elute the 
cDNA from the beads.  This was quickly placed on the magnet and the eluate was 
collected to a a PCR tube with an optically clear cap.  This solution was supplemented 
with PCR primers and DNA polymerase (0.5 µl 20 µM DP5 PAT, 0.5 µl 20 µM DP3 
PAT, and 0.5 µl Phusion DNA Polymerase (NEB).  SYBR Green I was diluted from 
10,000X to 50X in Phusion Wash buffer and 0.5 µl was added to the PCR reaction and 
mixed by pipetting.  Tubes were placed in the iQ5 Multicolor Real-Time PCR Detection 
System (Biorad) and pushed in place using a Kimwipe so as not to touch the lid.  The 
tubes were incubated at 98°C for 30 seconds and then cycled at 98°C for 10 seconds, 
60°C for 15 seconds, and 72°C for 20 seconds until the RFU signal reached ~800-1000.  
Note that the display is a cycle behind the detection so the tubes need to be removed 
when the display signals ~400-500 to account for doubling.  10 nM solution was 
submitted for sequencing and data analysis was done using the Galaxy platform 
(Hillman-Jackson et al. 2012) and using R Statistical Analysis Software (http://www.R-
project.org). 
DP5 PAT: 
5’-AATGATACGGCGACCACCGACAGGTTCAGAGTTCTACAGTCCGACG 
DP3 PAT: 
5'-CAAGCAGAAGACGGCATACGA  
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Illumina Small RNA Sequencing Primer: 
5’ -CGACAGGTTCAGAGTTCTACAGTCCGACGATC  
Mice 
Wild-type C57BL/6 mice (stock number 000664), Lck-Cre mice (stock number 003802), 
and A2.1 transgenic AAD mice (stock number 003475) were purchased from The 
Jackson Laboratory.  CD4-Cre mice (stock number 4196-F/M) were purchased from 
Taconic Farms.  HuRfl/fl mice were obtained from Dr. Dimitris Kontoyiannis (Katsanou et 
al. 2009).  HuD knock out mice were obtained from Dr. Hideyuki Okano (Akamatsu et al. 
2005).  
Ocular Blood Draw 
Mouse peripheral blood was obtained by ocular blood draw with heparinized capillary 
tubes.  5 drops were taken into 10 milliliters PBS. 
Flow Cytometry Intracellular Staining 
For intracellular staining, cells were incubated for 20 minutes at 4°C in the 
Fixation/Permeabilization solution from the Cytofix/Cytoperm kit (BD Biosciences).  
Cells were then permeabilized by washing in the BD Perm/Wash Buffer (PWB).  Cells 
were stained in PWB with the indicated primary antibodies, for example HuR specific 
mouse monoclonal antibody 3A2, for 1 hour rocking on ice and covered in foil.  Cells 
were washed twice and then incubated with anti-mouse IgG (Fc-specific) polyclonal goat 
F(ab')2 fragment conjugated with DyLight 649 (Jackson Immunoresearch) at a dilution of 
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1:1000 in PWB for 30 minutes rocking on ice and covered in foil.  After this incubation, 
cells were washed twice in PWB and once in FACS Buffer.  Cells were collected 
immediately on a BD FACScaliber machine and analyzed using Flowjo software 
(Treestar). 
Single Linker Ligation CLIP  
This protocol was used for Ago CLIP in HuR Wild-Type and cKO Mice.  Samples were 
prepared as described in the standard CLIP methods starting with T cell lysate 
preparation through the recovery of protein-RNA complexes and protease digestion, 
except that a different 3’ linker sequence was used which matches the Illumina small 
RNA sequencing primer. 
SRA3: 
5'-P UCGUAUGCCGUCUUCUGCUUG 3'-puromycin  
No 5’ linker ligation is used in this protocol and instead it follows the same cloning 
strategy as detailed in the ribosomal profiling and mRNA sequencing methods section 
starting at the reverse transcription step.  The only modifications from the ribosomal 
profiling methods are that different reverse transcription primers were used matching the 
3’ linker sequence instead of the stretch of poly-A’s and it was indexed as indicated for 
each sample.  The PCR and sequencing primers were the same as for ribosomal profiling 
and mRNA sequencing. 
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Index 1a GCAT: 
5’pGNNNNNNNNGATGCGATCGTCGGACTGTAGAACTCT/idSp/CAAGCAGAAG
ACGGCATACGA  
Index 2a GTCA: 
5’pGNNNNNNNNGTGACGATCGTCGGACTGTAGAACTCT/idSp/CAAGCAGAAG
ACGGCATACGA  
Index 3a ACTG: 
5’pGNNNNNNNNGCAGTGATCGTCGGACTGTAGAACTCT/idSp/CAAGCAGAAG
ACGGCATACGA  
Index 4a AGCT: 
5’pGNNNNNNNNGAGCTGATCGTCGGACTGTAGAACTCT/idSp/CAAGCAGAAG
ACGGCATACGA  
Index 6a TCGA: 
5’pGNNNNNNNNGTCGAGATCGTCGGACTGTAGAACTCT/idSp/CAAGCAGAAG
ACGGCATACGA  
 
Adenovirus production 
Recombinant adenoviruses expressing GFP, β-galactosidase, or HuD-GFP were produced 
by transduction of HEK293 cells (ATCC) and purified using the Adenopure Kit 
(Puresyn) according to the manufacturer’s instructions.  Viral titers were assessed by 
infection of HEK293 cells with serial dilutions of purified virus followed by 
determination of the number of virally infected cells after 20 hours by fluorescence or X-
Gal staining. 
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Adenovirus Immunizations 
6-8 week old mice were injected with 100 µl purified adenovirus (109 PFU/ml) 
intradermally and treated with pertussis toxin (Sigma) intraperitoneally at days 0 and 2.  
Mouse T cell in vitro Stimulation 
Around 3x107 splenocytes, or half a spleen per flask, from adenovirus-immunized mice 
were incubated at 37°C in upright T25 culture flasks (Corning) in R10 with 0.5 µM 
peptide for 7 days. For further rounds of re-stimulation, splenocytes were plated in 24 
well plates (2-6x105 splenocytes per well) with peptide-pulsed feeder cells in R10 with 50 
CU/ml recombinant human IL-2 (Chiron).  Feeder cells were prepared from spleens of 
naïve syngeneic mice by pulsing with 0.5 µM peptide for 1 hour at room temperature and 
irradiating at 3,000 Rads before plating. 
T cell Receptor Codon Optimization, Synthesis, and Cloning 
Sequences of previously cloned T cell receptors were codon optimized and synthesized 
by GeneArt (Santomasso et al. 2007).  Synthesized constructs contained restriction sites 
for insertion into pGEM4Z/GFP/A64 vector kindly provided by Dr. Eli Gilboa 
(Boczkowski et al. 1996). 
In vitro Transcription of RNA for Electroporation 
mRNA encoding GFP from pEGFP-N1 (Clontech) and mRNAs encoding TCR α and β 
chains were prepared from PCR products made using gene specific primer pairs 
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containing the T7 RNA polymerase promoter sequence. mMESSAGE mMACHINE High 
Yield Capped RNA transcription Kit (Ambion Inc. Austin, TX) was used to in vitro 
transcribe RNA according to the manufacturer’s instructions.  The RNA was then 
purified using an RNeasy Mini Kit (Qiagen) and purified RNA was resuspended in 
RNase free water at 1-3 mg/ml.   
Electroporation of in vitro transcribed RNA 
One vial of 108 PBMC was thawed into 100 ml of complete Stemline medium (CSM) 
(Stemline T cell Expansion Medium (Sigma) supplemented with 5% FBS (Hyclone), 
Glutamax (Invitrogen), and gentamycin).  Upon thawing, PBMC were stimulated with 
IL-2 (300 IU/ml, Chiron Corp) with 50 ng/ml OKT3 for 3 to 4 days.  After stimulation, 
CD8 T cells were isolated by positive selection. The purified CD8+ T cells were cultured 
in CSM with 300 IU/ml IL-2 without OKT3 for 10-17 days for expansion before 
electroporation and kept at a concentration of 106/ml.  The stimulated CD8 lymphocytes 
were resuspended in OPTI-MEM (Invitrogen) medium at a final concentration of 25x106 
cells/ml.  Cells and cuvettes were pre-chilled on ice for at least five minutes before 
electroporation.  Lymphocytes were mixed at a concentration of 2 µg in vitro transcribed 
RNA per 1x106 lymphocytes and electroporated in a 2 mm gap cuvette using an ECM830 
Electro Square Wave Porator (Harvard Apparatus BTX) at 500 Volts/500 μs. Warm 
media was added immediately to the cuvette and cells were transferred to fresh CSM with 
no IL-2 or OKT3 and rested for at least 6 hours.   
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Tetramer Staining 
Human cells were stained in Human FACS buffer (PBS supplemented with 1% FBS 
(Hyclone), and 1% PHS).  Mouse T cells were incubated for 10 minutes using 1 µg of 
anti-CD16/CD32 (FcγRII/III) in Mouse FACS buffer (the same as for human cells but 
also supplemented with %5 goat serum).  For tetramer staining, 105-106 human cells were 
incubated with 1:20 dilution of tetramer for 20 minutes at room temperature in the dark.  
Antibody to CD8 was then added for an additional 10 minutes.  The cells were then 
washed twice in FACS buffer and collected immediately on a BD FACScaliber and 
analyzed using Flowjo software (Treestar). 
Primary Ascites Cultures 
Received freshly isolated ascited fluid in sterile containers from the operating room.  The 
fluid was incubated with an equal volume of Growth Medium in a flask at 37°C with 5% 
CO2 and not disturbed for 3-4 days.  After this incubation period, the media was changed 
every 2-3 days until the flasks were confluent, which was typically between 7-10 days.  
To passage cells, the adherent cells were washed once in PBS and then trypsinized using 
a minimal volume of 0.06% w/v trypsin/EDTA (Cellgro) for 2-3 minutes at 37°C.  
Growth medium was then added to the disrupted cells and transferred to two new flasks.  
Stocks of ascites cells were frozen in RPMI (Mediatech) supplemented with 10% human 
serum albumin, and 10% DMSO (Sigma-Aldrich). 
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Preparation of Primary Murine Kidney Epithelial Cells (KECs) 
Kidneys from adult mice were mashed using the back of a syringe and pipetted until a 
single cell suspension was obtained. The cell suspension was passed over a 70 µm cell 
strainer and washed in D10 medium before plating in 10 cm dishes.  Cultures were fed by 
replacing D-0 on days 4 and 7.  On day 7, recombinant mouse IFNG (R&D Systems) was 
added at 10 units/ml medium. On day 8, 10 µl recombinant adenovirus at 109 PFU/ml 
was added to each cell culture dish and the cells were harvested on day 9 for use in an 
IFNG ELISPOT assay. 
Cell Lines 
T2 cells are a human lymphoblast cell line deficient in TAP function containing abundant 
HLA-A2 molecules on the cell surface that can be loaded with exogenous peptide (Salter, 
Howell, and Cresswell 1985).  EL4 cells are a murine lymphoblast cell line.  Other cell 
lines used include: Adenovirus (Ad)-5 transformed cell line HEK293 (CRC 1573; 
ATCC), the cervical carcinoma cell line HeLa (CCL- 2, ATTC), the ovarian carcinoma 
cell line COV413 provided by Dr. Victor Engelhard.  For IFNG treatments, recombinant 
mouse IFNG (R&D Systems) was added at 10 units/ml medium for 48 hours prior to use 
in assay. 
Peptides 
All peptides for cdr2, HuD, β-gal and Ova were purchased from American Peptide 
Company. 
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Tumor Killing Assay 
T cells were resuspended at 1x106 cells/ml and target cells were resuspended at 1x105 
cells/ml.  1 ml of T cells and target cells were plated together in a 6-well dish.  The cells 
were co-cultured overnight.  Cells were then harvested and TO-PRO 3 Iodide 
(Invitrogen) was used to stain dead cells as per manufacturer’s instructions.  Blank 
calibration beads (BD Biosciences) were added to the tube before flow cytometry 
collection to normalize acquisition between samples.  Cells were collected immediately 
on a BD FACScaliber and analyzed using Flowjo software (Treestar). 
Murine and Human IFNG ELISPOT Assays 
Enzyme-linked immunospot (ELISPOT) assay was used to quantify the number of 
antigen-specific IFNG producing lymphocytes in response to different target cells. 
Briefly, nitrocellulose-bottomed 96-well plates (MultiScreen HA, Millipore) were coated 
overnight at 4°C with anti-IFNG monoclonal antibody (clone AN18 at 5 μg/ml for mouse, 
clone 1-DIK at 10 μg/ml for human; both from Mabtech).  Wells were washed three 
times with PBS and blocked for 2 hours with R10 medium at 37°C.  For direct ex vivo 
mouse ELISPOTs, CD8 T cells were isolated by positive selection from spleens using 
MACS purification (Miltenyi Biotec) and 2x105 CD8 T cells were co-cultured with 5x104 
target cells. For ELISPOTs with T cell clones or otherwise in vitro stimulated cells, 1x104 
CD8 T cells were cocultured with 5x104 target cells. For human ELISPOTs with RNA 
electroporated human lymphocytes, 1x105 CD8 T cells were co-cultured with 5x104 
target cells.  All co-culture conditions were performed in triplicate wells.  After 
incubation for 20 hours at 37°C, the plates were washed 6 times with PBS supplemented 
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with 0.05% Tween-20.  Biotinylated IFN-γ mAb (clone R4-6A2 for mouse, Pharmingen; 
clone 7-B6-1 for human, Mabtech), the conjugate (avidin-peroxidase complex; 
Vectastain avidin-biotin complex method Elite Kit; Vector Laboratories) and AEC 
substrate (Sigma) were then used for spot development according to the manufacturer’s 
instructions.  After development, red spots on the membrane represent IFNG released by 
individual T cells and are reported as spot- forming-cells per 106 cells. The ELIPSOT 
plate quantification was performed in a blinded fashion by an independent evaluation 
service (Zellnet Consulting) using an automated ELISPOT reader (Carl Zeiss) with KS 
Elispot 4.8 software. 
CD107a assay 
105 tumor cells were placed into one well of a 24-well plate along with an equal number 
of TCR-electoporated or mock-electroporated CD8+ T cells in a total volume of 1 
milliliter R10.  20 µl of FITC-conjugated CD107a antibody and 1 μl of GolgiStop 
(Beckton Dickenson, San Jose, CA) were added to the well according to the 
manufacturer’s instructions. The co-culture was incubated for 4 h at 37°C followed by 
washing and flow cytometry. 
HuD peptide 321 specific CD8 T cell Cloning 
6-8 week old mice were injected with 100 µl purified adenovirus-HuD at 109 PFU/ml 
intradermally and treated with pertussis toxin (Sigma) intraperitoneally at days 0 and 2.  
On day 13 spleens were removed.  The red blood cells were lysed with ACK buffer 
(Biofluids) and splenocytes were plated for in vitro stimulation as described.  CD8 
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isolated T cells from IVS cultures were plated in an entire 96 well plate at a concentration 
of 3, 1 and 0.3 cells per well with 5x106 HuD peptide 321 pulsed irradiated feeder cells 
and 10 U/ml recombinant human IL-2 (Chiron) in a final volume of 200 µl R10.  After 
one week, plates with less than 33% positive wells were expanded by transferring each 
well into a separate well of a 24-well plate containing 106 HuD peptide 321 pulsed 
irradiated splenocytes and 10 U/ml recombinant human IL-2 in a final volume of 1 ml. 
Clones were maintained by weekly stimulations with irradiated feeders and expanded 6 
fold.  Adapted from (Galfrè and Milstein 1981).     
In Vitro CTL Chromium Release Assay 
For target cell preparation, 106 EL4 cells in 100 µl R10 were labeled with 10 µM peptide 
plus 100uCi 51Cr for 1 hour at 37°C, shaking every 10 minutes.  EL4 cells were then 
washed 3 times in 1 ml R10 and resuspended at 105/ml.  5x103 EL4 cells were plated per 
well in a round bottom plate with serial dilutions of T cells.  Plates were spun at 300 rpm 
for 5 minutes to sediment cells and incubated at 37°C for 4.5 hours. To harvest and 
measure radioactivity from the CTL assay, 100ul of supernatant from each well was 
pipetted into a sample plate for gamma measurement with 100 µl gamma scintillation 
fluid. 
Titermax Immunization 
C57BL/6 mice were injected in the footpad with a single peptide emulsified in Titermax 
adjuvant. To form the peptide emulsion, 75 µl of peptide at 10 mg/ml in 50% DMSO was 
added to 75ul ddH2O.  This solution was then added to a sterile eppendorf tube 
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containing 150ul Titermax adjuvant.  The tube was then vortexed for 30 minutes on high 
to form an emulsion of Titermax and peptide.  The peptide emulsion was drawn into an 
insulin syringe and 50 µl (approximately 125 µg of peptide) was injected per animal.  
After 7 days, the animal was sacrificed and the right popliteal and inguinal lymph nodes 
were removed. Lymph nodes were ground between two sterile frosted glass slides to 
obtain a single cell suspension.  
Bone Marrow Chimeras 
Bone marrow recipient mice were given two doses of 450 Rads whole body gamma-
irradiation to sub-lethally deplete bone marrow.  Bone marrow was collected from donor 
mice by extracting cells from the tibia and femur.  Red blood cells were lysed with ACK 
buffer (Biofluids) and the bone marrow cells were depleted of CD90.2 positive mature 
lymphocytes by MACS selection.  5x106 bone marrow cells were transferred into the 
irradiated hosts in the retro-orbital cavity and then were left to rest for two months to 
allow for bone marrow reconstitution before challenge.  
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CHAPTER 3.  The Efficiency and Activation of Purified Lymphocytes  
Using Different Isolation Techniques 
Introduction 
Cluster of differentiation eight (CD8) T cells are circulating lymphocytes that monitor 
and selectively kill infected, transformed, or damaged cells.  Generally, in virtually all 
cells, intracellular proteins are presented as peptides extracellularly to the immune system 
in major histocompatibility complex (MHC) I molecule complexes.  Each T cell 
expresses a unique T cell receptor that can bind a particular peptide-MHC complex.  In 
this way, T cells can initiate an immune response in an epitope and MHC-restricted 
manner.  Typically, non-self proteins that indicate that a cell has been compromised, such 
as viral proteins, will be detected on the cell surface by CD8 T cells and targeted for 
killing. 
In order to study the impact of the dynamic stimulus of T cell activation on RNA 
regulation within the T cell, we developed a system to analyze T cells in a resting state as 
well as after stimulation.  Our plan, as discussed in Chapter I and in subsequent chapters, 
was to compare and contrast HuR and Argonaute (Ago)-microRNA regulation in these 
cells.  To activate a polyclonal population of T cells without antigen dependency, 
antibody coated beads were used to mimic the signaling that a CD8 T cell would 
encounter from a cognate antigen-presenting cell (APC).  The first signal from the APC 
is directed towards the T cell receptor-CD3 complex that can be mimicked with an anti-
CD3 antibody.  Second, for complete activation and proliferative responses, co-
stimulation is needed through the CD28 co-receptor molecule on the surface of 
lymphocytes.  By using beads coated with antibodies against CD3 and CD28 the T cells 
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encounter both signals on a surface approximately the size of an APC, resulting in T cell 
activation. 
We developed a quantitative RNA-based assay as a surrogate to monitor the activation 
response of the lymphocytes.  In this assay, we measured the induction of two cytokine 
transcripts, IFNG and TNF, by isolating T cell RNA and performing reverse transcription 
for quantitative PCR (qPCR) analysis.  Stimulation of CD8 T cells with CD3 and CD28 
agonists leads to a dramatic increase in the expression of IFNG and TNF mRNA 
(Lindstein et al. 1989; Thompson et al. 1989; Wang et al. 2006).  These cytokines are 
critical to the activation response because both help to mediate effector functions of CD8 
lymphocytes.  For example, IFNG produced after T cell activation stimulates Janus 
Tyrosine Kinase (JAK) signaling and can directly inhibit viral replication and induce the 
starvation of intracellular pathogens.  IFNG can also induce the production of antigen 
processing machinery, which in turn increases the presentation of pathogenic antigen to 
the lymphocytes (Levy and Darnell 2002; Shuai and Liu 2003; Stark et al. 1998).  TNF 
stimulates the transcription of a wide array of cytokines and chemokines by cells in the 
local environment of the activated T cell.  In this way, IFNG synergizes with TNF to 
activate and recruit white blood cells to propagate the inflammatory response and aid in 
the clearance and killing of infected material (Boehm et al. 1997; Janeway and 
Medzhitov 2002; Rock and Goldberg 1999).  Therefore, these two transcripts were 
analyzed because of their early transcriptional induction with T cell activation and 
because they had been previously shown to be regulatory targets of HuR (Brennan and 
Steitz 2001; Mazan-Mamczarz et al. 2003; Wang et al. 2006).  
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Several prior studies were used to support this activation method and chosen time of one 
hour of stimulation.  For instance, the RNA binding protein HuR translocates from the 
nucleus to the cytoplasm in peripheral T cells by 45 minutes of in vitro stimulation with 
CD28 monoclonal antibodies.  One hour of activation also showed a consistently 
measurable change in the cellular status of lymphocytes by a detectable induction of 
immediate early genes (Lindstein et al. 1989; Thompson et al. 1989; Wang et al. 2006).  
Ago and HuR have also been shown to mediate rapid effects on mRNA localization and 
stability.  For example, these proteins can rapidly shuttle in and out of stress granules, to 
mediate translational silencing and potentially degradation of bound mRNAs 
(Bhattacharyya, Habermacher, Martine, Closs, and Filipowicz 2006a; 2006b; Leung and 
Sharp 2007; 2010).  Therefore, we chose to examine this early time point of T cell 
activation to investigate the direct dynamic regulatory control of RNA by Ago and HuR.   
In this chapter we develop methods to purify a sufficient quantity and quality of human 
lymphocytes for subsequent HuR, Ago and RNA profiling experiments.  We explore and 
optimize two main methodological issues:  the yield and purity of T cells from isolation 
procedures, and the impact of the isolation procedures themselves on T cell activation.  
Purification of sufficient T cell numbers for these studies depended upon the 
requirements for RNA analyses.  As will be detailed in subsequent chapters, high-
throughput sequencing of RNA isolated by crosslinking immunoprecipitation (HITS-
CLIP) studies and ribosomal profiling studies are variable in their sensitivity, depending 
on the abundance and avidity of RNA-protein interactions and RNA levels in 
polyribosomes.  Hence one variable we explore in this chapter is the impact of T cell 
activation on the levels of Ago. 
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In general, these studies suggest that sufficient numbers of cells for analysis may require 
isolation of 20 million peripheral lymphocytes for each activation state of a paired sample 
for HITS-CLIP analysis and additional material for other RNA profiling experiments.  
Achieving such yields from a peripheral human blood draw would be difficult.  Therefore, 
we turned to leukapheresis, a protocol we have utilized within the laboratory to purify 
PMBCs from patients with paraneoplastic neurologic disorders (Albert et al. 1998).  This 
protocol yields large numbers of peripheral blood mononuclear cells (PBMC), returning 
the remainder of the blood back to the donor.  For the purposes of the current study, we 
were approved by the Rockefeller University Hospital Institutional Review Board to 
obtain leukapheresates from normal healthy human volunteers. 
In these studies, it was important to assess whether our protocol to isolate peripheral 
blood lymphocytes for analysis perturbed their activation state.  Hence we compared 
different isolation protocols for purifying T cells from PBMC.  Typically, these protocols 
use antibodies against cell surface markers to isolate different cellular populations.  Two 
different approaches were assessed.  In one, T cells of interest were directly purified with 
antibodies to the T cell co-receptor CD8 molecule.  One concern here is that such 
purification might crosslink the receptors and initiate downstream signaling and 
activation of the T cells.  Therefore we compared this protocol with ones in which we 
isolated CD8 T cells by negative selection, using a mix of depleting antibodies specific 
for other cell surface markers present on all unwanted peripheral lymphocytes.  We 
assessed whether using negative selection could produce sufficient yield and purity of 
CD8 T cells while leaving the T cells naïve.  
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Results 
Purification of CD8 T cells by Negative Selection 
We first examined whether negative selection of CD8 T cells could be efficiently 
accomplished from 100-250 milliliters of peripheral blood collected from normal 
volunteers.  Heparinized and phosphate buffered saline (PBS)-diluted blood was purified 
over a Ficoll gradient to separate the PBMC from plasma and from a pellet of 
erythrocytes and granulocytes.  The number of circulating peripheral cells per unit 
volume was dependent on the donor but 240-960 million PBMC were isolated in each 
case.  T cells were then isolated by negative selection, by incubating the PBMC with a 
biotin-conjugated antibody mixture directed at non-CD8+ cells for depletion.  To ensure 
maximal purity of this isolation, we depleted cells using additional antibodies specific to 
B cells (CD19), NK cells (CD56), CD4 T cells, monocytes and macrophages (CD14).  
Using anti-biotin magnetic beads, non-CD8+ cells were bound to a magnetic column and 
CD8 lymphocytes were collected as the flow-through of the column.  This yielded 
between 7 and 40 million freshly purified CD8 T cells per donor.   
The isolated cells were analyzed for purity by flow cytometry.  Between 90% and 95% of 
the isolated cells were CD8 T cells based on expression of CD8 and the T cell lineage 
marker CD3.  By forward and side scatter profiles we determined the viability of these 
cells to be greater than 95% (Figure 3.1).  We concluded that purification of CD8 
lymphocytes by negative selection is effective for purifying small numbers of cells from 
peripheral blood and allowed isolation of a population of at least 90% pure CD8 T cells. 
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Figure 3.1 Purity of CD8 T Cells Purified by Negative Selection.  Representative CD8 
T cells purified from PBMC of normal human donors by negative selection.  (A) Forward 
and side scatter determined by flow cytometry.  The percentage of live cells (97.6%) is 
noted in the gated population.  (B-E) Stains indicated on each axis and percentages of 
cells for the indicated lineages are noted for each quadrant. 
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Purification of CD8 T cells by CD56 Depletion followed by CD8 Positive Selection 
To purify larger numbers of CD8 lymphocytes more efficiently, we explored the 
purification of CD8 T cells from PBMC by positive selection.  When isolating the cells 
by positive selection of the CD8 marker on the cell-surface of T cells, we found that the 
resulting lymphocytes contained a significant percentage of CD8+ CD56+ Natural Killer 
(NK) T cells.  Therefore, to remove this population of cells in subsequent purifications, 
we first depleted NK T cells using CD56 antibody-conjugated magnetic beads.  
We found that depletion of CD56+ cells followed by positive selection of CD8+ cells 
yielded enhanced purity of CD8 T cells as compared to negative selection (Figure 3.2).  
The average purity determined from five preparations of normal donor cells from 
leukapheresis and screened by flow cytometry was 97% CD8 T cells.  The non-CD8+ 
cells contaminating the preparation typically correspond to 2% each of CD4 T cells and 
CD8+ CD56+ NK T cells.  There is typically less than 0.5% contamination by CD14+ 
monocytes or macrophages, and by CD19+ B cells (Table 3.1). 
Furthermore, we found that this purity was preserved when processing larger amounts of 
cells from leukapheresis of normal healthy volunteers rather than relying on peripheral 
blood draw.  We collected between 120 and 150 milliliters of leukapheresate from normal 
donors and layered and centrifuged this material through a Ficoll gradient.  From this 
volume of material we were able to isolate 2-6 billion PBMC from each donor, which 
was roughly one hundred times more material than from a standard peripheral blood draw.  
After depletion of CD56 positive cells and selection of CD8 positive cells as described 
above, we were able to elute 400-800 million CD8 T cells.  After resting the cells 
69
!! !
 
 
 
Figure 3.2 Purity of CD8 T Cells Purified by CD56 Depletion and CD8 Positive 
Selection.  Representative CD8 T cells purified from PBMC of normal human donors by 
CD56 depletion and CD8 positive selection.  (A) Forward and side scatter determined by 
flow cytometry.  The percentage of live cells (97.4%) is noted in the gated population.  
(B-E) Stains indicated on each axis and percentages of cells for the indicated lineages are 
noted for each quadrant. 
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Table 3.1 Purification of CD8 T cells from Normal Human Donor Leukapheresis.  
Five normal healthy donors were leukapheresed.  CD8 T cells were purified by CD56 
depletion and CD8 positive selection.  Leukapheresates collected and resulting cell 
populations isolated are described.  Abbreviations: leukapheresate (Leuk.), peripheral 
blood mononuclear cells (PBMC).  
 
 
 
Leukapher-
esate
Volume
(ml)
Total 
PBMC
(x 109)
Selected
CD8
(x 106)
Rested
CD8
(x 106)
Live 
Cells
(%)
CD8+
T cells
(%)
CD4+ 
T cells
(%)
CD56+ 
NK T cells
(%)
CD19+ 
B cells
(%)
CD14+ 
Monocytes
(%)
Donor 1 150 3.5 560 410 96.2 97.4 3.19 1.39 0.19 0.20
Donor 2 150 2.0 420 277 97.4 98.5 1.06 1.11 0.18 0.64
Donor 3 140 6.0 780 560 95.8 97.6 3.24 2.49 0.29 0.54
Donor 4 120 3.0 496 261 97.1 96.9 1.39 2.00 0.31 0.37
Donor 5 140 2.6 595 455 95.6 92.7 1.87 0.39 0.11 0.03
Average 
+/- 
Standard 
Deviation
140
+/- 12
3.4
+/- 1.5
570
+/- 140
393
+/- 125
96.4
+/- 0.8
96.6
+/- 2.3
2.15
+/- 1.01
1.48
+/- 0.81
0.22
+/- 0.08
0.36 
+/- 0.25
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overnight in media, we recovered 250-600 million live CD8 T cells.  Therefore, we 
concluded that purifying lymphocytes by positive selection followed by resting them 
overnight was an efficient method to isolate large numbers of pure populations of normal 
human CD8 lymphocytes. 
Assessment of CD8 T cell Activation 
We assessed the degree to which the two isolation protocols activated the CD8 T cells.  
The lymphocytes were analyzed for activation by isolation of total RNA from the cells 
and assessing levels of TNF and IFNG mRNA, two transcripts that are rapidly induced 
from low baseline levels to high levels within one hour of T cell activation (Lindstein et 
al. 1989; Thompson et al. 1989; Wang et al. 2006).  To address whether T cell activation 
occurred during the process of cell isolation, normal donor samples were processed by 
either positive or negative selection in parallel and then evaluated immediately for their 
activation status, or after resting the cells overnight.  CD8 T cell RNA was isolated and 
reverse transcribed.  cDNA was used to measure the abundance of TNF and IFNG 
normalized to levels of GAPDH by qPCR, as a surrogate for the level of T cell activation.  
GAPDH mRNA levels did not vary significantly between resting and activated T cells.   
Cells that had been isolated by positive selection had increased levels of TNF and IFNG 
mRNA as compared to those isolated by negative selection (data not shown).  
Interestingly, the levels of T cell activation in cells that had been positively selected and 
rested overnight returned to the low baseline levels seen in T cells isolated by negative 
selection without resting (Figure 3.3).  It is likely that cells isolated by positive selection 
either revert to a resting state overnight or die overnight and are lost from analysis.  We 
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Figure 3.3 CD8 T Cell Activation qPCR Analysis.  IFNG and TNF mRNA in resting 
and activated CD8 T cells was analyzed by qRT-PCR.  (A) IFNG or TNF mRNA levels 
were normalized to GAPDH.  Plotted is the fold change of these transcripts in CD3/CD28 
stimulated CD8 T cells relative to resting CD8 T cells mRNA for five normal human 
donor samples prepared either by negative selection (NS) or positive selection (Donor).  
(B) Ct values for GAPDH mRNA were subtracted from the Ct values for IFNG mRNA 
(dCt) for resting or CD3/CD28 stimulated CD8 T cells for each donor.  Gray bars 
indicate the average dCt value for each group of T cells.  (C) Ct values for GAPDH 
mRNA were subtracted from the Ct values for TNF mRNA (dCt) for resting or 
CD3/CD28 stimulated CD8 T cells for each donor.  Gray bars indicate the average dCt 
value for each group of T cells.   
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conclude that where large numbers of cells are needed, it is preferred to take advantage of 
the increased efficiency and purity of the positive selection process and rest the cells 
overnight to return them to a quiescent state.  We observed that processing the cells for 
plating and harvesting them for one hour in media without CD3/CD28 stimulus after 
resting the cells also induced small but measurable amounts of cytokine production (data 
not shown).  Thus, to maximize the signal seen by activating the cells with the 
CD3/CD28 stimulus, ‘resting’ cells were collected and processed for the subsequent 
assays without any further manipulation or incubation.   
We also examined whether the level of activation with CD3 and CD28 stimulation would 
be altered by either isolation method or by resting the lymphocytes overnight.  We found 
that the cells reached a similar level of activation after an hour stimulus with the 
CD3/CD28 beads if they had been isolated by either negative selection or positive 
selection with resting overnight (Figure 3.3).  We concluded that the cells were able to 
achieve a maximal activation state with CD3/CD28 stimulation after either method of 
purification.  Consequently, the large difference in the fold change seen with activation of 
negatively selected or positively selected and rested CD8 T cells was due to a difference 
in the amount of TNF and IFNG transcript present in the resting T cells rather than a 
marked difference in the absolute amount of activation of the cells with one hour of 
stimulation.   
To maximize the purity of the isolated sample while preserving the resting state of the 
cells, we concluded that the T cells should be isolated by CD56 depletion and positive 
CD8 selection and then rested overnight.  Following the resting period, non-stimulated 
74
cells would be immediately processed and frozen for subsequent assays while another 
aliquot of cells would first be stimulated for an hour in culture with CD3/CD28 beads.   
Ago protein levels with T cell activation 
To determine if the levels of Ago increase during T cell activation, a pilot experiment of 
a stimulation time course was done for a series of time-points ranging from no 
stimulation to 72 hours of activation with CD3/CD28 beads.  We separated lysates by 
SDS-PAGE and visualized Ago protein by western blot.  We analyzed a fixed number of 
cells after different periods of time in culture with or without activation.  This showed 
that while there was no significant induction of Ago with one hour of stimulation, the 
levels of Ago protein per cell did increase with time in culture as noted at the 16-hour 
time point.  This induction stayed constant for cells grown in media alone, but continued 
to increase with time when stimulated with CD3/CD28 beads.  It was also seen that the 
Ago signal on a western blot of 300,000 T cells was comparable to that of less than 2% of 
a mouse cortex (Figure 3.4).  From this observation we estimate that the amount of Ago 
in a mouse cortex is roughly equivalent to that in 20 million human CD8 T cells.  We 
conclude that on the order of 10-100 million lymphocytes may be necessary for 
subsequent Ago HITS-CLIP assays and that activation of T cells for one hour does not 
significantly change the amount of Ago material available for analysis.  
Discussion 
In this chapter, we established a system for analysis of the effects of T cell activation on 
RNA regulation.  This entailed several aspects of investigation beginning with the 
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Figure 3.4 Ago Protein Levels with CD8 T Cell Activation in vitro.  (A) Cell-
equivalent aliquots of CD8 T cells were analyzed by western blotting for Ago (with 
Rabbit polyclonal Ago2/eIF2C2 specific ab32381) after the time in culture in media 
alone or with stimulation by CD3/CD28 beads as indicated above each lane.  Percentage 
of C57BL/6 wild-type cortex lysate analyzed as indicated.  (B) Quantitation of Ago levels 
by phosphoimager analysis of (A) normalized against time=0 hours (n=1). 
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establishment of methods to reproducibly obtain purified populations of CD8 
lymphocytes from normal human donors.  We examined the effects of these T cell 
purification methods on the activation state of the resulting lymphocyte populations using 
the qPCR assay we developed to compare levels of activation with and without 
stimulation.  Finally, we examined the corresponding abundance of Ago proteins after 
CD3/CD28 interrogation of the T cells. 
One hour of stimulation with CD3/CD28 beads was chosen for our assays because at this 
time point there was a dramatic increase in both TNF and IFNG mRNA and by this time 
it has been shown that HuR has already partially shuttled from the nucleus to the 
cytoplasm with stimulation (Lindstein et al. 1989; Thompson et al. 1989; Wang et al. 
2006).  Because Ago and HuR have been implicated in regulating rapid changes in 
mRNA localization and stability, such as the movement of targeted transcripts in or out 
of stress granules or active polysomes, we chose to investigate an early time point in the 
lymphocyte activation process (Bhattacharyya, Habermacher, Martine, Closs, and 
Filipowicz 2006a; 2006b; Leung and Sharp 2007; 2010).  It was hypothesized that at one 
hour of stimulation, a sufficient number of cells would be present in the activated status 
and that the regulation of the HuR and Ago could be determined during the initiation of 
the activation response and induction of the new transcriptional program.   
It would be interesting to examine the regulation by HuR and Ago at even earlier time 
points in this signaling cascade.  However, since each cell may not be activated 
simultaneously, the status evaluated biochemically at one hour can be seen as the sum of 
events leading up until this time.  Later time points could also be interesting to study, but 
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we thought it might be more straight forward to see direct effects of these regulators at an 
earlier time rather than a later one.  Hao and Baltimore described that the inflammatory 
response of macrophages in response to TNFα could be grouped into three sets of genes.  
Those that peaked in expression at half an hour after activation, after two hours of 
activation, and genes that increased more steadily with the stimulus and peaked at 12 
hours after activation (Hao and Baltimore 2009).  We thought that looking at the 
regulation of RNA at one-hour post T cell activation might provide interesting insight 
into the regulation of these rapidly changing transcripts as different groups of genes are 
being simultaneously induced and silenced during the inflammatory sequence (Hao and 
Baltimore 2009; Hargreaves, Horng, and Medzhitov 2009; Ramirez-Carrozzi et al. 2009; 
Smale et al. 2012).   
We examined the efficiency of purifying CD8 T cells using different protocols.  We 
found that we could generally achieve greater purity of the cell populations with positive 
selection than negative selection and could expect roughly 95% purity of CD8 
lymphocytes.  Interestingly, we found that the T cell purification process had a significant 
impact on cell activation.  Positive selection of CD8 lymphocytes left the cells in a more 
activated state than by negative selection as determined by our assay measuring TNF and 
IFNG transcription by qPCR.  We hypothesize that binding of antibody to the CD8 co-
receptor may have led to crosslinking of other cell surface receptors that mediate 
downstream signaling in the lymphocytes leading to the induction of immediate early 
genes.  Fortunately, we found that this activation during the purification process could be 
overcome by resting the cells in culture overnight.  This achieved a reversal of the 
activation of these transcripts that was seen with purification.  Furthermore, cells could 
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be activated to comparable levels with stimulation by CD3/CD28 beads after the resting 
period as seen with the stimulation of freshly negatively selected lymphocytes. 
It was important to first establish general mechanisms of regulation with T cell 
stimulation as described in this work to understand any processes unique to specific 
responses.  Nevertheless, the protocol we established suggests that this purification 
method could be extended to study more specific populations of T cells.  Antigen-specific 
cells can be purified by fluorescent-activated cell sorting using labeled synthetic MHC-
tetramers.  Our data suggest that if this extended isolation process led to activation of the 
cells, it is possible that they could be rested to return them to a quieter state in vitro prior 
to stimulation.  In this way, the molecular processes mediating such responses such as 
anti-viral, anti-tumor, or autoimmune reactions and the differences in signaling mediating 
them could be studied.  In these systems, using an APC could introduce difficulties 
distinguishing the responses of stimulators and responders in the subsequent assays.  
Thus, we thought using a cell-autonomous method for stimulation might decrease 
background and allow for analysis of earlier time points of cellular regulation without 
further purification of the lymphocytes from stimulators.  Nevertheless, we understand 
that stimulation with CD3/CD28 beads is a very strong agonist and that it can activate 
different subsets of cells simultaneously, which may be pre-programmed for different 
responses, confusing the subsequent results. 
Because Ago HITS-CLIP is less efficient than HuR in yield of the radiolabeled RNA co-
precipitated with each protein (data not shown), it was thought that stimulating the cells 
might increase this signal and help to decrease the number of cells needed for analysis.  
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The levels of Ago did increase with T cell stimulation in culture, but not within the 
timeline that was pursued for further experiments.  The size of the cells in culture also 
increased with activation and expansion and this difference in cellular volume could 
explain the increase in Ago with stimulation.  HuR expression has also been shown to 
increase with T cell stimulation and the induction of the cell cycle, still as in the case of 
Ago expression, it is unlikely that this would have a significant effect on these 
experiments due to the short time course of stimulation (Atasoy et al. 1998; Sakai et al. 
2003). 
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CHAPTER 4.  Determination of HuR in vivo Binding Sites  
in Resting and Activated T cells 
Introduction 
Lymphocytes are required to rapidly respond to changes within their host, such as during 
an encounter with antigen.  Therefore, it is logical that much of their protein expression 
be regulated at the translational level.  RNA-binding proteins can help to regulate mRNA 
translation in a number of ways.  These include the regulation of mRNA turnover, 
localization, and access to ribosomes, mechanisms that are not mutually exclusive.  For 
example, RNA-binding proteins can harbor latent transcripts in cytoplasmic granules as a 
means regulating their stability and ability to be translated.  In this state, transcripts can 
be translated almost instantaneously, which is congruous with the rapid responses seen 
from lymphocytes.  Alternatively, RNA-binding proteins can also rapidly shuttle in and 
out of stress granules, presumably in conjunction with bound mRNAs, to mediate 
translational silencing and potentially degradation (Anderson 2010).  
Within T cells, rapid changes in the production of proteins such as cytokines is known to 
involve RNA-binding proteins.  The expression of cytokines in T cells needs to be 
transient in order to avoid damage to cells in the surrounding microenvironment after an 
antigen-specific response.  RNA-binding proteins can ensure this by targeting cytokine 
mRNA transcripts for rapid degradation or repressing cytokine translation (Anderson 
2008).  To better understand the immune response in lymphocytes, and as a surrogate 
system for understanding general principles of dynamic RNA-binding protein regulation 
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of mRNA translation, we have undertaken a large-scale approach to analyze the post-
transcriptional regulation of T cell cytokines.   
We hypothesize that HuR plays a critical role in shaping the immune response with 
cluster of differentiation eight (CD8) T cell activation.  HuR has been shown to regulate 
cytokine production in T cells, including regulating interleukin (IL)-13, IL-4, interferon 
gamma (IFNG), and tumor necrosis factor (TNF) (Brennan and Steitz 2001; J. G. Wang 
et al. 2006; Yarovinsky et al. 2006).  HuR is thought to promote stabilization of cytokine 
mRNA transcripts upon T cell activation by binding to AU-rich elements (ARE) in the 3’ 
untranslated region.  HuR binding can either promote or inhibit translation due to 
cooperative and competitive interactions with other RNA-binding proteins.  Together the 
bound proteins determine the fate of the transcript (Anderson 2008; Casolaro et al. 2008; 
Fan and Steitz 1998; Myer, Fan, and Steitz 1997).  Most research to date investigating the 
targets and effects of HuR binding has been studied in vitro with reporter constructs or by 
over expressing HuR, leading to non-physiologic conditions.  Furthermore, there is 
evidence that RNA-binding proteins can associate with transcripts after a cell has been 
lysed for immunoprecipitation leading to false targets of regulation (Mili and Steitz 2004).  
Thus, previous studies examining HuR function during T cell activation using RNA 
immunoprecipitation without crosslinking may not represent in vivo interactions between 
HuR and RNA and do not point to discreet binding sites within the RNA molecule.  
Moreover, HuR binding sites have been mapped using the photoactivatable 
ribonucleoside crosslinking and immunoprecipitation (PAR-CLIP) approach, but its 
requirement for incorporating a photo-activatable nucleotide analog into RNA limits is 
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use to cell culture systems that may not preserve biologically meaningful binding sites or 
dynamic changes in cellular states (Mukherjee et al. 2011). 
Here we have employed more rigorous biochemical techniques for analyzing RNA-
protein interactions in live cells to the study of lymphocyte dynamics.  We have used a 
powerful platform technology developed in the lab, high-throughput crosslinking 
immunoprecipitation (HITS-CLIP) (Figure 4.1).  In this procedure, live cells are 
ultraviolet (UV) irradiated to crosslink protein to bound RNA. Crosslinking allows us to 
harshly wash immunoprecipitated RNA-protein complexes to remove cross-reacting or 
co-precipitating contaminants.  The RNA is partially digested so that full transcripts will 
not be bound to the protein, but rather only RNA “tags” which are radioactively labeled.  
After gel-purifying the RNA-protein complexes, the protein can be digested and ligated 
RNA linkers are used to reverse transcribe the CLIP tags.  High-throughput sequencing 
enables us to identify genome-wide targets of the protein of interest (Licatalosi et al. 
2008; Ule et al. 2003; 2005).  In this chapter we develop HITS-CLIP to examine HuR-
RNA interactions in resting and activated CD8 T cells from normal human donors.   
Results 
Immunoprecipitation of HuR from T cell Lysate 
In order to begin an experiment utilizing HITS-CLIP, it is necessary to develop a means 
of purifying the RNA binding protein of interest after crosslinking it to its RNA targets in 
cells.  Most commonly used such purifications consist of immunoprecipitation.  To 
examine whether HuR could be efficiently immunoprecipitated from normal human 
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Figure 4.1 HuR HITS-CLIP Methods Schematic.  UV-B irradiation penetrates live 
cells to induce covalent crosslinks between RNA and bound proteins that are within ~1 
Ångstrom distance.  Cells are lysed and treated with DNase to remove DNA and partially 
RNase digested to reduce RNA to small fragments.  Once covalently bound, protein-
RNA complexes can be purified under harsh conditions to remove interactions with non-
crosslinked RNA and potential contaminating proteins.  SDS-PAGE and transfer to 
nitrocellulose purify these complexes and radiolabeled RNA is visualized by 
autoradiogram.  After size selection, the protein-RNA complexes are isolated form the 
membrane and proteinase K digestion removes the RNA-binding protein.  The cloning 
method utilizes linker ligations, reverse transcription, and PCR to amplify bound targets 
which are analyzed by high-throughput sequencing. 
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An additional advantage of this modiWcation is that it
yields more eYcient ligation reactions. Originally, the 5!
linker ligation was done before 3! linker ligation, which
allowed self-ligation and circularization of the 5! phosphor-
ylated CLIP tag, potentially leading to the loss of a subset
of RNA tags. This can be prevented by out competing the
self-ligation with a large concentration of 5! linker. How-
ever, in the current protocol the Wrst ligation step is per-
formed on-bead, therefore it is not feasible to use such a
high concentration of RNA linkers. Instead, the current
protocol dephosphorylates the RNA tags before ligation,
ensuring that they cannot circularize. Introduction of the
phosphatase step also potentially allows cloning of siRNAs
and other short RNA species in the cell. The dephosphoryl-
ated RNA tags are Wrst ligated to the 3! linker, which is
blocked at the 3! end by puromycin, preventing self-ligation
of the RNA tag during the subsequent ligation of the 5!
linker.
Fig. 1. A schematic representation of CLIP procedure for id ntiWcati  of protein binding sites on RNAs in the context of intact cells. Dissociated cells are
UV-irradiated on ice, leading to formation of a covalent bond between protein and RNA. This allows partial digestion of RNA after lysis, followed by strin-
gent protein puriWcation, such as immunopr cipitation, SDS–PAGE electrophoresis and transfer to nitrocellulose. Prior to SDS–PAGE, RNA is dephospho-
rylated, ligated to 3! RNA linker and radioactively labeled by 5! !32P. After transfer to nitrocellulose, the membrane is exposed to X-ray Wlm, and a thin
region of the membrane corresponding to protein–RNA complexes of appropriate size is excised, protein is digested by proteinase K, and 5! RNA linker is
ligated to free RNA. The CLIP tags are then ampliWe  by RT-PCR using the DNA primers with sequence complimentary to the RNA linkers.
Table 1
Comparison of the previously reported CLIP protocol [35] with the protocol described here
Original protocol Current protocol Reason for change BeneWt of the change Validation
Ligation of RNA 
linkers to free 
RNA (after 
protein 
digestion)
On-bead 
ligation of 3! RNA 
linker to 
CLIP RNA tags 
that are bound to 
the protein
Ligation to free RNA requires that 
signiWcant amount of RNA is 
extracted to ensure that it is the 
major portion of cloned sequences, 
rather than the bacterial rRNA 
contaminants from the 
recombinant ligase or proteinase K
On-bead ligation of the 3! linker 
allows puriWcation of the ligated 
CLIP tags and removal of the 
bacterial rRNA and free linker 
using stringent washing of the 
beads, SDS–PAGE and 
nitrocellulose transfer
Cloning CLIP tags from the 
same amount of starting 
material (25 mg) gives 53% 
mouse and 47% bacterial 
sequences using the original 
method, and 100% mouse 
sequences using the current 
method
Sequential 
ligation of 
RNA linkers
Several 
puriWcation steps 
between 3! and 5! 
linker ligation
Sequential ligation of linkers 
allows ligation of 5!linker to 3! 
linker, which can then be ampliWed 
by the RT-PCR
PuriWcation steps between 3! and 
5! linker ligation prevent 
formation of linker-linker 
products
If starting with small amounts 
of CLIP RNA, the linker-linker 
products are ampliWed using 
the original, but not the current 
protocol
Phosphorylation 
of CLIP RNA 
tags before 
ligation of the 
Wrst RNA
linker (5!)
Dephosphorylatio
n of CLIP RNA 
tags before 
ligation of the Wrst 
RNA linker (3!)
A large excess of 5! linker needs to 
be added to prevent self-ligation 
and circularization of 
phosphorylated CLIP RNA tags
Dephosphorylation of CLIP tag 
allows use of lower 
concentration of RNA linker, 
which enables use of larger 
reaction volume during on-bead 
ligation
Dephosphorylation is required 
for eYcient on-bead ligation
Separation of free 
RNA on 
urea–PAGE is 
necessary
Separation of free 
RNA on urea–
PAGE is not 
necessary
In the current ligation procedure, 
5! linker–3! linker product does not 
form and separation is thus not 
necessary
Allows cloning of small 
quantities of RNA that would 
not be detected when separated 
on the urea–PAGE
Separation of the ampliWed 
RT-PCR products gives a 
similar result as the separation 
of free RNA (Fig. 4)
Ago
HuR
Ago
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donor T cells, we developed an IP protocol using a mix of two mouse monoclonal 
antibodies (mAbs) to HuR to increase avidity to the protein (Harlow and Lane 1988).  We 
first bound a bridging rabbit anti-mouse mAb to protein A Dynabeads and then mixed the 
beads with two mouse HuR mAbs, clones 3A2 and 19F12 (Gallouzi et al. 2000; W. 
Wang et al. 2000).  As a negative control, an aliquot of protein A Dynabeads was bound 
with the same bridging antibody and an irrelevant mAb to a mouse protein.  The 
antibody-bead complexes were incubated with the isolated primary T cell lysate, and, 
after a series of washes in different stringency buffers, the immunoprecipitated proteins 
were eluted from the beads.  The eluted proteins were separated on a sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS PAGE) gel and transferred to a 
nitrocellulose membrane.  The membrane was blotted with HuR mAb 3A2 and a 
secondary HRP-conjugated donkey anti-mouse antibody (Figure 4.2).   
A strong immunoreactive band was evident in the HuR mAb immunoprecipitation at the 
molecular weight of HuR (~36 kD; Figure 4.2, Lane 5).  Moreover, we observed a 
reduction of protein at this molecular weight in the supernatant of the 
immunoprecipitation (Figure 4.2, Lane 3) relative to the input sample (Figure 4.2, Lane 
1).  As expected, we did not see an immunoreactive band in the irrelevant mAb 
immunoprecipitation (Figure 4.2, Lane 4) and the quantity of HuR was not significantly 
depleted in that supernatant (Figure 4.2, Lane 2).  Together, these data indicated that the 
HuR antibody specifically immunoprecipitates a protein of the size expected of HuR. 
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Figure 4.2 HuR Immunoprecipitation.  Human CD8 T cell lysate was 
immunoprecipitated for HuR (with monoclonal HuR specific 3A2) or using irrelevant 
antibody (mouse monoclonal FMRP specific 7G1) and analyzed by western blotting for 
HuR (with monoclonal HuR specific 3A2).  Equivalent aliquots of T cell lysate input to 
immunoprecipitation, supernatant from immunoprecipitation, or immunoprecipitated and 
eluted material were analyzed as indicated.  Film exposures for 30 seconds or 5 minutes 
are shown. 
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Pilot HuR HITS-CLIP Experiment on Human T cells expanded in Culture with IL-2 
The HITS-CLIP methods were used to investigate what RNA targets HuR binds in 
activated T cells.  In preliminary experiments, we assessed whether HuR could be 
immunoprecipitated with crosslinked RNA in CD8 T cells expanded and growing in 
culture with IL-2.  The T cells were crosslinked, lysed, and the RNA was partially 
digested prior to the immunoprecipitation to shorten the RNA “tags” that would be bound 
to HuR.  HuR crosslinked to RNA targets was immunoprecipitated using the mixture of 
monoclonal antibodies specific to HuR bound to protein A Dynabeads.  To optimize the 
stringency of the assay, IPs were washed with a series of high stringency buffers 
containing differing amounts of detergents and salt concentrations. RNA tags were then 
ligated to 3’ linkers for later PCR amplification and labeled with polynucleotide kinase-
mediated incorporation of radioactive ATP.  The material was separated by SDS-PAGE 
and transferred to a nitrocellulose membrane (Figure 4.3A, Lanes 2,4). Protein-RNA 
complexes were cut from the membrane, the protein was digested and the RNA extracted.  
After adding 5’ linkers and performing an RNase-free DNA digestion to remove any 
contaminating DNA, RNA tags were reverse transcribed, PCR amplified, and high-
throughput sequenced (Figure 4.3B,C). 
This first HuR CLIP pilot experiment produced nearly 9 million pre-filtered CLIP tags, of 
which roughly 6 million could be mapped to the human genome unambiguously.  More 
than 300,000 were determined to be unique binding events, which is a large data set of 
mapped HuR regulation.  Approximately half of the tags mapped to deep intergenic 
regions and a third were intronic sequences.  Only 1% of the tags mapped to coding 
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Figure 4.3 HuR CLIP: mAb Specific to HuR.  (A) Autoradiogram of 
immunoprecipitation results from human CD8 T cells expanded in culture in IL-2 and 
crosslinked.  Lysate was immunoprecipitated with irrelevant antibody (mouse 
monoclonal FMRP specific 7G1-1) in lanes 1 and 3, or with HuR antibodies (mouse 
monoclonal HuR specific 3A2 and 19F12) in lanes 2 and 4.  Lysate treated with high 
RNase A concentrations in lanes 1 and 2, and low RNAse A concentrations in lanes 3 and 
4.  3’linker was added to RNA and then labeled by PNK with 32P-γ-ATP, protein-RNA 
complexes were separated on SDS-PAGE, transferred to nitrocellulose and imaged by 
autoradiography.  32P-labeled RNA was evident in HuR immunoprecipitation but not in 
irrelevant control immunoprecipitation.  Dots indicate regions of nitrocellulose processed 
for RNA purification.  (B) After protease digestion of the radioactive RNA-protein 
complexes, 5’ linker was added and products amplified by RT-PCR; products of the 
expected size, 100-150 nucleotides, were seen after 26 cycles from HuR CLIP.  (C) Final 
PCR products after amplification of CLIP tags with high-throughput sequencing 
compatible primers. 
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sequence with the remaining tags falling in the region surrounding the genes and in the 5’ 
and 3’ untranslated regions of genes (data not shown).   
Although these data only represent one experiment, a large proportion of the genes that 
had the most tags in this data set matched CLIP tag maps from other neuronal Hu protein 
family members in the mouse brain that are being studied by other members of the 
laboratory in other systems, suggesting that the data are robust and that HuR targets are 
evolutionarily conserved. 
Radioactive RNA Signal on the Autoradiogram is Specific to the HuR Antibodies  
To ensure that the labeled RNA signal seen on the autoradiogram was specific to HuR 
and not due to an artifact of the protein A beads or the bridging antibody used to bind the 
monoclonal antibodies for HuR.  In addition to labeling protein A beads with the bridging 
antibody and the two HuR monoclonal antibodies, we had prepared another aliquot of the 
protein A beads with bridging antibody and used another mouse monoclonal antibody 
that was specific to a mouse protein and should not specifically recognize any proteins in 
human T cell lysate.   
Following immunoprecipitation with the irrelevant antibody bound beads, there was no 
radioactive signal from the lysate prepared with either high RNase concentration (Figure 
4.3, Lane 1) or low RNase concentration (Figure 4.3A, Lane 3).  As a control, we cut 
from the membrane at the same molecular weight as in the HuR immunoprecipitation and 
continued to prepare the two RNA samples in parallel.  The amplified cDNA products 
from the HuR immunoprecipitation were visible on the gel beginning around 24 PCR 
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cycles.  In the control sample, the cDNA was not visible until later cycle numbers and the 
characteristic smearing pattern of the RNase treated samples was not apparent from the 
irrelevant immunoprecipitation (Figure 4.3B).  We isolated DNA from the lane 
containing products from 26 PCR cycles for both the HuR and the irrelevant antibody 
immunoprecipitation.  Additionally we prepared DNA from the upper and lower bands in 
the irrelevant immunoprecipitation that were visible at 32 PCR cycles. 
In the control PCR reactions with the irrelevant antibody purification material from 26 
cycles of the first PCR, we were not able to amplify products to add the sequencing 
compatible sequences.  The contaminating bands that had been visible with later PCR 
cycles from the irrelevant immunoprecipitation were not overlapping in size with the 
smear seen from the HuR immunoprecipitation (Figure 4.3C).  Thus, we concluded that 
the RNA material isolated with the HuR immunoprecipitation was specific to the mix of 
HuR monoclonal antibodies.  
Radioactive signal on the Autoradiogram is Sensitive to RNase A Digestion 
During the CLIP experiment, we rely on radiolabeling of the RNA to visualize the 
material associated with the protein during immunoprecipitation.  To ensure that the 
signal is from RNA, we treated the cellular lysate prior to immunoprecipitation with 
different concentrations of RNase A to show sensitivity to this digestion.  With a high 
concentration of RNase, the RNA should be almost entirely degraded and the signal seen 
on the autoradiogram should be roughly that of the protein alone.   
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A discrete signal at around 38 kDa was visible on the autoradiogram with over digestion 
of the sample (Figure 4.3, Lane 2).  In this lane, there are other bands at higher molecular 
weights, such as near 80 kDa, which is not present in the irrelevant antibody control, so is 
therefore specific to immunoprecipitation with the HuR monoclonal antibodies.  We 
speculate that this could represent a dimer of HuR because it is running at double the 
molecular weight of the protein alone.  However, it is also possible the band represents a 
contaminating RNA-binding protein.  To ensure that these complexes do not contaminate 
the samples, we were careful to cut below this size when purifying RNA for cloning.   
Digestion of the T cell lysate with a lower concentration of RNase A trims HuR-bound 
transcripts to RNA fragments.  The small length of the RNA fragments will allow for 
precise determination of the RNA-binding site footprint of HuR rather than identifying 
the entire transcript as a target of regulation.  These digested fragments will not be 
uniform in size and will therefore appear as a smear of RNA signal above the expected 
size of the protein.  In Figure 4.3, lane 4, we observed the labeled signal initiating above 
the size of the collapsed band in the over digested sample in lane 2.  Thus, the radioactive 
labeling pattern on the membrane is RNase A sensitive, demonstrating that the labeled 
material immunoprecipitated with HuR is RNA. 
Radioactive RNA Signal on the Autoradiogram is Dependent on Crosslinking 
In order to study native in vivo binding interactions between HuR and RNA, we rely on 
crosslinking live cells to covalently link the RNA binding protein to its targets.  The UV 
irradiation should only crosslink interactions that are on the order of a single angstrom in 
distance.  With sufficiently stringent washing protocols, we can dissociate non-
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crosslinked RNA from immunoprecipitating with the protein of interest and deplete re-
association artifacts of the protein with RNA during the immunoprecipitation.   
To confirm that radiolabeled protein-RNA complexes are UV-dependent, we used both 
crosslinked and non-crosslinked samples as the input to immunoprecipitation.  Using 
crosslinked samples, we were able to see labeled signal in both the high and low RNase 
treated samples at the expected size of HuR or a smear above that size respectively.  But, 
without crosslinking, we were unable to detect an RNA signal (Figure 4.4).  Therefore, 
the RNA signal is dependent on the in vivo crosslinking and not due to random 
association of the protein and RNA available during immunoprecipitation.  Furthermore, 
the lysis and washing conditions are sufficient to dissociate all measureable RNA signal 
from immunoprecipitated HuR. 
HuR CLIP in Mouse CD8 T cells 
The HuR protein is highly conserved between human and mouse.  In addition to the 
human lymphocytes, we crosslinked mouse T cells to determine if we could detect an 
RNA signal from immunoprecipitation of murine HuR.  We purified CD8 T cells from 
mouse spleen by negative selection similarly to the protocol outlined for human 
peripheral blood cells.  Briefly, spleens were quickly extracted from sacrificed C57BL/6 
mice.  The spleens were mashed with the back of a syringe in ice cold PBS until a single 
cell suspension was achieved.  These cells were harvested into a tube and spun down.  
The cells were then incubated in a suspension of PBS, fetal bovine serum, and magnetic 
beads with antibodies conjugated to a mix of non-CD8 T cell surface markers.  Non-
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Figure 4.4 HuR-RNA Complexes are Crosslinking Dependent.  Autoradiogram of 
immunoprecipitation results from human CD8 T cells expanded in culture in IL-2 and 
prepared with or without crosslinking.  Lysate was immunoprecipitated with HuR 
antibodies (mouse monoclonal HuR specific 3A2 and 19F12).  32P-labeled RNA was 
evident in HuR immunoprecipitation with crosslinked lysate, but not from non-
crosslinked lysate. 
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CD8+ cells were bound to a magnetic column and CD8+ cells were collected as flow-
through, with roughly 90% purity (Figure 4.5). 
Cross-linked and non-cross-linked cells were processed for HuR CLIP as described 
above.  As seen with the material from the human immunoprecipitation, with a high 
concentration of RNase A treatment of the lysate, the labeled RNA bound to HuR 
collapsed to a band at the expected size of the protein.  With lower amounts of RNase 
added to the lysate, a smear of RNA was seen above the expected size.  Unfortunately, in 
this experiment, even the low concentration of RNase yielded products that appeared 
slightly over digested, although there was still ample signal for subsequent cloning.  
Importantly, the RNA signal was crosslinking dependent, as no signal was observed in 
the lane on the membrane that derived from non-crosslinked T cell lysate (Figure 4.5).  
We were encouraged that the results we were able to see in the human samples were not 
species specific.  
Numbers of T Cells Necessary for HuR CLIP 
The first human HuR T cell CLIP experiment previously described was performed on 
cells that had been expanded in culture.  Although this is a valid method to produce large 
numbers of T cells, prolonged activation in vitro is likely to undermine the physiologic 
relevance of the system.  To assess the number of lymphocytes required for HuR CLIP, 
we titrated the amount of crosslinked T cell lysate that was used as input for HuR 
immunoprecipitation.  The RNA bound to HuR was radiolabeled and visualized by 
autoradiogram after being separated by SDS-PAGE and transferred to nitrocellulose.  We 
could visualize a strong signal from immunoprecipitated RNA from the lysate of 0.5 
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Figure 4.5 HuR Mouse CD8+ T Cell CLIP.  (A) CD8 T cells purified from splenocytes 
of wild-type C57BL/6 mice and purified by negative selection. CD3 and CD8 staining 
determined by flow cytometry.  Percentages of cells are noted in each quadrant.  (B) 
Autoradiogram of immunoprecipitation results from resting and CD3/CD28 stimulated 
mouse CD8 T cells prepared with or without crosslinking.  Lysate was 
immunoprecipitated with HuR antibodies (mouse monoclonal HuR specific 3A2 and 
19F12).  32P-labeled RNA was evident in HuR immunoprecipitation with crosslinked 
lysate from resting and activated mouse lymphocytes, but not from non-crosslinked lysate. 
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million normal human T cells, almost twenty-fold less than we used for the pilot 
experiment described above (Figure 4.6).  This will allow for the use of fresh samples 
that have not been distorted by cell culture conditions.  With the ability to use low 
numbers of cells for the identification of HuR-bound RNA, these methods may be 
applied to the investigation of antigen-specific lymphocyte responses from patient 
samples or other cellular populations of interest.  Still, the complexity of the pool of 
sequenced RNA may be proportional to the amount of starting material due to our current 
dependence on PCR amplification of cloned tags, so the initiation of the protocol from 
larger cell numbers would be preferred. 
HuR HITS-CLIP from Five Normal Donor Resting and Activated CD8 T cells 
As described in the previous chapter, CD8 lymphocytes were isolated from normal 
human donors and prepared for analysis by HITS-CLIP.  Briefly, five healthy normal 
donors were leukapheresed and the material was layered onto and spun through a Ficoll 
gradient.  The resulting layers of collected PBMCs were depleted of CD56+ cells and 
then positively selected for CD8+ cells.  The eluted CD8 lymphocytes were rested 
overnight in media.  The following morning, T cells were harvested and aliquots of 
lymphocytes were crosslinked immediately or after being stimulated in culture for one 
hour with CD3/CD28 beads.  The T cells were crosslinked with UV-B irradiation.  The 
purity of the cells was determined by flow cytometry to be greater than 90% CD8 
lymphocytes, and analyzing TNF and IFNG mRNA levels by RT-qPCR confirmed the 
activation status (Table 3.1).  The cells displayed between roughly 300 and 600 fold 
inductions of TNF mRNA and 1000 to 8000 fold inductions of IFNG mRNA (Figure 3.3). 
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Figure 4.6 HuR CLIP CD8+ T Cell Titration.  Autoradiogram of immunoprecipitation 
results from human CD8 T cells expanded in culture in IL-2 and crosslinked.  Aliquots of 
lysate corresponding to 10 million (C,D), 5 million (A,B,E), 1 million (F), 0.5 million (G), 
or 0.1 million T cells (H), were immunoprecipitated with HuR antibodies (mouse 
monoclonal HuR specific 3A2 and 19F12) (B, D-H) and irrelevant antibody (mouse 
monoclonal FMRP specific 7G1-1) (A,C).  32P-labeled RNA was evident in HuR 
immunoprecipitation from lysate starting at 0.5 million T cells. 
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For three of the five donors, the T cell lysates were prepared and used first for Ago HITS-
CLIP experiments described in the Chapter 5.  HuR was then immunoprecipitated from 
the same lysates to perform comparisons with identical starting material.  However, this 
approach raised the potential concern that carry-over from the Ago experiment could 
contaminate HuR HITS-CLIP data. To address this possibility, HuR HITS-CLIP for the 
other two donor samples was performed without prior Ago depletion.  Additionally, 
different, uniquely indexed RNA linkers were used for these two additional donors so 
that potential contamination of sequenced RNA tags with tags from previous experiments 
could be unambiguously assessed.  HuR HITS-CLIB was performed as described above. 
Overview of RNA Tag Statistics 
In total, we sequenced material from five normal donor CD8 T cell samples activated for 
one hour with CD3/CD28 beads and from four paired resting samples.  From each sample 
we were able to get between 9 and 38 million sequencing reads from each high-
throughput sequencing run.  Because of the PCR amplification and saturation of 
sequencing of samples, the number of total reads did not necessarily dictate the final 
counts of unique mappable reads.  For example, the largest number of processed usable 
RNA tags came from a sample that had a starting number of only 13.6 million total reads, 
while the smallest number of unique mappable reads, from a sample sequenced in its own 
lane, started with 28 million total reads.  To process this large amount of data, first we 
removed all duplicate copies of reads, leaving only one of each exact sequence.  This 
reduced the total number of reads to between 1.8 to 10.4 million sequences.  These 
sequencing reads were then mapped to the hg18 build of the human genome.   The 
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percentages of sequences mapping to unique positions within the genome ranged from 41 
to 70% (Table 4.1).   
In preparing the sequencing libraries, we used ligated RNA linkers to clone and amplify 
the RNA bound to HuR.  Within the sequence of the 5’ RNA linker, we included a four 
base random degenerate code, which can consist of 256 different possible sequences.  
Different degenerate barcodes would therefore be ligated to each individual piece of 
RNA to be cloned from the same genomic location.  This barcode is meant to distinguish 
between identical cross-linked tags that were independently isolated and ligated to linker, 
which are biologically informative, from likely PCR amplified duplicates, which are not.  
This also gives us the ability to monitor contamination between the preparations of 
different sequencing libraries.  These barcodes allowed us to collapse sequences that 
mapped to exactly the same start and stop site in the genome and also contained the 
identical barcode; we term these collapsed products unique mappable reads or CLIP tags.  
Each sample produced between 400,000 and 1.2 million unique mappable reads (Table 
4.1). 
In addition to the four nucleotide degenerative barcode, for the three samples prepared 
from fresh T cell lysate, we used an additional two-nucleotide index within the 5’ linker.  
These additional bases allowed us to distinguish the sequences from each sample when 
the final material was pooled and sequenced together.  For these samples, together the 
sequencing produced over 500,000 unique mappable reads which then collapsed to 
roughly 150,000 unique reads per sample (Table 4.1).  In Table 4.1, the colors 
highlighting each individual donor sample will be used to indicate sequencing reads from 
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Table 4.1 HuR CLIP Tag Statistics. 
 
 
 
Resting
HuR Total Reads
Total Reads
(One Copy)
Mappable 
Reads 
(One Copy)
Unique 
Mappable 
Reads
% Total Reads 
(One Copy)
Donor 1 34,680,120 8,423,102 3,934,897 658,968 7.82
Donor 2 37,475,646 10,390,637 4,593,807 706,821 6.80
Donor 3 28,162,328 5,254,520 2,538,822 400,103 7.61
Multiplex: 30,671,330 1,914,692 1,190,522 515,861
Donor 4 --- --- --- 143,101
Activated
HuR Total Reads
Total Reads
(One Copy)
Mappable 
Reads 
(One Copy)
Unique 
Mappable 
Reads
% Total Reads 
(One Copy)
Donor 1 13,595,577 3,029,521 2,093,555 1,154,523 38.11
Donor 2 11,851,138 2,297,658 1,412,266 587,257 25.56
Donor 3 9,047,999 1,848,374 1,105,861 539,178 29.17
Donor 4 --- --- --- 175,523
Donor 5 --- --- --- 141,819
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that donor in the CLIP tag representations in subsequent figures from the genome 
browser.  This enables us to distinguish the results between the donors and compare the 
binding events between activation states for each donor. 
In total, we cloned 1.9 million unique tag reads for the resting T cells and 2.6 million in 
the activated state.  These CLIP experiments were the first to produce such large numbers 
of data and represent an expansive network of HuR regulation of RNA in the resting and 
activated states of CD8 lymphocytes.   
Reproducibility of Binding between Biologic Replicate Samples 
We were interested in focusing on sites of regulation where the binding events were 
abundant and reproducible between the different donor samples.  To do this, we 
developed a program to cluster CLIP tags.  We designated tags as belonging to a cluster 
if their genomic locations overlapped by at least 5 nucleotides.  Next we specified that 
within each cluster there must be 5 tags overlapping in at least one nucleotide genomic 
position, termed a peak height of at least 5.  For this analysis, we excluded nine clusters 
that had over 1,000 reads because they seemed to skew the correlations to be higher and 
we were not sure if these were specific binding events.  To determine the reproducibility 
of binding between the data sets produced from the different samples, we calculated the 
absolute value of the Pearson correlation coefficient of the number of tags per cluster 
between each donor in both the resting and activated states shown in Figure 4.7.   
We found very high correlations, r of greater than 0.9 between the datasets for the donors 
processed from the same activation state and prepared from the same kind of lysate 
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Figure 4.7 Pairwise Correlation of HuR CLIP Clusters.  Upper half of table: Pair-wise 
scatter plots displaying the number of tags per cluster of HuR CLIP tags contributed to 
the cluster by each resting (r) or activated (a) donor sample as indicated.  Lower half of 
table: absolute value of the pair-wise Pearson correlation coefficient of the number of 
tags contributed to each cluster by each resting or activated donor sample.  The size of 
text is scaled to the correlation value.  Clusters needed to contain a minimum of 5 
overlapping tags at one nucleotide position to be included in either analysis.   
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(either supernatant from prior Ago immunoprecipitation or fresh T cell lysate).  There 
was slightly lower correlations between samples processed from the same kind of lysate 
but in different activation states, ranging from r=0.84-0.89 which may represent the 
differences in HuR binding with and without T cell activation.  The correlations were a 
little lower still for comparing samples processed from Ago supernatant to those from 
fresh T cell lysate.  This may represent some difference in the lysates due to the Ago 
immunoprecipitation in one and not the other, but we think it is more likely that the 
differences are due to the sequencing depths between these samples.  Because we started 
with lysate from a larger number of cells for those prepared from the Ago supernatant, we 
were able to clone a larger number of unique reads (ranging from 400,000 to over 1 
million reads).  The samples from fresh T cell lysate were not only just from smaller 
numbers of starting material, but were also multiplexed and sequenced on in the same 
lane of the sequencer which resulted in less than 200,000 unique reads for those samples.  
Moreover, as the sequencing depth was lower, it is more likely that a tag from those 
experiments will not be represented in any given cluster, lowering the correlation 
coefficient.  Even with these caveats, the correlation coefficient between any two samples 
was at least r=0.68 which represents great reproducibility of binding. 
For further analysis, we also specified that there be at least three of the five donor 
samples represented in each cluster in either the resting or the activated state to demand 
biologic reproducibility in each binding site.  Additionally, for each cluster we required 
that at least one tag be present from the multiplexed barcoding experiment to ensure that 
the cluster was not due to an artifact of the Ago immunoprecipitation.  With these criteria, 
we determined over 24,000 sites of robust and reproducible HuR binding.  Nearly 6,000 
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of these clusters showed reproducible binding of at least biologic complexity of 3 and a 
peak height of 5 in both the resting and the activated states.  Interestingly, there were a lot 
of clusters that changed dynamically with activation and were only present at this 
stringency in either the resting state (3,481 clusters) or the activated state (14,657 
clusters) (Figure 4.8).  We were surprised to find more than 4-fold the number of robust 
binding sites exclusively in the activated state as compared to the resting state with only a 
third more unique reads.  These results began to demonstrate the dynamic changes in 
HuR binding that quickly occur with T cell activation. 
Genomic Distribution of HuR Binding Sites 
In order to gain a global view of HuR regulation, we determined the location of HuR 
Clusters of biologic complexity 3 (including a tag from the indexed experiment) and peak 
height of 5.  We were surprised to find that half to two-thirds of reproducible HuR 
binding sites fell in the intronic regions of target RNA molecules.  The next most 
represented region of RNA was the 3’ untranslated region (3’UTR) or within 10 
kilobases of stop codons, which most likely denote un-annotated 3’UTR regions of 
transcripts (Licatalosi et al. 2008).  These regions at the 3’ end of transcripts represented 
21-30% of HuR clusters.  Less than 10 percent of clusters fell within the 5’UTR, coding 
sequence, or deep intergenic regions of the genome.  These intergenic clusters may 
represent un-annotated RNAs.  The distribution of HuR binding along target transcripts 
was not altered greatly between the data sets of regulation seen in resting T cells or 
activated T cells.  In clusters present in both the resting and the activated states, we saw a 
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Figure 4.8 HuR Clusters Activation State Distributions.  Venn diagrams show the 
overlap between HuR target clusters in the indicated activation states with the number of 
clusters including 3 biologic donor samples and a peak height of at least 5 CLIP tags 
shown.  
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3,481 14,657
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larger proportion of binding in the 3’UTRs of transcripts than in either state alone (Figure 
4.9). 
Top Hexameric Sequences Represented in HuR Binding Dataset 
To investigate whether there was a conserved motif in the binding sites across different 
clusters that were biological complexity of 3 and had a peak height of 5, we calculated 
the number of times each hexameric sequence appeared within the HuR binding sites.  
We compared the counts for all of the HuR binding sites together, for resting and 
activated sites separately, and also for binding sites that were reproducible in both the 
resting and activated state.  For all cases, the top hexamer seen in the data sets was 
UUUUUU (Table 4.2). One interesting observation was the high frequency of both 
GUGUCA and UGUCAG in the data.  These overlapping sequences were the third and 
fourth highest ranked hexamers in clusters present in both the resting and activated state.  
It was also interesting that these were less represented in the resting alone dataset and 
even more so in the activated dataset.  This may represent different binding preferences 
of the protein in different cellular states.  As expected, uracil was the most frequently 
represented base followed closely by adenine and then cytosine and guanine at a lower 
rate (Figure 4.10).  These data correlate well with previously reported binding 
preferences for Hu proteins.  HuR has been shown to bind U-rich elements in previously 
reported targets of regulation and previous work from our laboratory showed similar 
binding sites for the neuronal Hu family members (de Silanes et al. 2004; Ince-Dunn et al. 
2012; Kishore et al. 2011; Mukherjee et al. 2011).   
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Figure 4.9 HuR Clusters Genomic Distribution.  Distribution of clusters, comprised of 
at least 3 biologic donor samples in the resting and or activated state and a peak height of 
at least 5 CLIP tags, among HuR target transcripts represented by pie chart. 
9%
7%
14%
63%
4%3%
5‘UTR Exon CDS Exon Intron
3‘UTR Exon Downstream 10K Deep Intergenic
7%
7%
23%
53%
6%
5%
HuR Resting HuR Activated
5%
6%
18%
62%
6%4%
HuR Resting & Activated
A B C
107
! !
Table 4.2 Top Hexameric Sequences in HuR Clusters.  Listed are the top 25 hexamers 
found in all HuR clusters representing at least three biologic donors in one activation 
state (biologic complexity three: BC3) and having at least five tags in the peak position of 
binding (peak height five: ph5).  Hexamers were sorted by comparing the ratio of the 
observed to the expected frequency of each hexamer within CLIP tags.  The ranking and 
absolute count of each hexamer within subsets of clusters BC3 and ph5 for the resting, 
activated state, or both are shown. 
 
 
 
Overall
Rank Hexamer
Observed 
Count
Observed 
Frequency
Observed/
Expected 
Frequency
Resting:
Rank 
(Count)
Activated:
Rank 
(Count)
Both:
Rank 
(Count)
1 UUUUUU 18006 0.00699 28.6 1 (2166) 1 (10191) 1 (5649)
2 AAAAAA 8875 0.00344 14.1 2 (1233) 2 (5016) 2 (2626)
3 UUAUUU 6912 0.00268 11.0 3 (857) 3 (4030) 5 (2025)
4 UAUUUU 6663 0.00259 10.6 5 (765) 4 (3884) 6 (2014)
5 UUUAUU 6433 0.00250 10.2 4 (788) 5 (3711) 8 (1934)
6 AUUUUU 6303 0.00245 10.0 7 (672) 6 (3673) 7 (1958)
7 UUUUUA 5967 0.00232 9.5 6 (681) 7 (3383) 9 (1903)
8 UGUUUU 5388 0.00209 8.6 10 (606) 8 (3177) 12 (1605)
9 UUUUAU 5375 0.00209 8.5 9 (613) 9 (3114) 11 (1648)
10 UUUUAA 5362 0.00208 8.5 12 (602) 10 (3033) 10 (1727)
11 UUUUCU 5087 0.00197 8.1 8 (628) 12 (2937) 15 (1522)
12 UUUGUU 5047 0.00196 8.0 15 (580) 13 (2903) 14 (1564)
13 UUGUUU 5007 0.00194 8.0 17 (567) 11 (2966) 17 (1474)
14 UUUUGU 4981 0.00193 7.9 16 (572) 14 (2828) 13 (1581)
15 UUUCUU 4747 0.00184 7.5 11 (603) 15 (2705) 18 (1439)
16 UUUAAA 4614 0.00179 7.3 20 (504) 16 (2623) 16 (1487)
17 GUGUCA 4561 0.00177 7.3 13 (595) 46 (1676) 3 (2290)
18 UUUUUC 4477 0.00174 7.1 22 (499) 17 (2613) 20 (1365)
19 UUCUUU 4387 0.00170 7.0 14 (589) 18 (2433) 21 (1365)
20 AUUUUA 4281 0.00166 6.8 21 (501) 20 (2430) 22 (1350)
21 UUUUUG 4246 0.00165 6.7 24 (459) 18 (2472) 23 (1315)
22 CUUUUU 4245 0.00165 6.7 23 (490) 22 (2381) 19 (1374)
23 UGUCAG 4231 0.00164 6.7 18 (536) 52 (1551) 4 (2144)
24 UUAAAA 4143 0.00161 6.6 26 (438) 21 (2400) 24 (1305)
25 UCUUUU 3936 0.00153 6.3 19 (506) 24 (2238) 27 (1192)
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Figure 4.10 Nucleotide Frequency in HuR Clusters.  The percentage of each 
nucleotide (adenine, cytosine, guanine, uracil) present in HuR CLIP clusters comprised of 
at least 3 biologic donor samples in the resting and or activated state and a peak height of 
at least 5 CLIP tags, represented by pie chart. 
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HuR Binding Changes with Activation 
To help give context to HuR binding patterns and changes with activation, we did 
RNAseq on other aliquots of resting and activated T cells from the same pools of 
lymphocytes used for HITS-CLIP, absent UV-crosslinking.  This allowed us to overlay 
HuR regulation with the expression levels of target transcripts using calculated values of 
reads per kilobase per million (RPKM) for each RNA transcript.  Then, for each cluster 
we assigned a score for the relative HuR binding and transcript abundance in the resting 
and activated states.  
As diagramed in Figure 4.11, we pooled the HuR CLIP tags from both the resting and 
activated state together and required that the tags overlapped at least 5 nucleotide 
positions to be included in a cluster.  For this analysis, we specified that clusters had to be 
at least of biologic complexity 4 in the resting and or activated state and have a minimum 
combined peak height of 10 tags between the resting and activated states together.  For 
each cluster we calculated the percentage of tags that originated from the activated state 
out of the total number of resting and activated tags in that cluster.  Finally, we grouped 
binding sites into bins of whether the HuR binding and transcript expression in the 
activated state was greater than, roughly equal to, or less than the resting state based on 
cutoffs at 40 and 60 percent.  We required that transcripts have a minimum of an RPKM 
of 15 in either the resting or activated state for inclusion in this analysis to ensure that the 
read depth changes for each transcript with activation was evaluable.  
Interestingly, more than two-thirds of HuR binding sites shifted in binding intensity 
dramatically with T cell activation, with about 28% of these binding changes mirroring 
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Figure 4.11 Cluster Scoring System.  Schematic representing the cluster scoring system.  
CLIP tags for each protein were clustered based on overlapping genomic positions of at 
least 5 nucleotides.  Clusters were included in the analysis if they were comprised of at 
least 4 donor samples in the resting and or activated state and had a peak height of at least 
10 tags between both activation states.  The number of tags in each state was calculated 
and the percentage of tags in the activated state out of the total number of tags in that 
cluster from both states was calculated.  Clusters were binned into whether the binding 
increased (>60% activated tags), decreased (<40% activated tags), or showed little to no 
significant change (between 40% and 60% activated tags) with T cell activation. 
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changes in transcript abundance.  Overall, 45% of the binding distribution of HuR 
between the resting and activated state for the cluster could be explained by parallel 
distributions in gene expression for that transcript.  In only 7% of clusters did the 
transcript abundance shift between activation states without a dramatic change in HuR 
binding, although HuR binding was seen to shift in 45% of clusters without a substantial 
change in gene expression.  Interestingly, it was a small minority of clusters, less than 3%, 
in which HuR binding and transcript abundance changed dramatically in opposite 
directions (Table 4.3A).  The transcripts with the top changes in cluster binding between 
resting and activated lymphocytes are listed in Table 4.3B.   
The most impressive changes in HuR regulation were seen in the activated state of early 
activation genes and markers.  While these transcripts had very low transcript expression 
in the resting state and very weak levels of HuR binding, within the one hour of 
stimulation, HuR appeared to coat these transcripts.  One example of this is the EGR3 
transcript that showed the most striking HuR change with CD3/CD28 stimulation.  As 
shown in Figure 4.12, there are only a few HuR tags at the end of the annotated 3’UTR in 
the resting state, the coding region and UTRs of EGR3 are littered with robust clusters 
with activation.  It was unexpected that these changes would be seen so dynamically with 
only an hour of stimulation of the lymphocytes.  We also see that the binding extends 
beyond the annotated 3’UTR for EGR3 and may represent a longer isoform than is 
represented in the RefSeq database. 
Another top HuR target with T cell activation is the IFNG transcript.  As seen in Figure 
4.13, there are only a few HuR binding sites mapped to IFNG in the resting state in 
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!Table 4.3 Combining HuR CLIP with RNAseq.  (A) This table shows the number of 
clusters binned in each category based on the scoring system outlined in Figure 4.11.  (B) 
This table lists the transcripts with the largest changes in cluster binding between resting 
and activated states.  First are HuR clusters with the largest decreases in binding with T 
cell activation, then the largest increases in binding, and finally clusters where HuR 
binding most opposes the changes in transcript abundance. 
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Figure 4.12 HuR Binding on Human EGR3.  The position of individual HuR unique 
CLIP tags in biologic complexity two clusters plotted relative to their mapped position on 
the human EGR3 transcript.  From top to bottom: chromosomal location, HuR CLIP tags 
from activated CD8 T cells (colors represent each donor sample as shown in Table 4.1), 
HuR CLIP tags from resting CD8 T cells, Gene diagram from RefSeq. 
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Figure 4.13 HuR Binding on Human IFNG.  The position of individual HuR unique 
CLIP tags in biologic complexity two clusters plotted relative to their mapped position on 
the human IFNG transcript.  From top to bottom: chromosomal location, HuR CLIP tags 
from activated CD8 T cells (colors represent each donor sample as shown in Table 4.1), 
HuR CLIP tags from resting CD8 T cells, Gene diagram from RefSeq. 
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intronic regions and in the 3’UTR, but not more than biologic complexity of 2 or peak 
height of 2.  In contrast, almost the entire IFNG transcript is coated with robust HuR 
binding clusters after an hour with CD3/CD28 stimulation.  Most surprisingly, it appears 
that HuR binds to the unprocessed pre-mRNA.  This suggests that HuR may deposit on 
the immature IFNG RNA co-transcriptionally and may accompany it from the nucleus to 
the cytosol for processing. 
Discussion 
In this chapter we explored the regulation of RNA by HuR in CD8 T cells in the resting 
and activated states from five normal human donors.  We were able to establish 
conditions to effectively immunoprecipitate HuR from lymphocyte lysate and 
demonstrated that the isolated RNA during CLIP was HuR monoclonal antibody specific, 
crosslinking-dependent, and also achievable in mouse T cells.  Using HITS-CLIP we 
were able to define robust and reproducible binding sites across different human donors 
samples that represented regulation in the resting and activated states of CD8 
lymphocytes.  We uncovered large sets of HuR regulatory sites that dynamically changed 
within one hour of T cell stimulation. 
We also demonstrated that only small numbers of T cells were needed to clone RNA 
bound to HuR, therefore, this methodology may be easily applied to study more specific 
populations of T cells.  It could be possible to isolate antigen-specific T cells or other 
small subsets of cellular populations and apply the HuR HITS-CLIP methods without 
expansion of these cells in culture.  This would allow for the molecular mechanisms of 
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HuR control to be elucidated in physiologically relevant human donor cells for the study 
of different disease states and for lymphocytes in an antigen specific manner. 
We found that a majority of HuR binding sites was located in intronic regions of targeted 
transcripts, followed by between 21 and 30 percent of binding falling in 3’UTR regions 
of genes (Figure 4.9).  Our finding that the vast majority of binding occurring in intronic 
and 3’UTR regions of targeted genes corresponded to studies reporting HuR binding sites 
determined by PAR-CLIP (Mukherjee et al. 2011).   Interestingly, these binding patterns 
contrast from those of the neuronal Hu proteins, which showed a binding preference to 
the 3’UTR in nearly three quarters of highly reproducible clusters.  This previous result 
was seen for clusters of biologic complexity of 5 out of 6 sequenced samples, while lower 
biologic complexity clusters showed a reduced preference towards the 3’UTR (Ince-
Dunn et al. 2012).  It is therefore possible that the increased percentage of 3’UTR clusters 
in T cells that were reproducible in both the resting and activated states is a reflection of 
the enhanced robustness of these clusters as being at least a total of biologic complexity 
of 6 and total peak height of 10 rather than a difference in the biology of this dataset.   
Still, it is clear that the genomic distribution of binding appears to be different between 
HuR and its neuronal family members.  These binding patterns could represent multiple 
possibilities.  If the binding patterns are determined by the RNA sequence, then the 
distribution of Hu binding sites might be different in the brain and T cells.  Or there could 
be other variables that influence HuR binding preferences such as the cooperative or 
antagonistic interactions with other RNA-binding proteins, which might differ in 
repertoire, abundance, and regulation in the two systems.  Furthermore, differences 
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between the regulation of RNA in the steady state of the brain from the acutely activated 
and proliferating T cells could account for differences seen in the proportion of intronic 
binding.  Comparatively, there is more active transcription in these lymphocyte 
populations and therefore likely more mRNA, leaving the possibility for increased co-
transcriptional and intronic associations of HuR. 
While we found that more than two-thirds of HuR binding clusters shifted in their 
dominance between the resting and activated state, by combining this data with RNAseq 
transcript abundance levels, we determined that much of the binding patterns can be 
explained by gene expression levels.  We saw that 45% of binding distribution between 
the resting and activated states mirrored transcript abundance levels in these cells.  Still, 
in an additional 45% of clusters, HuR binding changes with activation were more 
dramatic than changes in transcript abundance.  This differs greatly from the reciprocal 
scenario, where only 7% of genes that changed dramatically with T cell activation 
showed roughly equivalent HuR binding in both states.  It was very rare, in 3 percent of 
clusters, for HuR binding to change in the opposite direction of a significant change in 
transcript abundance (Table 4.3).   
The largest changes in HuR binding were seen in early activation genes and markers of T 
cell activation.  Some of the largest differences in HuR tags between the resting and 
activated states were seen in the EGR3 and IFNG mRNA.  While robust binding was 
seen along both of the transcripts, it was notable that for EGR3 while it appeared that 
HuR bound solely exonic and UTRs, for IFNG it appeared to bind in intronic regions as 
well.  We were interested to find such robust HuR binding on the pre-processed transcript 
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and consider that HuR appears to be deposited co-transcriptionally.  Still, the largest 
binding sites for both of these genes were seen in the 3’UTR.  It would be interesting to 
investigate the binding patterns of these and other genes at additional time points 
following T cell stimulation.  For example, it would be interesting to see if the HuR 
binding resolved at later time points to include only processed mRNA sites or to the 
3’UTR alone.  Similarly it could be informative to study earlier time points to gain 
insight into how these binding sites accumulate along the transcript.  Nevertheless, at one 
hour of activation, the view we are given of HuR regulation is most likely the population 
average of activation time points leading up to one hour because it is unlikely that all of 
the T cells encounter CD3 and CD28 antibody at time zero.   
In this study, the activation and crosslinking was done at a short time point, so it would 
be interesting in future studies to observe the binding of HuR to targets affects transcript 
stability and translation at subsequent time points.  It is possible that while HuR mirrors 
transcript abundance with the new burst of transcriptional changes with CD3/CD28 
stimulation that the presence or absence of HuR binding sites may help dictate the fate of 
these transcripts as the activated biology resolves. 
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CHAPTER 5.  Determination of Ago in vivo Binding Sites 
in Resting and Activated T cells 
Introduction 
As described in previous chapters, T cells must transition very quickly from a quiescent 
state to an active state to perform various functions to maintain immunity within a host, 
such as when they encounter cognate antigen and transmit signals through their T cell 
receptors.  Because of the rapid nature of these encounters, while they utilize regulated 
gene expression at every level, the regulation of protein expression from pre-synthesized 
mRNA provides the most rapid means of response. Such translational regulation occurs 
in many ways, but a common feature is regulation by RNA-binding proteins that help 
control the localization and stability of target transcripts, keep them poised for quick 
translation into proteins, or help them be swiftly degraded to begin, reshape, or terminate 
an immune response.  Transcripts encoding cytokines are good examples of such 
remodeling because they are needed to initiate antigen-specific responses but need to be 
terminated just as abruptly so that lymphocytes do not harm surrounding cells after 
antigen encounter (Anderson, 2008).  Understanding the post-transcriptional control of 
RNA is essential to understanding the biology of the dynamic regulation of lymphocyte 
activation. 
Argonaute (Ago)-microRNA complexes provide one well-studied mechanism to regulate 
translation of extant mRNAs, and there is emerging evidence that they may do so in a 
dynamic manner.  For example, the CAT-1 mRNA has been showed to localize to stress 
granules by microRNA mediated repression.  Upon amino acid starvation, HuR mediates 
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de-repression from Ago by mobilization of this transcript from stress granules and into 
active polysomes (Bhattacharyya, Habermacher, Martine, Closs, & Filipowicz, 2006a; 
2006b).  Vasudevan and Steitz showed that Ago and FXR1 associate together with the 
TNF 3’ untranslated region (3’UTR) during serum starvation and recruit bound mRNA to 
actively translating polysomes during the induction of cell cycle arrest (Vasudevan & 
Steitz, 2007; Vasudevan, Tong, & Steitz, 2007).  The localization of Ago to stress 
granules upon the induction of stress conditions is microRNA mediated and rapidly 
reversible in less than one minute.  It appears that Ago helps to exchange mRNA 
localization between these cytoplasmic foci and actively translating ribosomes (Leung, 
Calabrese, & Sharp, 2006).  Work from other groups has also demonstrated that 
microRNA can be regulated to impact rapid changes within the retina and other neuronal 
systems (Krol et al., 2010). 
The abundance of microRNAs in different T cell lineages has also been studied 
extensively, but has not taken into account the activation state of these cells or the 
binding preferences of Ago therein (Landgraf et al., 2007; Monticelli et al., 2005; Salaun 
et al., 2011; Wu et al., 2007).  The genetic manipulation of specific microRNAs in mice 
has demonstrated that many are necessary for the maintenance of a healthy immune 
system, with ablation or overexpression of microRNAs showing various deleterious 
results such as aberrant cell death, the induction of multiple autoimmune disorders, and 
cancer (Xiao & Rajewsky, 2009).  Mice lacking Ago2 in bone marrow derived cells 
showed deficiencies in the development of the B cell and erythroid cell compartments 
(O'Carroll et al., 2007).  Dicer is essential for the production of mature microRNA and 
mice deficient for this enzyme in the T cell lineage showed greatly impaired lymphocyte 
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differentiation, with heightened defects in the development of CD8 T cells (Cobb, 2005; 
Muljo et al., 2005).  Zhang and Bevan examined the role of Dicer in mature mouse 
cluster of differentiation eight (CD8) T cells and found that cells lacking Dicer were able 
to respond more quickly to T cell activation in vitro including quicker expression of 
CD69 and prolonged expression of this marker following withdrawal from the T cell 
receptor stimulus.  They also found that certain microRNAs were increased after 
stimulation in culture (Zhang & Bevan, 2010).  Still, these analyses were on the order of 
days in culture and did not represent the potential dynamic changes of Ago regulation 
immediately following T cell stimulation ex vivo or the identification directly mapped 
binding events.   
We have previously demonstrated the ability to use high-throughput sequencing cross-
linking immunoprecipitation (HITS-CLIP) to establish a precise and genome-wide map 
of Ago-microRNA-mRNA ternary interactions (Chi, Zang, Mele, & Darnell, 2009). This 
work examined Ago binding in the mouse brain in a steady state and did not explore the 
dynamics of Ago regulation. Ago binding maps in WT and miR-155 deficient mouse 
regulatory CD4 T cells were recently published, but these studies focus on a different 
subset of T cells in mice and represent data from cells stimulated in culture for four days 
(Loeb et al., 2012). Thus, to our knowledge studying the regulation of Ago in normal 
human CD8 lymphocytes and with acute T cell stimulation has not been previously 
examined.  In this work we aim to map RNA-binding patterns of Ago in resting and 
activated normal human CD8 T cells to decipher the mechanics of T cell activation and 
probe the dynamic regulation of RNA. 
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Results 
Ago HITS-CLIP from Five Normal Donor Resting and Activated CD8 T cells 
Five healthy normal volunteers were leukapheresed and the collected material was used 
to purify CD8 T cells for HITS-CLIP, as described in previous chapters.  Briefly, We 
used a Ficoll gradient to isolate the PBMC from leukapheresate that were then depleted 
of CD56+ cells using antibody bound magnetic beads and magnetic columns.  The CD56 
depleted PBMC were then subjected to CD8 positive selection and the resulting 
lymphocytes were rested in media overnight.  After resting, T cells were UV-B irradiated 
to crosslink RNA to protein either immediately or after stimulation for one hour with 
CD3/CD28 beads.  As shown in Chapter 3, the cells were analyzed by flow cytometry to 
confirm that their purity was greater than 90 percent (Table 3.1).  Their activation status 
was confirmed by analyzing RNA from a non-crosslinked aliquot of the T cells by RT-
qPCR for levels of TNF and IFNG (Figure 3.3).  Each sample had between a 280 to 610-
fold induction of TNF mRNA and between 1250 to 7600-fold induction of IFNG mRNA. 
For three of the donors, Ago immunoprecipitation was performed using protein A beads 
with bound rabbit anti-mouse antibodies supporting a broader net of Ago specific 
monoclonal antibody 2A8 (Harlow & Lane, 1988).  For the other two, we used protein G 
beads bound directly to the Ago antibody 2A8.  We saw a reduced RNA signal in the 
protein G immunoprecipitation as compared to with protein A.  In pilot experiments, we 
compared the signal to noise from both immunoprecipitation methods and found that 
protein A samples contributed more unique CLIP reads than protein G samples, but that 
CLIP tags from both methods clustered in many of the same genomic locations (data not 
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shown).  The correlations between the protein A and G immunoprecipitation methods 
used in the lymphocyte Ago CLIP described in this chapter will be discussed below.  
Thus, although the resulting data from the two methods produced differing amounts of 
data, we included both in the analysis moving forward. 
The HITS-CLIP protocol is schematized in Figure 4.1.  Ago was immunoprecipitated 
from CD8 T cell lysate that had been DNAse treated, to degrade DNA, and partially 
RNase digested to reduce the size of RNA molecules in the samples to clonable 
fragments and to determine the exact binding position of Ago on its target transcripts.  
The protein-RNA complexes captured on the Ago antibody coated protein A beads or 
protein G beads were then thoroughly washed on bead.  The samples were heated to 
remove the Ago-RNA complexes from the beads and dissociate free RNA.  Next these 
complexes underwent size selection after being run on an SDS-PAGE gel and being 
transferred to a nitrocellulose membrane.  As in HuR CLIP, free RNA not crosslinked to 
Ago would not be expected to co-migrate with Ago on the gel and then subsequently to 
the nitrocellulose and should have been removed during these rigorous processes.  
Because of these purifications, there was no signal seen at the size of Ago bound to RNA 
on the autoradiogram in non-crosslinked samples (Figure 5.1A).  Thus, we concluded that 
the isolation of mRNA was cross-linking dependent.  Also, the signal seen from the Ago-
RNA complexes collapsed to the expected size of Ago bound to microRNA with over 
digestion of the sample with a high concentration of RNase A (Figure 5.1A).  This 
showed that the signal seen above the molecular weight of RNA was RNase sensitive. 
124
! !
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1 Ago HITS-CLIP.  (A) Autoradiogram of immunoprecipitation results from 
human CD8 T cells prepared with or without crosslinking.  Lysate was 
immunoprecipitated with HuR antibodies (mouse monoclonal Ago specific 2A8).  32P-
labeled RNA was evident in Ago immunoprecipitation with crosslinked lysate, but not 
from non-crosslinked lysate.  With high RNAse treatment, the size of the RNA-protein 
complexes approach the modal size of Ago.  With a lower RNAse treatment, RNA-
protein complexes of ~110 kD are visible, corresponding to the size of Ago-microRNA 
complexes, and also ~130 kD, corresponding to the size of Ago bound predominantly to 
partially digested mRNA.  (B) PCR products amplified after linker ligation of microRNA 
and mRNA products excised from the membrane shown in A. 
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We isolated protein-RNA complexes from the nitrocellulose membrane at the size of Ago 
bound to microRNA and also at a higher molecular weight of Ago bound to larger 
fragments of mRNA.  After this size selection, we digested Ago with Proteinase K and 
cloned the RNA by ligating RNA linkers to either end of the isolated RNA.  Then we 
utilized reverse transcription and amplified the resulting cDNA samples by PCR for high-
throughput sequencing (Figure 5.1B).  During the PCR for the samples prepared from 
protein A immunoprecipitation, we used small aliquots of the total sample to determine 
the minimum number of cycles needed to visualize the resulting products on a Urea-
PAGE gel with SYBR gold staining without over amplification.  Ideally, we want to 
amplify these products for a minimum number of cycles to isolate enough material for 
high-throughput sequencing, but to preserve the complexity of the cloned RNA 
sequences.  Once the minimal cycle numbers were established for each sample, those 
PCR cycles were performed on the remaining aliquot of the sample and they were gel 
purified.  The products from each donor were pooled together to increase the complexity 
of the samples to be sequenced.   
Overview of RNA Tag Statistics 
We sequenced samples produced from the CD8 lymphocytes of five healthy normal 
donors in both a resting state and after being stimulated for an hour with CD3/CD28 
beads.  Each Ago associated mRNA sample produced between 21 and 35 million 
sequencing reads.  We collapsed duplicate reads, to minimize the bias introduced from 
PCR amplification.  With only one representation of each sequence in the library, we had 
between 4 and 10 million reads for each sample.  This dramatic decrease is most likely 
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due to both over sequencing of the sample and PCR duplication of CLIP tags.  Each 
sample was then mapped to its location in the hg18 build of the human genome (Table 
5.1), yielding between 800,000 to 4.5 million uniquely mapping RNA CLIP tags. 
The 5’ RNA linker contained a four nucleotide degenerative sequence.  Comparing the 
four-nucleotide barcodes allowed us to distinguish between unique Ago binding events 
that occur on different mRNA molecules at the same position and yielded identical RNA 
sequences and PCR duplications of a single Ago interaction.  We removed duplicates that 
had the same starting and ending genomic coordinates and the same four-nucleotide code 
in the linker sequence.  After this computation, the samples were reduced to under 
100,000 reads for the protein G samples and between 300,000 and 1.25 million unique 
CLIP tags for the protein A samples.  The colors used to highlight each donor sample in 
the table correspond to the colors of the tag representations in subsequent analyses on the 
genome browser (Table 5.1).  In this way, we can compare the data in each state from 
matching donor samples and relate binding changes to the sequencing depth of each 
sample.  The Ago sample coloring also matches HuR CLIP data from the same donors, 
presented in Chapter IV.  These Ago HITS-CLIP analyses in lymphocytes in the resting 
and activated state from five normal donors resulted in the generation of an extensive 
dataset of Ago bound RNA. 
Reproducibility of Binding between Biologic Replicate Samples 
As with our analysis of HuR binding, we wanted to focus on Ago sites of regulation 
where the cloned binding events were robust and reproducible between different donors.  
To begin this exploration, we used a program to group CLIP tags that mapped to regions 
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Table 5.1 Ago CLIP mRNA Tag Statistics. 
 
 
 
Resting
Ago Total Reads
Total Reads
(One Copy)
Mappable 
Reads 
(One Copy)
Unique 
Mappable 
Reads
% Total Reads 
(One Copy)
Donor 1 32,542,843 8,079,941 3,655,774 556,098 6.88
Donor 2 26,822,766 6,789,815 3,525,705 690,355 10.17
Donor 3 29,655,003 9,280,766 4,407,580 1,009,902 10.88
Donor 4 34,142,134 6,983,614 1,671,612 75,346 1.08
Donor 5 31,620,159 4,443,870 791,461 24,852 0.56
Activated
Ago Total Reads
Total Reads
(One Copy)
Mappable 
Reads 
(One Copy)
Unique 
Mappable 
Reads
% Total Reads 
(One Copy)
Donor 1 32,467,147 8,807,525 4,026,449 1,301,022 14.77
Donor 2 21,768,315 4,433,931 1,699,750 305,414 6.89
Donor 3 21,658,925 4,930,455 2,425,804 1,218,059 24.70
Donor 4 30,981,793 4,959,913 1,147,922 50,879 1.03
Donor 5 28,363,457 4,605,741 965,624 46,980 1.02
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of the genome that overlapped at least 5 nucleotides.  Within each cluster of tags, we 
designated that in at least one position there be at least 5 tags overlapping the same 
nucleotide.  We calculated the number of tags overlapping at the peak nucleotide position 
of each cluster and call this the peak height.  To look at the correlation between the ten 
samples, we excluded 8 clusters that had a sum of over 1,000 CLIP tags grouped together.  
We did this to have a more conservative estimation of the correlation, because these 
clusters improved the correlations and we were concerned that these were not accurate 
depictions of Ago regulation.   
To assess the reproducibility of our HITS-CLIP assay, we then calculated the absolute 
value of the Pearson correlation coefficient between the numbers of tags per cluster that 
originated from each normal donor from either resting or activated T cells (Figure 5.2).  
For the samples prepared from protein A immunoprecipitation, we saw at least a 
correlation of r=0.88 between samples from different donors in the same activation state.  
These high correlations were slightly reduced, but very robust of at least r=0.77, 
comparing protein A samples derived from activated T cells compared to resting T cells.  
Because of the low read depth in the protein G prepared samples, the correlations 
between them was lower than those from protein A, between 0.65 and 0.84.  And they are 
even lower when comparing protein G samples to protein A.  These lower correlations 
are most likely due to the lower probability of a unique read from the protein G samples 
being present in a cluster formed by the larger numbers of reads from the protein A 
samples.  Still, there is the possibility that the different immunoprecipitation protocols 
introduce bias into the samples.  
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Figure 5.2 Pairwise Correlation of Ago CLIP Clusters.  Upper half of table: Pair-wise 
scatter plots displaying the number of tags per cluster of Ago CLIP tags contributed to 
the cluster by each resting (r) or activated (a) donor sample as indicated.  Lower half of 
table: absolute value of the pair-wise Pearson correlation coefficient of the number of 
tags contributed to each cluster by each resting or activated donor sample.  The size of 
text is scaled to the correlation value.  Clusters needed to contain a minimum of 5 
overlapping tags at one nucleotide position to be included in either analysis.  !
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For more stringent analysis, we also specified that there be at least three of the five donor 
samples represented in each cluster in either the resting or the activated state to demand 
biologic reproducibility in each putative Ago binding site.  With these conditions, we 
defined over 38,000 sites of robust Ago mRNA binding.  More than 40 percent of these 
clusters had robust binding in both the resting and activated states. 28 percent of clusters 
were present at this stringency level only in the resting state (10,839 clusters) and 41 
percent of clusters were in the activated state alone (15,740 clusters) (Figure 5.3).  
Interestingly, while there were more clusters with Ago binding sites in the activated state, 
we saw less of a difference in the percentages of clusters distributed between resting and 
activated states with Ago regulation than with HuR (Figure 4.8).  In summary, these data 
demonstrate the reproducibility of the Ago HITS-CLIP method between different normal 
human donor samples.   
Genomic Distribution of Ago Binding Sites 
To examine the role of Ago in regulating mRNA in T cells, we next determined which 
regions of target transcripts were represented by the Ago binding sites.  We mapped 
clusters that represented tags from at least three of the five donors and a peak height of 5 
in either the resting state (Figure 5.4A), activated state (Figure 5.4C), or both (Figure 
5.4B).  As in the HuR dataset, we were surprised at the large number of robust clusters 
that mapped to intronic regions of target transcripts.  In all three groups we saw more 
than two thirds of clusters mapping to intronic regions of regulation, while 3’UTR 
binding represented a smaller, but significant portion of Ago regulation (13-15%).  An 
even smaller proportion of clusters mapped to the coding region and 5’UTR of genes.  
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Figure 5.3 Ago Clusters Activation State Distributions.  Venn diagrams show the 
overlap between Ago target clusters in the indicated activation states with the number of 
clusters representing 3 biologic donor samples and a peak height of at least 5 CLIP tags 
shown. 
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Figure 5.4 Ago Clusters Genomic Distribution.  Distribution of clusters, comprised of 
at least 3 biologic donor samples in the resting and or activated state and a peak height of 
at least 5 CLIP tags, among Ago target transcripts represented by pie chart. 
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Thus, the binding regions of Ago on target transcripts were reproducible between binding 
states and lymphocytes may provide a strong model system to study the roles of Ago in 
intronic RNA binding. 
Ago bound MicroRNA Analysis 
In addition to mapping Ago-binding events in mRNA target transcripts, we also cloned 
and sequenced bound microRNA molecules from two donors in both the resting and 
activated states.  From these samples we mapped between 21 and 35 million microRNA 
tags (Table 5.2).  We identified 271 microRNA that were present in at least one of the 
four sequenced samples, but the top 35 sequenced microRNAs represented over 98% of 
the sequencing reads.  These top microRNAs are listed in order of total sequencing 
frequency in Table 5.3.  The top microRNA found in the CD8 lymphocytes was miR-
142-3p.  miR-142 is specific to the hematopoietic lineage and was shown previously to 
be the most represented microRNA in T cells, confirming that our data correlates well 
with previous findings (Landgraf et al., 2007). 
To examine whether microRNAs changed in their binding status to Ago during T cell 
activation we calculated the number of tags sequenced for each microRNA normalized to 
the total read depth so that they could be compared between samples.  We determined the 
ratio of tags in the activated and resting state for each microRNA for both of the two 
donors.  We included microRNAs that were more than 1.5 fold changed in either 
direction but in the same direction with CD3/CD28 stimulation in both of the donor 
samples.  We included these small changes in microRNA fluctuations because these were 
shown to be potentially biologically meaningful in many contexts, for instance, the light 
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Table 5.2 Ago CLIP microRNA Tag Statistics. 
 
 
 
Mappable 
miRNA Reads
Resting Ago
Donor 3 29,655,003
Donor 4 34,142,134
Activated Ago
Donor 3 21,658,925
Donor 4 30,981,793
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Table 5.3 Ago CLIP: Top 35 microRNAs.  Listed are the top 35 microRNAs 
represented in the Ago CLIP microRNA dataset ranked by the total number of CLIP 
reads for each microRNA from all four sequencing experiments pooled together. 
 
 
 
Top 35 
miRNA 
Donor 3 
Resting
Donor 3 
Activated
Donor 4
Resting
Donor 4
Activated
Total 
Reads
% Total 
Reads
hsa-miR-142-3p 8,515,220 6,696,915 8,817,909 8,332,644 32,362,688 34.122
hsa-miR-30e 1,392,825 1,487,372 3,909,695 4,685,356 11,475,248 12.099
hsa-miR-27a 1,650,403 1,935,439 4,046,307 2,875,217 10,507,366 11.079
hsa-miR-26a 1,145,899 1,169,916 2,823,385 3,565,442 8,704,642 9.178
hsa-miR-146b-5p 609,620 567,185 2,054,043 1,937,224 5,168,072 5.449
hsa-miR-374a 603,602 754,739 1,834,183 1,845,924 5,038,448 5.312
hsa-miR-30d 553,358 714,481 1,490,311 1,700,847 4,458,997 4.701
hsa-miR-150 515,547 532,214 998,918 966,580 3,013,259 3.177
hsa-miR-19b 358,778 290,837 303,262 608,323 1,561,200 1.646
hsa-miR-181a 146,886 156,775 470,628 595,160 1,369,449 1.444
hsa-miR-374b 157,360 186,928 435,675 449,082 1,229,045 1.296
hsa-miR-101 236,535 245,996 333,864 400,586 1,216,981 1.283
hsa-miR-21 314,130 318,429 239,254 273,519 1,145,332 1.208
hsa-miR-20a 116,350 126,002 207,719 195,158 645,229 0.680
hsa-miR-16 118,932 117,031 189,527 193,081 618,571 0.652
hsa-miR-186 143,883 120,637 169,311 157,836 591,667 0.624
hsa-let-7i 121,066 116,858 115,255 140,371 493,550 0.520
hsa-miR-222 115,497 134,916 80,877 127,151 458,441 0.483
hsa-miR-29b 155,622 109,587 96,612 92,757 454,578 0.479
hsa-miR-17 68,345 72,967 124,358 127,512 393,182 0.415
hsa-miR-19a 92,935 74,627 56,256 106,223 330,041 0.348
hsa-miR-26b 67,407 61,673 67,048 88,771 284,899 0.300
hsa-miR-31 74,834 64,612 48,024 58,200 245,670 0.259
hsa-let-7g 70,368 63,330 45,329 48,572 227,599 0.240
hsa-miR-30b 48,111 62,490 53,251 62,742 226,594 0.239
hsa-miR-92a 51,946 48,263 45,599 64,291 210,099 0.222
hsa-miR-142-5p 59,166 58,643 39,219 44,112 201,140 0.212
hsa-miR-30a 29,167 25,415 39,905 46,708 141,195 0.149
hsa-miR-155 27,260 25,858 33,528 37,810 124,456 0.131
hsa-miR-181b 15,069 14,618 32,433 51,007 113,127 0.119
hsa-miR-30c 30,893 30,747 25,484 25,953 113,077 0.119
hsa-miR-106b 14,344 20,174 39,123 28,142 101,783 0.107
hsa-miR-140-5p 29,568 21,862 20,733 26,551 98,714 0.104
hsa-miR-146a 23,109 21,528 22,782 21,337 88,756 0.094
hsa-let-7a 25,371 23,861 15,695 16,880 81,807 0.086
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and dark adaptation of the retina (Krol et al., 2010).  Finally, we ranked these changes by 
taking the ratio of the sum of normalized reads in the activated and resting state for the 
two donors together.  As enumerated in Table 5.4, there were 33 microRNA with 
reproducible changes in Ago binding with T cell activation of at least 1.5 fold change.  
Still, it is unclear whether these changes are biologically significant, because the most 
highly abundantly sequenced microRNA in this list, miR-32, had a normalized rank of 
68th out of the 271 sequenced microRNAs.  As mentioned above, a very small number of 
microRNAs represented the vast majority of sequencing reads and the microRNAs 
ranked above miR-32 accounted for 99.7% of the total reads sequenced.  While the 
largest changes were among microRNAs with low levels of Ago binding, it is possible 
that the identified fluctuations could represent the dynamic control of lymphocyte 
activation acutely at one hour of CD3/CD28 stimulation. 
Ago mRNA Binding Changes with Activation 
As described in the previous chapter, RNAseq was done on non-crosslinked aliquots of 
the same pools of cells that were prepared for HITS-CLIP.  Using this data, we can give 
context to the regulation by Ago and HuR by considering the transcript abundance of 
target and non-target RNAs.   In this manner we were able to compare the dynamic 
changes in both transcript binding by Ago and HuR with the dynamic changes in gene 
expression seen with lymphocyte activation. 
Using the same criteria as for HuR tags outlined in Figure 4.11, we clustered Ago CLIP 
tags together from the resting and activated states of the five donors sequenced.  For each 
cluster we specified that the CLIP tags overlap at least 5 nucleotides in their genomic loci, 
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Table 5.4 MicroRNAs Shifting More than 1.5 Fold with Activation.  MicroRNAs are 
ranked by the total number of CLIP reads for each microRNA from all four sequencing 
experiments pooled together. 
 
 
 
Donor 3 
Resting
Tags
Donor 3 
Activate
d
Tags
Donor 4
Resting
Tags
Donor 4
Activate
d
Tags
Total 
Reads
Donor 3 
Resting
Norm.
Donor 3 
Activate
d
Norm.
Donor 4
Resting
Norm.
Donor 4
Activate
d
Norm.
Act/
Rest
(Norm.)
hsa-miR-365 0 24 0 46 70 0.00 0.79 0.00 2.74 ---
hsa-miR-941 0 36 0 18 54 0.00 1.19 0.00 1.07 ---
hsa-miR-151-5p 0 1 0 4 5 0.00 0.03 0.00 0.24 ---
hsa-miR-769-3p 1 37 3 43 84 0.03 1.22 0.17 2.56 18.90
hsa-miR-99b 10 63 20 72 165 0.34 2.07 1.11 4.29 4.40
hsa-miR-548e 0 363 58 35 456 0.00 11.95 3.21 2.09 4.37
hsa-miR-1977 4 80 23 38 145 0.13 2.63 1.27 2.26 3.47
hsa-miR-132 97 761 201 360 1,419 3.27 25.05 11.14 21.45 3.23
hsa-miR-98 74 271 80 162 587 2.50 8.92 4.43 9.65 2.68
hsa-miR-200b 630 2,306 330 504 3,770 21.25 75.92 18.29 30.03 2.68
hsa-miR-192 611 1,718 1,135 1,701 5,165 20.61 56.56 62.90 101.36 1.89
hsa-miR-874 105 498 733 1,118 2,454 3.54 16.39 40.62 66.62 1.88
hsa-miR-503 35 55 31 58 179 1.18 1.81 1.72 3.46 1.82
hsa-miR-320b 184 287 82 143 696 6.21 9.45 4.54 8.52 1.67
hsa-miR-182 0 255 112 11 378 0.00 8.39 6.21 0.66 1.46
hsa-miR-940 0 41 23 1 65 0.00 1.35 1.27 0.06 1.11
hsa-miR-579 0 46 43 13 102 0.00 1.51 2.38 0.77 0.96
hsa-miR-32 4,459 2,594 3,872 2,383 13,308 150.43 85.40 214.59 142.00 0.62
hsa-miR-338-3p 217 46 503 258 1,024 7.32 1.51 27.88 15.37 0.48
hsa-miR-339-3p 149 62 169 74 454 5.03 2.04 9.37 4.41 0.45
hsa-miR-100 47 0 68 36 151 1.59 0.00 3.77 2.15 0.40
hsa-miR-1277 5 0 75 24 104 0.17 0.00 4.16 1.43 0.33
hsa-miR-135b 131 1 465 154 751 4.42 0.03 25.77 9.18 0.31
hsa-miR-130b 144 35 95 25 299 4.86 1.15 5.26 1.49 0.26
hsa-miR-548n 2 0 3 1 6 0.07 0.00 0.17 0.06 0.25
hsa-miR-548i 3 1 1 0 5 0.10 0.03 0.06 0.00 0.21
hsa-miR-362-3p 56 0 27 10 93 1.89 0.00 1.50 0.60 0.18
hsa-miR-1972 0 1 74 11 86 0.00 0.03 4.10 0.66 0.17
hsa-miR-331-5p 2 1 31 0 34 0.07 0.03 1.72 0.00 0.02
hsa-miR-212 112 0 43 0 155 3.78 0.00 2.38 0.00 0.00
hsa-miR-545 2 0 16 0 18 0.07 0.00 0.89 0.00 0.00
hsa-miR-744 3 0 14 0 17 0.10 0.00 0.78 0.00 0.00
hsa-miR-499-3p 1 0 15 0 16 0.03 0.00 0.83 0.00 0.00
Act
Rest
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that there be four of five donors represented in the resting and or activated state, and that 
there be a position in the cluster where at least 10 tags from either activation state overlap.  
We calculated the percentage of tags in each cluster that originated from activated cells 
and then binned the clusters into whether the binding increased (>60 % activated tags), 
decreased (<40% activated tags), or showed little to no significant change (between 40% 
and 60% activated tags) with T cell activation.  For the gene expression for each cluster, 
we binned the RNAseq values into the same three groups with the same cutoffs 
depending on the percentage of RPKM values from sequencing the activated T cells for 
each gene.  Furthermore, to ensure that the RNAseq data was interpretable, we specified 
that the transcript have a minimum of an RPKM of 15 for inclusion in the subsequent 
analysis. 
As shown in the summarized results in Table 5.5A, nearly two thirds of robust Ago 
clusters showed dramatic changes in binding patterns with T cell activation.  Of these 
dynamically changing Ago clusters, 37% reflected parallel changes in transcript 
abundance in the cells.  Globally, more than half of Ago clusters had paired gene 
expression changes with their binding changes.  It was in only 7% of robust Ago binding 
sites that gene expression changed between the resting and activated state without a 
dynamic change in Ago binding and in less than 2% of clusters in which Ago binding and 
gene expression shifted in opposite directions.  Thus, we can conclude that while Ago 
binding clearly shifts dramatically and dynamically with lymphocyte activation, much of 
these differences at one hour of CD3/CD28 stimulation can be explained by changes in 
transcript abundance. 
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!Table 5.5 Combining Ago CLIP with RNAseq.  (A) This table shows the number of 
clusters binned in each category based on the scoring system outlined in Figure 4.11.  (B) 
This table lists the transcripts with the largest changes in cluster binding between resting 
and activated states.  First are Ago clusters with the largest decreases in binding with T 
cell activation, then the largest increases in binding, and finally clusters where Ago 
binding most opposes the changes in transcript abundance. 
 
 
 
351 625 861
1837
Ago
Rest > Act
Ago
Rest ≈ Act
Ago
Rest < Act
251
RPKM
Rest > Act
108 111 32
1215
RPKM
Rest ≈ Act
241 488 486
371
RPKM
Rest < Act
2 26 343
Clusters: Ago ⬇ 
with CD3/CD28
Clusters: Ago ⬆ 
with CD3/CD28
Clusters: Ago
 
Opposing RPKM
WDR68 EGR2 IFI16
STX2 NR4A3 TAF15
BRWD1 EGR3 PLEC1
C6orf190 EGR1 ZC3H18
ENO2 NR4A2 SFRS8
MGAT4A CD69 SRRM1
SLC4A7 IFNG SESN3
FYB MYC ARGLU1
ARRDC3 IL2 NFATC2
UBQLN1 NR4A1 ANKRD10
A B
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Similarly to HuR, the biggest changes in Ago binding occurred with T cell activation in 
early activation genes and markers (Table 5.5B).  These transcripts had very minimal 
expression in the resting state and virtually no Ago binding.  After an hour of T cell 
activation, Ago crosslinked throughout these transcripts in high abundance.  Using the 
same examples as for HuR binding, in Figure 5.5 we see Ago coating the coding region, 
UTRs and downstream of the 3’UTR of the EGR3 transcript.  We did not expect to see 
such dynamic changes in binding within one hour of stimulation with CD3/CD28 
antagonists.  Similarly, Ago binding on the IFNG transcript increased dramatically with 
lymphocyte activation (Figure 5.6).   
Finally, Ago binding in some clusters decreased dramatically with lymphocyte activation.  
One of the more dynamic examples of such changes was in the intronic region of FYB 
(Figure 5.7).  This example illustrates robust binding in the resting state that has less than 
biologic complexity of two binding in the activated state.  While the FYB gene decreases 
slightly with T cell activation, it is binned with the group of genes that do not show 
dramatic shifts in transcript abundance and shows more dynamic binding preferences by 
Ago.  As seen in Figure 5.4 the intronic regulation by Ago as seen in the IFNG transcript 
is not limited to the activated state and is not necessarily linked to dramatic induction of 
transcription within the T cell.  In summary, we identified reproducible Ago binding 
clusters in lymphocytes in both the resting and activated states.  Many of these clusters 
show dramatic quantitative changes in binding events with T cell stimulation and 
generally the majority of binding patterns in each state mirror the RNA level of that 
target.  
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Figure 5.5 Ago Binding on Human EGR3.  The position of individual Ago unique 
CLIP tags in biologic complexity two clusters plotted relative to their mapped position on 
the human EGR3 transcript.  From top to bottom: chromosomal location, Ago CLIP tags 
from activated CD8 T cells (colors represent each donor sample as shown in Table 5.1), 
Ago CLIP tags from resting CD8 T cells, Gene diagram from RefSeq. 
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Figure 5.6 Ago Binding on Human IFNG.  The position of individual Ago unique 
CLIP tags in biologic complexity two clusters plotted relative to their mapped position on 
the human IFNG transcript.  From top to bottom: chromosomal location, Ago CLIP tags 
from activated CD8 T cells (colors represent each donor sample as shown in Table 5.1), 
Ago CLIP tags from resting CD8 T cells, Gene diagram from RefSeq. 
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Figure 5.7 Ago Binding in Human FYB Intron.  The position of individual Ago unique 
CLIP tags in biologic complexity two clusters plotted relative to their mapped position on 
an intron of the human FYB transcript.  From top to bottom: chromosomal location, Ago 
CLIP tags from activated CD8 T cells (colors represent each donor sample as shown in 
Table 5.1), Ago CLIP tags from resting CD8 T cells, Gene diagram from RefSeq. 
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Discussion 
In this chapter we examined the binding patterns of Ago in the resting and activated 
states of CD8 lymphocytes from five normal human donors.  Using two different 
immunoprecipitation configurations with protein A or protein G beads, we were able to 
amass a large dataset of reproducible binding sites for Ago in T cells on mRNA and 
microRNA.  As alluded to above, we think the difference in complexity between the 
protein G and protein A samples is due to a increased efficiency of the 
immunoprecipitation using protein A and a bridging antibody to maximize the antigen 
binding surface of the Ago monoclonal antibody.  Also, using a larger proportion of the 
isolated cDNA to be amplified and pooled from lower cycle numbers in the PCR 
reactions helped increase the overall complexity of the sequenced material during the 
protein A sample preparations.   
We found many clusters of Ago binding in the resting state alone, both states, and a 
slightly larger number of clusters in the activated state alone.  This represents the first in 
vivo dataset of mapped Ago regulation in human T cells with a physiologic biologic state 
change and it was interesting to discover that Ago binding changes quite dramatically 
within one hour of CD3/CD28 stimulation in CD8 lymphocytes.  While the distribution 
of binding within clusters and between transcripts did shift dramatically with T cell 
activation, we did not see a global shift in the regions of transcripts that are bound by 
Ago in the different states.  We were surprised to find that, while 3’UTR binding 
represented a significant portion of Ago regulation (13-15%), the majority of robust Ago 
clusters were found in intronic regions of transcripts.  This contrasts with the maps 
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previously determined in the lab for Ago function in the mouse brain, where only 12% of 
clusters biologic complexity greater than or equal to two mapped to intronic sequences.  
In the Ago brain map, about one third of clusters mapped to the 3’UTR regions of 
transcripts and a quarter to coding regions, while less than half of those percentages did 
in T cells (Chi et al., 2009).   This may represent differences in the biology of 
lymphocytes, which unlike the brain are actively dividing cellular populations.  Loeb et al. 
also reported a lower percentage of Ago CLIP tags mapping to 3’UTR regions within T 
cells.  These studies used a polyclonal antibody specific to Ago2 for immunoprecipitation 
and not a pan-Ago antibody as we did (Loeb et al., 2012).  Thus we speculate that it is 
possible that some of the increased intronic binding seen in our samples could be due to 
regulation by the other Ago proteins in T cells or other binding preferences of the 
antibodies in isolating populations of Ago within the T cells. 
Similar to other studies measuring microRNA abundance in lymphocyte populations, we 
found that miR-142 was the most represented in our CD8 T cells (Landgraf et al., 2007; 
Salaun et al., 2011; Wu et al., 2007).  While we were able to identify almost 300 
microRNA bound to Ago in either the resting and activated states, similar to previous 
work, we found that a small number of microRNA represented the vast majority of Ago-
bound sequencing reads (Chi et al., 2009).  The top 35 microRNA found in our T cell 
dataset represented over 98% of the total reads.  We identified 33 microRNAs that 
changed in their Ago binding status between the resting and activated state and more than 
1.5 fold with activation.  Although these may be robust differences, it is unclear whether 
these shifts in microRNAs that are representative of far less than 0.5% of Ago binding 
could greatly influence the biology of T cells.  Further analysis and studies are needed to 
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determine if these shifts in these Ago bound microRNA help define the biology of the 
resting and activated T cell phenotypes.  
While we did not observe large differences in Ago-bound mature microRNAs cloned in 
our CLIP experiments, we did observe an increase in binding in many microRNA host 
genes and pre-microRNA transcripts (data not shown).  Previous studies have 
demonstrated that the levels of many microRNAs can be regulated in the reaction to 
different stress responses (Leung & Sharp, 2007).  It would therefore be informative to 
consider the Ago-bound microRNA repertoire with respect to the cellular pool of 
microRNAs at later time points with activation to examine the kinetics of Ago-
microRNA interactions and determine if and when there is a shift to reflect this changing 
population of small RNAs in the cell. 
As observed in HuR binding pattern changes with activation, although nearly two thirds 
of Ago binding sites shift quantitatively with CD3/CD28 stimulation, the majority of Ago 
binding changes are parallel to variations in transcript abundance.  It was surprising to 
find that Ago binding correlated well with transcript expression levels, because it is 
typically assumed that increased Ago binding leads to decreased expression of its targets 
(Bartel, 2009).  One possible interpretation is that the dynamic Ago binding map 
determined here after one hour of T cell stimulation may be too short of a time course to 
see the downstream effects of Ago binding in terms of transcript abundance.  It would 
therefore be informative to look at RNA levels, ribosomal occupancy, and protein levels 
at later time points to elucidate the ultimate effects of Ago regulation during T cell 
activation. 
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With one hour of stimulation, the most dramatic shifts in Ago-binding patterns were in 
early activation gene transcripts and T cell activation markers.  Although in the EGR3 
and IFNG transcripts, the largest clusters of Ago binding could be seen in the 3’UTR, 
like for HuR, we observed binding throughout the entire transcript including intronic 
regions.  This was even more unexpected for Ago than HuR because it was assumed that 
a majority of Ago regulation was occurring in the cytoplasm and on processed mRNA 
transcripts rather than pre-mRNA.  It was also surprising for these and other transcripts 
that Ago coated the newly transcribed RNAs in a manner that does not appear to be 
microRNA specific but rather that Ago may be deposited co-transcriptionally.  This 
differs from the binding seen by Ago in the brain where intronic clusters are less 
represented.  This may reflect differences between these two biologic systems (Chi et al., 
2009).  These top Ago transcript targets overlapped impressively with HuR targets and 
led us to investigate the potential combinatorial control of Ago and HuR in resting and 
activated lymphocytes. 
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CHAPTER 6.  Exploring the Combinatorial Control of Ago and HuR  
RNA Regulation During T cell Activation 
Introduction 
The instruction of transcriptional and translational control by (Argonaute) Ago and HuR 
are both critical for immune function.  As described in the previous two chapters, we 
have used high-throughput sequencing crosslinking immunoprecipitation (HITS-CLIP) to 
establish regulatory maps for both of these RNA-binding proteins in the resting and 
activated states of cluster of differentiation eight (CD8) lymphocytes.  Interestingly, we 
saw similar binding changes in key Ago and HuR target mRNAs.  Therefore, we 
undertook to study the combined regulation of these proteins during lymphocyte 
activation. 
The pronounced specificity of Ago targeting mRNA sites cannot be explained solely by 
the presence of target sequences complementary to the six-nucleotide microRNA seed 
region, because potential target sites far outnumber true Ago binding sites in the 
transcriptome.  Additionally, many Ago binding sites have been identified without having 
clear microRNA pairings (Bhattacharyya, Habermacher, Martine, Closs, & Filipowicz, 
2006a; 2006b; Chi, Hannon, & Darnell, 2012; Chi, Zang, Mele, & Darnell, 2009; Leung 
et al., 2011; Loeb et al., 2012).  Predicted microRNA target sites are abundant in AU-rich 
elements (ARE), creating the possibility for combinatorial regulation of mRNA by Ago 
and other RNA-binding proteins, such as HuR (Chang et al., 2012; Meisner & Filipowicz, 
2010).  Studies investigating the control of joint mRNA targets of both Ago and HuR 
have signaled the importance of these interactions, but their focus on specific transcripts 
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and varied outcomes on the regulation of these messages has indicated the need for more 
systematic study of their combinatorial regulation.  
For instance, CAT-1 protein levels can increase during stress responses without a 
corresponding change in transcription.  While the translational repression of this message 
is mediated by Ago-miR-122 sequestration of CAT-1 to P-bodies, upon the activation of 
a stress response, HuR binds this 3’UTR in ARE and allows for the association of CAT-1 
with active polysomes.  Thus, upon the induction of cellular stress, HuR mitigates Ago 
repression of CAT-1 (Bhattacharyya, Habermacher, Martine, Closs, & Filipowicz, 2006a; 
2006b; Kim et al., 2009).  Furthermore, Ago and HuR were shown to compete for 
regulation of Vegf-a and the balance of this regulation influenced the development of 
angiogenesis in mice and zebrafish (Chang et al., 2012; Glorian et al., 2011; Kundu, 
Fabian, Sonenberg, Bhattacharyya, & Filipowicz, 2012).  Conversely, HuR was shown to 
be necessary for microRNA let-7 mediated repression of c-Myc.  Manipulation of HuR 
and let-7 levels within HeLa cells showed that each negatively correlated with c-Myc 
mRNA and protein levels.  The binding region in the 3’UTR for HuR was shown to be 
adjacent to a let-7 site and HuR was necessary for Ago binding to the 3’UTR to mediate 
down regulation of c-Myc (Kim et al., 2009; Lebedeva et al., 2011). Other work 
investigating the combinatorial control of Ago and HuR utilizing in vitro systems has 
also elucidated further examples of Ago and HuR interdependence for the regulation of 
RhoB and IL-1B mRNA (Glorian et al., 2011; Kundu et al., 2012; Mukherjee et al., 
2011).  
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Recent work integrating Ago and HuR binding maps produced by PAR-CLIP has 
produced conflicting results on whether their binding patterns are similar.  In comparing 
genome-wide HuR binding sites in HeLa cells with Ago maps identified in HEK293 cells, 
a preference for binding in areas of Ago targeting was not observed (Lebedeva et al., 
2011; Mukherjee et al., 2011).  These differences may represent differences in the 
regulation of these proteins between the cell lines explored.  Mukherjee et al. compared 
this same HEK293 cell Ago PAR-CLIP data with HuR PAR-CLIP binding sites from 
HEK293 cells expressing a tagged HuR protein.  This group reported significant 
overlapping patterns of regulation for the two proteins, suggesting a potential for 
competition of these proteins for regulatory binding of target transcripts.  Still, the 
mRNA level changes observed in these cells with HuR knockdown could be explained 
with or without the presence of overlapping or adjacent microRNA binding sites.  The 
authors suggest that HuR may physically compete with Ago for access to binding sites to 
regulate the fate of targets (Levy & Darnell, 2002; Mukherjee et al., 2011).  Therefore, 
more work is needed to understand the relationship of these RNA-binding proteins, 
especially in the context of physiologic systems and dynamic cellular state changes.  In 
this section we study the Ago and HuR HITS-CLIP binding maps from resting and 
stimulated human CD8 T cells to determine their roles in combinatorial regulation of 
target mRNAs.  
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Results 
Ago and HuR HITS-CLIP Summary 
As previously described, we purified CD8 lymphocytes from five healthy normal 
volunteers.  We crosslinked both rested cells and T cells that were stimulated for one 
hour with CD3/CD28 beads.  The purity of the cells was established to be over 90% CD8 
T cells by flow cytometry and RT-qPCR analysis of TNF and IFNG levels confirmed the 
activation state of non-crosslinked aliquots of the lymphocytes.  The T cells showed a 
280 to 610-fold induction of TNF mRNA and 1250 to 7600-fold induction of IFNG 
mRNA.  Using these CD8 T cells, we have amassed datasets from paired samples for 
Ago and HuR CLIP and the summarized sequencing results are found in Table 6.1.  As in 
previous chapters, the color highlighting each donor for Ago and HuR sequencing 
statistics in the table corresponds to the color of the tags represented on the tracks of the 
genome browser.  This allows us to compare the Ago and HuR tags from each donor 
easily and relate the binding maps to the overall read depth of each sample as we examine 
the regulatory patterns of the proteins on each target transcript. 
Ago and HuR Bind EGR3 and IFNG   
Because the transcripts with the largest dynamic changes in binding patterns for Ago and 
HuR with T cell activation appeared to be very similar, we compared the binding maps of 
the two proteins.  We began by examining the binding patterns on the previously 
discussed EGR3 (Figure 6.1) and IFNG (Figure 6.2) transcripts.  We found that the 
binding patterns of Ago and HuR on these transcripts appeared very similar although they 
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Table 6.1 HITS-CLIP Sequencing Summary.  Abbreviations: Ago 
immunoprecipitation supernatant (Ago Sup), CLIP reads containing an additional 2-
nucelotide sequence in the linker region to identify them as coming from unique 
experimental replicates (2 nt Index). 
 
 
 
RESTING ACTIVATED
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Figure 6.1 Ago and HuR bind Human EGR3.  The position of individual Ago and 
HuR unique CLIP tags in biologic complexity two clusters plotted relative to their 
mapped position on the human EGR3 transcript.  From top to bottom: chromosomal 
location, Ago CLIP tags from activated CD8 T cells (colors represent each donor sample 
as shown in Table 6.1), Ago CLIP tags from resting CD8 T cells, HuR CLIP tags from 
activated CD8 T cells, HuR CLIP tags from resting CD8 T cells, Gene diagram from 
RefSeq. 
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Figure 6.2 Ago and HuR bind Human IFNG.  The position of individual Ago and HuR 
unique CLIP tags in biologic complexity two clusters plotted relative to their mapped 
position on the human IFNG transcript.  From top to bottom: chromosomal location, Ago 
CLIP tags from activated CD8 T cells (colors represent each donor sample as shown in 
Table 6.1), Ago CLIP tags from resting CD8 T cells, HuR CLIP tags from activated CD8 
T cells, HuR CLIP tags from resting CD8 T cells, Gene diagram from RefSeq. 
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were not identical.  Interestingly, while the amount of HuR binding exceeded that of Ago 
on EGR3, the opposite was true for IFNG, where there was much more binding of Ago.  
Because we were able to observe both patterns, and some of the HuR samples were not 
prepared from Ago supernatant and with different RNA linkers, we were able to rule out 
the concern that Ago depleted target sites from being clonable for HuR or that there was 
contamination between samples.  Additionally, Ago and HuR bind with different 
stoichiometry on individual target transcripts. 
For both transcripts, the largest clusters of binding were found on the 3’ untranslated 
regions (3’UTRs) and their binding sites overlap between the two proteins.  As 
mentioned previously, it was interesting to observe the binding pattern of both Ago and 
HuR on the IFNG transcript in both the intronic and coding regions.  This suggested that 
the two proteins might be deposited throughout the newly transcribed message either co-
transcriptionally or at least prior to being processed to become a mature transcript.  
Although HuR and Ago proteins are found in the nucleus, it was unexpected to find 
robust binding events at such early stages of mRNA processing. 
Overlapping Binding of Ago and HuR 
In order to study the intersection of regulatory regions of Ago and HuR in more depth, 
we computed the overlap of CLIP tag clusters on a genome-wide scale.  The calculations 
are diagrammed in Figure 6.3.  To begin, we clustered together all of the resting and 
activated tags for Ago and separately for HuR.  We then specified that each Ago or HuR 
cluster needed to contain reads from four out of five samples in the resting and or 
activated states and that at least 10 tags from either state must overlap in one genomic 
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Figure 6.3 Ago and HuR Cluster Overlap Parameters.  Schematic representing cluster 
and binding footprint definitions used as input into cluster overlap analysis.  CLIP tags 
for each protein were clustered based on overlapping genomic positions of at least 5 
nucleotides.  Clusters were included in the analysis if they were comprised of at least 4 
donor samples in the resting and or activated state and had a peak height of at least 10 
tags between both activation states.  Cluster regions overlapping genomic repeats, 
pseudogenes, ncRNA, or snoRNA were removed from analysis.  The binding footprint of 
each cluster was defined as including 32-nucleotides 5’ and 3’ of the peak position.  Ago 
and HuR clusters were designated as overlapping if their binding footprints overlapped at 
least 1 nucleotide. 
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position.  To make the analysis more stringent, we also removed clusters in low 
complexity repeat regions, pseudogenes, non-coding RNAs and snoRNAs.  We 
calculated the peak binding position of each cluster, where the most tags overlapped, and 
defined a footprint for each cluster of 32 nucleotides up and downstream of the peak 
location.  Finally, we identified clusters from Ago where the footprint of binding 
overlapped with the footprint of HuR clusters.  It was possible for more than one Ago 
cluster to overlap an HuR cluster and vice versa.   
We had roughly 2,500 Ago clusters and 7,500 HuR clusters of biologic complexity of 4 
and peak height of 10 as input into the intersection analysis.  Remarkably, we defined 
over 1,000 intersecting regions that represented over 40% of Ago clusters and 14% of 
HuR clusters.  Figure 6.4 shows a histogram of the distance between the peak positions of 
overlapping Ago and HuR clusters.  Interestingly, not only do large numbers of Ago and 
HuR clusters overlap within a small distance, but their peak positions are also highly 
superimposable suggesting that in many cases Ago and HuR are binding in the exact 
same positions on many transcripts.  Our HuR CLIP samples processed from separate 
lysate from Ago and with distinguishing indexing linker sequences provided a control 
that these binding similarities were not an artifact of having done the 
immunoprecipitation from the same lysate or due to contamination from previous 
experiments.  Similar results were recently published showing a high degree of overlap 
between Ago clusters in HEK293 cells and HuR clusters in HEK293 cells expressing an 
epitope-tagged HuR, providing further support for our finding (Mukherjee et al., 2011). 
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Figure 6.4 Histogram of Ago and HuR Cluster Overlap.  Histogram of the number of 
overlapping cluster footprints with a given distance from the peak position of the HuR 
cluster to the peak position of the Ago cluster. 
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To see whether the overlap of Ago and HuR regulation differed between activation states, 
we repeated the cluster intersection calculations using HuR or Ago clusters that had 
biologic complexity of 4 for each state without consideration of the biologic complexity 
in the opposing state for that protein.  In Figure 6.5, we demonstrate that Ago and HuR 
clusters have high levels of overlap regardless of which states they originated from.  We 
see the same distribution pattern for individual T cell activations states as with all clusters 
together; the most represented position of overlap is at the peak position of the clusters of 
Ago and HuR.  As in the previous analysis, we find that a higher proportion of Ago 
clusters were found to overlap than HuR, but in both cases, this is most likely due to the 
differences in the starting numbers of clusters for each protein as HuR had roughly three-
fold more clusters as input into the analysis. 
Examining Dynamic Changes in Ago and HuR Binding within Overlapping Transcript 
Regions 
In order to understand the interactions between Ago and HuR in overlapping clusters, we 
examined the binding changes in these intersecting regions with lymphocyte stimulation.  
For each cluster, we calculated the log2 ratio of CLIP tags in the activated state to the 
resting state.  In Figure 6.6 these ratios are plotted for intersecting clusters of Ago versus 
HuR.  As shown in Chapters 4 and 5, the majority of Ago or HuR binding changes with T 
cell activation mirror transcriptional changes in these levels.  Consistent with this 
observation, the binding changes with activation were often in the same direction for Ago 
and HuR.  This could suggest agonism between Ago and HuR binding.  For example, on 
the IFNG transcript discussed previously, there is more binding seen in the activated state 
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Figure 6.5 Ago and HuR Cluster Overlap in Resting and Activated States.  Clusters 
were defined as described in Figure 6.3, with the addition of each cluster being 
designated as resting or activated if there was biologic complexity of four (BC4) in that 
state.  Histograms of the number of overlapping cluster footprints with a given distance 
from the peak position of the resting or activated HuR cluster to the peak position of the 
resting or activated Ago cluster.  The number of intersecting clusters is indicated in each 
panel.  Y-axis denotes the number of clusters.  X-axis is the distance (bp) from HuR peak 
to Ago peak. 
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Figure 6.6 Dynamic Ago and HuR Changes in Overlapping Clusters.  Scatter plot of 
the Log2 ratio of the number of activated tags and resting tags in an Ago cluster versus the Log2 ratio of the number of activated tags and resting tags in an HuR cluster with a 
footprint intersecting the Ago footprint. 
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for both Ago and HuR than in the resting state, which reflects the levels of IFNG mRNA 
in each T cell state.  Still, although the changes on IFNG and other transcripts were 
shifting in the same directions, there were many overlapping regions where Ago or HuR 
binding changes were not directly proportional to each other with CD3/CD28 stimulation.  
In the example of IFNG, Ago binding was increased more at one hour than HuR and the 
opposite was observed for EGR3. 
There were also many clusters represented in the upper left and lower right quadrants of 
the graph where Ago and HuR binding changes were in opposite directions, suggesting 
that the proteins could function antagonistically.  For example, a region of overlapping 
Ago and HuR regulation in the 3’UTR of IRF9 is highlighted in the upper left quadrant of 
Figure 6.6.  For these overlapping clusters, the amount of Ago binding increased with 
activation, while the HuR binding decreased.  This cluster is highlighted in the genome 
browser representation of IRF9 in Figure 6.7.  Interferon Regulatory Factor 9 (IRF9) is 
part of the transcriptional regulatory machinery that activates gene expression through 
Tyrosine Kinase (JAK) signaling in response to type I interferon interrogation of cell 
surface receptors.  IRF9 has been demonstrated to increase in response to IFNG which is 
induced substantially with CD3/CD28 activation (Levy & Darnell, 2002).  Thus, IRF9 
might need to be dynamically controlled with T cell stimulation, although transcript 
levels do not shift drastically.  In this example it appears that while both proteins bind 
robustly in both states, that the reduction of HuR binding with activation corresponds 
with the induction of Ago binding.  This suggests that the two proteins may be competing 
for this site of regulation. 
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Figure 6.7 Reciprocal Changes in Ago and HuR Binding in the Human IRF9 3’UTR.  
The position of individual Ago and HuR unique CLIP tags in biologic complexity two 
clusters plotted relative to their mapped position on the human IRF9 transcript.  The 
CLIP cluster showing dynamic reciprocal Ago and HuR binding changes is outlined in 
the 3’UTR.  From top to bottom: chromosomal location, Ago CLIP tags from activated 
CD8 T cells (colors represent each donor sample as shown in Table 6.1), Ago CLIP tags 
from resting CD8 T cells, HuR CLIP tags from activated CD8 T cells, HuR CLIP tags 
from resting CD8 T cells, Gene diagram from RefSeq. 
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Another example of where the binding pattern shifted between T cell activation states in 
an opposing manner for each protein is in the SATB1 transcript.  This cluster is 
highlighted in the scatter plot in Figure 6.6 and the binding map is displayed in Figure 6.8.  
The SATB1 protein regulates chromatin structure organization by recruiting histone 
modifiers to its targets’ genomic loci and its gene regulation has been shown to be 
important in T cell differentiation and proliferation (Burute, Gottimukkala, & Galande, 
2012).  While the binding sites for both Ago and HuR are robustly represented in both 
activation states in this overlapping cluster, the number of HuR tags increases with T cell 
activation while Ago binding decreases, indicating that they may compete for regulation 
at this binding position. 
Examining Ago and HuR Binding in the Context of Transcriptional Levels of Target RNA 
In previous chapters, we examined the binding changes of HuR and Ago in the context of 
the levels of target transcripts as determined by RNAseq.  By comparing binding maps 
with transcript abundance, we can begin to understand the cellular context for the 
regulation by these RNA binding proteins and the dynamic state changes that occur 
quickly with T cell stimulation. 
As diagrammed in Figure 4.11, we designated each Ago or HuR binding site and each 
transcript as being more represented in the resting state, more represented in the activated 
state, or relatively unchanged between the two.  This was accomplished by tabulating the 
percentage of reads for each feature in the activated state as a proportion of the total 
number of reads for that cluster or transcript.  We applied cutoffs at 40 or 60 percent 
representation in the activated state to bin each one into a category, as previously 
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Figure 6.8 Reciprocal Changes in Ago and HuR Binding in the Human SATB1 
3’UTR.  The position of individual Ago and HuR unique CLIP tags in biologic 
complexity two clusters plotted relative to their mapped position on the human SATB1 
3’UTR.  The CLIP cluster showing dynamic reciprocal Ago and HuR binding changes is 
outlined.  From top to bottom: chromosomal location, Ago CLIP tags from activated CD8 
T cells (colors represent each donor sample as shown in Table 6.1), Ago CLIP tags from 
resting CD8 T cells, HuR CLIP tags from activated CD8 T cells, HuR CLIP tags from 
resting CD8 T cells, Gene diagram from RefSeq. 
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described.  Therefore, for each overlapping Ago and HuR cluster, the site is scored on the 
relative amount of binding in the activated state compared to the total binding at that site 
for both Ago and HuR, and the relative amount of transcript abundance in the activated 
state compared to both states together.   As in the other chapters, we also specified that 
the RPKM of target transcripts be at least 15 in either the resting or activated state for 
inclusion in this analysis.  This ensured that there was robustly measured transcript 
abundance for the targeted message in at least one of the states for it to be considered.  
This reduced the number of clusters being analyzed to roughly 700 intersecting regions 
out of the 1,000 regions defined above.   
The results of this combinatorial analysis are summarized in Table 6.2.  In more than 
60% of clusters, Ago and HuR follow a similar pattern of binding with CD3/CD28 
stimulation. In 60% of those clusters, Ago and HuR both follow the same trend as their 
target transcript levels.  More than one fifth of Ago and HuR overlapping clusters are 
synchronized in having a more exaggerated change than that of the transcript level.  In a 
little over a quarter of clusters, while transcript abundance does not shift with T cell 
activation, the binding of either Ago or HuR does dramatically shift binding patterns with 
CD3/CD28 stimulation.  These findings suggest that much of the dynamic change seen in 
binding patterns for Ago and HuR are reflective of the transcriptional changes in the cell, 
although in some cases the RNA-binding map may be even more responsive than 
changes in steady state levels of transcript within the cell.  It is rare that there is a change 
in transcript level without some dynamic change in the binding of Ago and or HuR.  
Interestingly, when transcript abundance increases with T cell activation, there are no 
Ago and HuR intersecting clusters where either protein has more tags in the resting state.  
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Table 6.2 Combining Overlapping Ago and HuR CLIP with RNAseq.  (A) This table 
shows the number of overlapping Ago and HuR clusters binned in each category based 
on the scoring system outlined in Figure 4.11.  (B) This table lists the transcripts with the 
largest changes in cluster binding in the resting and activated states between Ago and 
HuR. 
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This might reflect that lymphocyte stimulation induced increases in gene expression of 
transcripts that are not present in the steady state of a quiescent T cell.  
The FYB transcript was among the top clusters with opposing changes in overlapping 
Ago and HuR binding.  FYB mRNA abundance was scored as relatively unchanged with 
T cell stimulation.  Therefore the dynamic shifts in Ago and HuR binding are not due to a 
dramatic change in transcript level.  While this is the same gene as discussed in Figure 
5.6, the previously analyzed region only contained a robust binding site for Ago and 
therefore was not included in the overlap analysis here.  For all of the clusters of FYB 
identified in either analysis, the binding of Ago was either relatively unchanged or 
decreased with activation.  Here we see overlapping HuR clusters where the binding 
pattern is increased with T cell stimulation.  In the two examples in Figure 6.9, there are 
biologically reproducible binding sites for Ago and HuR in both the resting and activated 
state that overlap.  The quantitative direction of the binding changes, increased HuR 
binding in the activated state with a decrease in Ago binding, suggest that although robust 
binding is present in both states, the two proteins may compete for regulation between the 
resting and activated states and seem to shift the predominantly bound protein in those 
sites with stimulation. 
Ago and HuR and microRNAs 
To begin to probe whether the co-regulation of Ago and HuR was microRNA dependent, 
we examined whether HuR associated with specific Ago-microRNA complexes.  To do 
this, we searched each Ago binding footprint for a microRNA seed match from the top 
microRNAs sequenced in our Ago CLIP samples.  In Figure 6.10A we plotted the 
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Figure 6.9 Reciprocal Changes in Ago and HuR Binding in the Human FYB Gene.  
The position of individual Ago and HuR unique CLIP tags in biologic complexity two 
clusters plotted relative to their mapped position on the human FYB transcript in a coding 
exon (A) or 3’UTR (B).  From top to bottom: chromosomal location, Ago CLIP tags 
from activated CD8 T cells (colors represent each donor sample as shown in Table 6.1), 
Ago CLIP tags from resting CD8 T cells, HuR CLIP tags from activated CD8 T cells, 
HuR CLIP tags from resting CD8 T cells, Gene diagram from RefSeq. 
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Figure 6.10 Ago Clusters with Matches in each Seed Family.  (A) Scatter plot of the 
number of Ago clusters containing a seed family match for clusters with footprints not 
overlapping HuR binding footprints versus clusters with footprints overlapping HuR 
binding footprints.  Overlaid is a solid line representing the linear regression of the points 
with ninety-five percent confidence intervals in red.  Additionally, a black dotted line is 
displayed with a slope that corresponds to the ratio of the number of Ago clusters not 
overlapping HuR to the number of Ago clusters overlapping HuR.  (B) Top 7-mers 
identified in the 22-nucleotide region 5’ and 3’ of Ago peak positions for clusters 
including at least four biologic replicate samples (biologic complexity 4: BC4) and at 
least ten nucleotides in the peak position of the cluster (peak height 10: ph10).  Each 7-
mer was ranked by the p-value of the binomial test comparing the frequency of each 7-
mer (observed) as compared to the frequency of a shuffled sequence of that 7-mer 
(shuffled).  The 7-mers with the ten highest p-values and matching microRNA seed sites 
are listed.  (Top) All Ago clusters of BC4 ph10.  (Middle) Ago clusters BC4 ph10 not 
overlapping an HuR cluster.  (Bottom) Ago clusters BC4 ph10 overlapping an HuR 
cluster. 
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number of Ago clusters with or without overlapping HuR binding sites that matched each 
seed family.  The solid regression line with 95% confidence intervals in red is overlaid on 
top of the plotted points.  Additionally, a dotted line is shown displaying the ratio 
between the number of Ago clusters without HuR to the number of Ago clusters that 
intersect HuR clusters.  We found that a lot of seed matches seemed to hover near the 
cluster number corrected line, but that there were seed families which showed preference 
for binding with or without HuR.  The top microRNA cloned in the Ago CLIP sample 
was miR-142-3p, which represented about a third of the total number of reads in the 
sequenced material.  This microRNA showed a strong preference for binding in Ago 
clusters that did not overlap HuR.  There were roughly five-fold more Ago clusters that 
contained miR-142-3p seed sequences than in sites that overlapped with HuR binding.   
Next we identified the top 7-mer sequences that were most significantly represented 
within 22 nucleotides up or downstream from the peak position of the Ago cluster.  We 
began with Ago clusters of biologic complexity 4 and peak height 10 and also split these 
into two groups whether the Ago cluster was alone or overlapped with an HuR cluster.  
We ranked each sequence by the p-value of the binomial test comparison of the 
frequency of each 7-mer as compared to the frequency of the 7-mer within shuffled 
sequences of the same nucleotide composition of the Ago footprint regions (Figure 
6.10B).    
We see in the top table in Figure 6.10B that permutations of the 8mer targeting sequence 
of miR-142-3p is found in seven out of ten of the most significantly enriched 7-mers 
surrounding the peak of robust Ago clusters.  The other sequences consisted of a stretch 
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of adenine, which may represent sequencing error, or the presence of AU-rich elements 
in these footprints.  The other sequences matched seeds of miR-103/miR-107 and miR-
29a.  These matches were more unexpected because they did not represent microRNAs 
that were highly cloned from our Ago CLIP microRNA dataset (Table 5.3).  Consistent 
with the plot in Figure 6.11A, almost all of the 7-mers from Ago clusters not overlapping 
with HuR clusters, listed in the middle table, represented matches with miR-142-3p.  This 
microRNA was absent in the list of top microRNA matches for Ago clusters overlapping 
HuR.  Of the other top enriched 7-mers in Ago clusters overlapping HuR, the only 
microRNA that was highly cloned in Ago CLIP was miR-31.  We also note that miR-
362-3p was listed in the previous chapter as being potentially down regulated with T cell 
activation, while it had a very low level of sequencing in Ago CLIP.  
Another interesting result was found in examining Ago and HuR binding at primary 
microRNA loci, especially in regions that represent microRNA clusters that are 
independently transcribed, as opposed to processed from pre-mRNA introns.  We did a 
closer examination at the miR-17-92 locus because five of the six microRNA encoded on 
the same primary transcript, miR-7, miR-19a, miR-19b, miR-20a, and miR-92a, were in 
the top 35 sequenced Ago CLIP microRNA (Table 5.3).  Only miR-18a was not 
represented as frequently and was ranked 87th overall.  The Ago tags shown in Figure 
6.11 map to sites that will become mature microRNA, but do not represent binding to 
mature microRNA because the cloned sequences were longer than processed microRNA 
sequences, with each tag being at least 27 nucleotides in length.  We have observed this 
affinity for Ago binding to preprocessed microRNA stem loops in previous Ago CLIP 
datasets derived in the lab.   
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Figure 6.11 Ago and HuR bind the Human microRNA-17-92 Locus.  The position of 
individual Ago and HuR unique CLIP tags in biologic complexity two clusters plotted 
relative to their mapped position on the human microRNA-17-92 locus. From top to 
bottom: chromosomal location, Ago CLIP tags from activated CD8 T cells (colors 
represent each donor sample as shown in Table 6.1), Ago CLIP tags from resting CD8 T 
cells, HuR CLIP tags from activated CD8 T cells, HuR CLIP tags from resting CD8 T 
cells, Gene and microRNA diagram from RefSeq. 
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It was interesting to see that HuR bound robustly in the miR-17-92 locus and that the 
binding appeared to map to regions either between the inferred structure of microRNA 
stem loops or mostly excluding what would become the mature sequences.   We found 
this same pattern of Ago binding to eventual mature microRNA sequences and HuR 
binding surrounding these sequences in many other microRNA loci (data not shown).  
The HuR cluster binding sites from the miR-17-92 cluster are highlighted in orange in 
Figure 6.12, adapted from (Chaulk et al., 2011).  The exceptions to this binding pattern of 
HuR being limited to between the microRNAs in this region were binding sites coating 
the entire miR-20a stem loop, and minor binding sites not highlighted in the figure on 
miR-17 and miR-19b which each contained less than 10 tags between the resting and 
activated state. 
Discussion 
We have defined reproducible genome-wide maps of Ago and HuR RNA binding sites 
before and after T cell activation and have identified differences in the binding maps of 
both Ago and HuR in resting and activated T cells.  Both Ago and HuR rapidly assemble 
on newly transcribed RNA such as EGR3 and IFNG.  In the latter case these proteins 
were found to bind pre-processed message as determined by the coating of binding sites 
along intronic regions in addition to coding sequence and UTRs.  The inclusion of RNA-
binding events on intronic regions suggest that Ago and HuR may play a role in the 
regulation of processing of these and other nascent transcripts.  While Ago and HuR 
proteins are present in the nucleus of the cell, their role there is less defined.  We 
speculate that shuttling of HuR out of the nucleus with T cell activation may involve the 
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Figure 6.12 HuR binding sites mapped onto miR-17-92 Locus.  Predicted secondary 
structure of microRNA-17-92 locus with RNAse T1 cleavage sites indicated with arrows 
from Chaulk et al. 2011.  Highlighted in orange are the sequences found in robust human 
HuR binding sites.  The mature microRNA sequences are indicated with black lines. 
Adapted from Chaulk et al., 2011.
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transport of RNA molecules poising them for post-transcriptional regulation.  This would 
allow quick association of targets with active polysomes or the combination of Ago and 
HuR binding might lead to the competition of these transcripts for active translation or 
storage in stress granules.  As mentioned in previous chapters, while the binding maps at 
one hour of activation most likely represent not only an hour of stimulation but a 
combination of earlier time points, it would be interesting to see how these binding maps 
resolve at earlier and later time points and if intronic binding persists with increased time 
after stimulation. 
Interestingly, the stoichiometry of Ago and HuR binding in the activated states differs for 
these two examples.  While there is more binding of HuR on the EGR3 transcript, Ago 
binding predominates in the IFNG transcript.  We hypothesize that these differences may 
help determine the fate of these transcripts with time after stimulation.  While both 
transcripts are greatly induced with CD3/CD28 activation, the ultimate fate of these 
transcripts is most likely determined by RNA-binding protein regulation.  We speculate 
that the dominant Ago binding on the IFNG transcript may help to temper the induction 
of translation of the cytokine while the HuR predominance on EGR3 may be transiently 
increasing the stability of this transcript.  It would be interesting to study the Ago and 
HuR binding events at earlier and later time points to examine whether these ratios shift 
over time to help mediate the fluctuations in the availability of these transcripts and their 
necessity in different sequential points of the inflammatory response.  Also, studying the 
translational status of these transcripts over time with paired binding maps would help 
elucidate these regulatory mechanisms. 
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Many Ago-binding footprints on a given transcript overlap with those of HuR, and our 
results suggest that in these clusters the peak position of Ago and HuR are quite 
superimposed.  We also observed the overlapping of Ago and HuR binding events in both 
resting and activated T cell states suggesting that the coincident binding is not solely a 
function of T cell stimulation or the rapid increases in transcription therein.  One 
interpretation of these observations is that Ago and HuR are directly competing for 
binding interactions on the same transcript in the same cell. However, since HITS-CLIP 
data represent cellular population averages, it is also possible that Ago and HuR bind to 
the same sites on distinct transcript populations.  In both cases, it is interesting that the 
two proteins share so many sites of regulation.  Because the binding patterns of both 
proteins often reflect changes in transcript abundance, it appears that the binding status is 
very much reflective of the abundance of targets within the cell.   Also, because these 
binding changes with T cell stimulation are so similar, it appears that Ago and HuR could 
be binding to these transcripts cooperatively to regulate post-transcriptional control.  This 
would lead to the determination of the fate of the transcripts in terms of its translational 
status, stability, and cellular localization.  It will be interesting to study whether this 
combinatorial control results in competition between these pathways mediated by each 
individual protein or whether they work in concert to determine the outcome of the target. 
While overlapping Ago and HuR binding patterns are often mirrored with T cell 
activation, we were able to identify examples of binding sites where the two proteins 
change dynamically in opposite directions with CD3/CD28 stimulation.  We highlighted 
the IRF9 and SATB1 3’UTRs and the FYB transcript which show robust overlapping 
binding of both proteins in both T cell states, but have opposite dynamic quantitative 
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shifts for Ago and HuR with T cell stimulation.  These binding interactions may represent 
competition between Ago and HuR for binding sites on these transcripts.  These shifts 
may act to quickly change the processing of these targets during the initiation of T cell 
activation.  Still, the biologically reproducible binding sites in both activation states for 
both of these targets indicate that the binding may not be as simple as a complete switch 
between the two with T cell stimulation.  These sites could in fact represent a dependence 
on one protein for recruitment of the other or could represent antagonistic binding where 
one protein blocks binding sites from the other in opposing stimulation states.  
Furthermore, since the data represent the population average of the T cells, it is possible 
that while the two proteins may compete for these binding sites that only one protein 
occupies the 3’UTR in any one, or the two could be regulating the same individual 
transcripts. 
The microRNA seed matches and top 7-mers represented in Ago binding footprints differ 
between the group of clusters that overlap with HuR or do not.  We found that the most 
highly cloned microRNA in Ago CLIP, miR-142-3p was overrepresented in clusters of 
Ago regulation that did not overlap with HuR binding sites.  Interestingly, most of the 
highly represented microRNAs predicted to be in Ago clusters that overlap HuR were not 
highly abundant in Ago CLIP cloning of microRNAs.  In other words, there may be 
enrichment of Ago to binding sites for rare microRNAs by HuR, perhaps acting as a 
chaperone.  At this point, it is unclear whether these microRNAs were underrepresented 
in the CLIP results, or whether in clusters where Ago and HuR both bind, if the 
microRNA is less critical to the specificity of Ago binding at those sites.  It would be 
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interesting if HuR helped recruit Ago to binding sites in a non-microRNA specific 
manner to help regulate transcript ability and protein abundance. 
We also considered Ago and HuR binding in primary microRNA regions.  While we saw 
very large and reproducible Ago clusters on transcript sites that would be processed to 
become mature microRNAs, we saw reduced HuR binding there.  This is consistent with 
our finding that we did not see microRNAs being amplified from HuR 
immunoprecipitation even when we cut at lower molecular weights from CLIP 
nitrocellulose membranes (data not shown).  Surprisingly, we saw very robust HuR 
binding directly adjacent to and between the sequences that would become mature 
microRNAs in many regions.  The stem loops and tertiary structures of these transcripts 
are important for the regulation of the mature sequences and the primary microRNAs can 
be involved in transcript targeting in the absence of processing (Chaulk et al., 2011; Liu, 
Min, Yue, & Chen, 2008; Meisner & Filipowicz, 2010; Trujillo, Yue, Tang, O'Gorman, 
& Chen, 2010; S.-B. Yue, Trujillo, Tang, O'Gorman, & Chen, 2011).  Thus, it will be 
interesting to examine the implications of HuR binding on the regulation of microRNA 
processing and targeting.   
Comparing the Ago and HuR HITS-CLIP genome-wide maps suggests agonistic and 
antagonistic actions of these two proteins to confer microRNA-mediated regulation of 
mRNA transcripts.  Our results suggest that differences in RNA interactions occur 
quickly after T cell activation and provide important insight into the specificity of how 
microRNA translational regulation may mediate the inflammatory response. 
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CHAPTER 7.  Characterization of Ribosomal Profiling 
of Resting and Activated T cells 
Introduction 
It has been demonstrated that the levels of mRNA expression are not perfectly correlated 
with protein levels in a mammalian cell.  In a study by Vogel et al. combining microarray 
and shotgun proteomic analysis, it was described that only roughly two thirds of protein 
expression can be modeled by mRNA levels and sequence properties such as transcript 
length, amino acid usage and secondary structure (Vogel et al., 2010).  Another study 
estimated that less than half of protein expression could be explained by mRNA levels 
and that translational efficiency was the best predictor of protein abundance 
(Schwanhäusser et al., 2011).  Therefore, in order to understand the biological 
implications of dynamic changes in the RNA binding sites of HuR and (Argonaute) Ago, 
it is important to consider factors beyond steady state RNA levels. 
HuR and Ago have been shown to positively and negatively regulate gene expression at 
transcriptional and translational levels.  Although much work studying HuR has focused 
on transcript stability, HuR has also been linked to dynamic control of translation such as 
in the study of UV-C irradiation of cancer cell lines (Lal et al., 2004; Mazan-Mamczarz 
et al., 2003).  HuR was also shown to promote translation of cytochrome c, as evidenced 
by levels and synthesis of cytochrome c being directly correlated to levels of HuR as 
determined by knockdown and overexpression experiments without observable changes 
in cytochrome c mRNA expression (Kawai et al., 2006).  HuR overexpression studies in 
macrophages, in an inducible mouse model, displayed a reduction in TNF protein levels 
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with increased HuR expression.  This was despite augmented levels and stability of TNF 
mRNA, showing that stabilization of transcripts by HuR can be uncoupled from 
translational increases (Katsanou, Dimitriou, & Kontoyiannis, 2006).  This work and that 
by Sureban et al., describe competition between HuR and other RNA binding proteins for 
regulation of RNA targets.  For example, in vitro studies showed that CUGBP2 competes 
with HuR to mitigate the effect of HuR promoting increased translation of COX-2 
mRNA (Sureban et al., 2007).  Additionally, HuR has also been shown to relieve 
microRNA localization of CAT-1 mRNA to P-bodies within the cell upon amino acid 
starvation and linked to the subsequent translational de-repression of CAT-1 
(Bhattacharyya, Habermacher, Martine, Closs, & Filipowicz, 2006a; 2006b).   
There is evidence that microRNAs can mediate changes in protein expression without 
affecting steady state levels of mRNA targets, poly-A tail length, or polysome association 
of the transcript (Olsen & Ambros, 1999).  Still, others have found that decreases in 
mRNA levels by microRNA mediated repression can predominantly account for the 
protein expression changes of their targets (Baek et al., 2008; Guo, Ingolia, Weissman, & 
Bartel, 2010; Hendrickson et al., 2009).  It has also been reported that the timing for 
translational control may precede the corresponding changes in mRNA expression 
(Bazzini, Lee, & Giraldez, 2012; Selbach et al., 2008).  Other mechanisms of 
translational control by Ago have been proposed as well, such as the microRNA mediated 
deadenylation of mRNA targets leading to degradation of target transcripts but uncoupled 
from translational control, or microRNA interaction with targets inhibiting initiation of 
translation (Pillai et al., 2005; Wu, Fan, & Belasco, 2006).  While most studies have 
focused on microRNA mediated repression of translation, it has also been reported that 
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there are cases were Ago binding helps to mediate translational activation of its targets 
(Henke et al., 2008; Jopling, Yi, Lancaster, Lemon, & Sarnow, 2005; Vasudevan & Steitz, 
2007; Vasudevan, Tong, & Steitz, 2007; 2008; Ørom, Nielsen, & Lund, 2008). 
In summary, microRNA mediated targeting of mRNA targets has been implicated in 
enhancing or repressing translation of those targets both with and without effecting 
changes in target abundance and by interfering with multiple other mechanisms of 
translational control.  The majority of these studies of Ago and HuR function have been 
performed in cell lines with overexpression or knockdown of microRNAs or with 
reporter constructs.  It is therefore important to study RNA regulation and translational 
control in a biologically meaningful dynamic setting of primary cells in the context of the 
combinatorial control of Ago and HuR regulation. 
To accomplish this, we sought to use a technique that measures the steady state 
translational profile of the cell via a high-throughput sequencing approach.  As proteins 
are being synthesized, ribosomes translocate along transcripts to determine the ultimate 
amino acid sequence to be produced.  These ribosomes are able to protect around 30 
nucleotides of bound RNA from nuclease digestion.  After digesting surrounding and 
unbound message in a cell, ribosomes and their protected RNA can be isolated and 
cloned (Guo et al., 2010; Ingolia, Brar, Rouskin, McGeachy, & Weissman, 2012; Ingolia, 
Ghaemmaghami, Newman, & Weissman, 2009).  By sequencing fragments of ribosomal 
protected material, we can gain quantitative insight into which transcripts are actively 
being translated into protein at any point in time in a living cell. 
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In order to determine a global view of the translational profile of the cells as it relates to 
the transcriptional setting, cells were treated with cycloheximide to arrest ribosomal 
complexes from translocating and thereby blocking translational elongation.  The resting 
and activated cluster of differentiation eight (CD8) T cells were each split into two 
aliquots for analysis of the ribosomal footprints in the cells and the levels of mRNA.  
From one aliquot, the cells were lysed and the RNA was digested with micrococcal 
nuclease to reduce the RNA into fragments that were protected by the ribosome.  The 
lysate was spun over a sucrose gradient and then fractions were collected to separate the 
monosomes from the remaining material.  The ribosomal protected fragments (RPFs) 
were purified from the monosome fraction.  In parallel, total RNA was isolated from the 
second aliquot of cells.  The poly-A RNA was selected using Oligo (dT)25 beads to enrich 
for mRNA from the lymphocytes.  The poly-A RNA was alkaline hydrolyzed to reduce 
the mRNA into small fragments.  Both the RPFs and poly-A RNA fragments were then 
cloned, amplified, and were used for high-throughput sequencing to determine the 
ribosomal and transcriptional profiles of the cells (Figure 7.1). 
Results 
Nuclease Titration of CD8 T cells for Sucrose Gradients 
To isolate fragments of RNA protected by the ribosomal complex, it was necessary to 
determine an optimal nuclease digestion protocol to sufficiently degrade non-protected 
RNA, but also to leave the ribosomal complexes intact so that they could be purified on 
the sucrose gradient.  We found that multiple cell types responded very differently to 
nuclease treatment, presumably because of their endogenous nuclease activities, so a 
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Figure 7.1 Ribosomal Profiling and RNA Sequencing Schematic.  CD8 T cells were 
treated with cycloheximide and snap frozen.  (Left) Aliquots of CD8 T cells were lysed 
and treated with micrococcal nuclease to digest RNA to ribosomal protected fragments 
(RPFs).  (Right)  Total RNA was extracted from aliquots of CD8 T cells and poly-A 
selected.  Poly-A RNA was alakaline hydrolyzed to reduce RNA to fragments of similar 
length to RPFs.  RNA fragments were purified, size selected, cloned, and amplified for 
high-throughput sequencing.  (Adapted from Guo et al. 2010).  
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titration with comparable starting material to the experimental cells was necessary.  To 
determine the optimal nuclease digestion protocol, we subjected equivalent aliquots of 
CD8 T cells to different nucleases at varying concentrations and for different periods of 
time.  Next we spun the lysate through a 10%-50% linear sucrose gradient and examined 
the profile of the resulting ribosomes. 
When the cells were lysed, but not treated with any nuclease, a large monosomal peak 
was present and then smaller peaks to the right of the monosome peak represented the 
presence of polysomes within the sample (Figure 7.2.A).  For ribosomal profiling, it 
would be ideal to digest the RNA so that the polysomes are reduced to monosomes so 
that all ribosomes would be present in the same sucrose fractions protecting RNA of 
uniform size.   
When we digested the lysate with RNase I, we found that although the presence of 
polysomes may have decreased, we saw a drastic reduction of the monosome peak that 
was further diminished with increased digestion time and or increased RNase I 
concentration (Figure 7.2B,C,D).  We concluded that the RNase I was not only digesting 
mRNA, but also breaking apart the ribosome itself.  This is not the desired outcome, as 
we intended to clone all the ribosomal protected material. 
We also digested T cell lysate with micrococcal nuclease.  When we treated the cells with 
1,000 units of the nuclease per milliliter of lysate for 25 minutes at room temperature, the 
size of the monosome peak was greatly increased as compared to the non-digested 
sample and the polysome peaks smoothed out slightly (Figure 7.2E).  When we increased 
the digestion to 20,000 units for the same time period, the monosome peak decreased 
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Figure 7.2 Sucrose Gradients After Nuclease Titration.  Cell-equivalent aliquots of 
CD8 T cells were nuclease digested with the indicated protocols and applied to 10%–
50% sucrose gradients. A254 traces of total RNA distribution are shown. 
A
B C D
E F
A:  No Nuclease
B:  RNAse I (0.5 U/ul), 15 min. RT
C:  RNAse I (0.5 U/ul), 45 min. RT
D:  RNAse I (2.5 U/ul), 45 min. RT
E:  Micrococcal Nuclease (1000 U/ml), 25 min. RT
F:  Micrococcal Nuclease (20,000 U/ml), 25 min. RT
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dramatically (Figure 7.2F).  Therefore we determined that using 1,000 units per milliliter 
lysate micrococcal nuclease would be optimal to maximize the number of monosomes 
collected during sucrose fractionation. 
Poly-A mRNA selection and Alkaline Hydrolysis Titration 
In order to clone poly-A RNA in parallel with the RPFs, we fragmented the RNA into 
smaller pieces so that the ribosomal protected and total RNA could be processed and 
sequencing in the same manner.  To determine the optimal amount of hydrolysis, total 
RNA was Trizol extracted and ethanol precipitated from lymphocytes.  The resulting 
RNA was then poly-A selected using Oligo (dT)25 beads.  Next, sodium hydroxide was 
added to the RNA sample to increase the pH and hydrolyze the RNA into smaller 
fragments.  We incubated the samples at 37°C for different amounts of time ranging from 
5 to 90 minutes and then quenched the base with hydrochloric acid and added buffer to 
help stabilize the pH of the sample.  The RNA was precipitated and analyzed on a Urea 
Acrylamide gel (Figure 7.3).  After only 5 minutes of digestion, the RNA remained in 
large pieces and much of the sample did not enter the gel, remaining in the well at the top 
of the lane.  With increasing time the modal size of the RNA decreased in a stepwise 
fashion.  We determined that digestion for 30 minutes would hydrolyze the RNA 
sufficiently so that much of the sample would be between 30 and 50 nucleotides. 
Preparation of CD8 T cells for Ribosomal Profiling and RNA Sequencing 
We asked one of our normal donors (donor 1) from our CLIP experiments to return for a 
repeat leukapheresis.  This allowed us to acquire enough starting material to perform the 
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Figure 7.3 Urea gel of Alkaline Hydrolysis Duration Titration.  Poly-A RNA from 
lymphocytes was alkaline hydrolyzed with sodium hydroxide.  At the indicated amounts 
of time, the basic solution was quenched with hydrochloric acid.  20% Urea-Acrylamide 
gel with separated RNA fragments is shown.  MicroRNA Marker (New England Biolabs, 
N2102S), Low Range ssRNA Ladder (New England Biolabs, N0364S), and RNA 32-mer 
oligonucleotides are shown with indicated sizes. 
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ribosomal profiling and RNA sequencing experiment while genetically matching the 
samples used to create our previous datasets.  To isolate CD8 lymphocytes using the 
same protocol as for CLIP, the leukapheresate was layered and spun through a Ficoll 
gradient to collect PBMCs.  The PBMCs were depleted of CD56+ cells and then selected 
for CD8 T cells.  After resting the sample overnight, the resulting sample was 97% live 
cells and 94% CD8 T cells.  In this preparation there were about 4% contaminating CD4 
T cells and less than 1% each of B cells, monocytes, and NK cells present in the sample 
(Figure 7.4A and data not shown).  After the over night resting period, an aliquot was 
stimulated for one hour with CD3/CD28 beads.  The resting and activated T cells were 
cycloheximide treated and frozen for ribosomal profiling and RNA sequencing analysis.  
The cells were determined to be sufficiently activated with an almost 4,000 fold induction 
of IFNG and close to 200-fold induction of TNF RNA in the activated T cells compared 
to the resting ones (Figure 7.4B).  This activation profile is within the range of the 
activation seen in the lymphocytes prepared for HuR and Ago CLIP.   
Sucrose Gradient Profile of Resting and Activated Lymphocytes 
To isolate ribosomal protected fragments of RNA, an aliquot of resting and activated 
CD8 lymphocytes were lysed and treated with micrococcal nuclease to digest RNA to the 
size of protected pieces by ribosomes.  The digested lysate was layered and spun through 
a 10%-50% linear sucrose gradient.  This material was run by upward displacement 
through a gradient fractionator and sucrose fractions were collected.  The A254 traces 
showed the monosome peak was in fractions 6 through 8 and the relatively smooth trace 
following the monosome peak showed a decrease in polysomes in the sample (Figure 
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Figure 7.4 CD8+ T Cell Characteristics of Donor 1 for Ribosomal Profiling 
Experiment.  CD8 T cells purified from PBMC of normal human donors by CD56 
depletion and CD8 positive selection.  (A) Forward and side scatter determined by flow 
cytometry.  The percentage of live cells (97.4%) is noted in the gated population (left 
panel).  CD3 and CD8 staining determined by flow cytometry.  Percentages of cells are 
noted in each quadrant (right panel).  (B) IFNG and TNF mRNA in resting and activated 
CD8 T cells was analyzed by qRT-PCR.  Plotted is the fold change of these transcripts in 
CD3/CD28 stimulated CD8 T cells relative to resting CD8 T cells mRNA.  Fold increase 
for each transcript is noted above each bar. 
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7.5A).  To be sure that the peak in the A254 trace represented the monosomes, we spotted 
a nitrocellulose membrane with 2 microliters of each sucrose fraction and probed the 
membrane with RPL7 antibody.  This confirmed that the bulk of ribosomal material 
resided in fraction 7 for both the resting and activated cells (Figure 7.5B).  We therefore 
pooled the material from fractions 6 through 8 for the resting and activated T cell samples.   
Ribosomal Protected Fragments and Poly-A RNA Isolation, Size Selection, and 
Amplification 
We isolated RPFs from the material pooled from sucrose fractions 6, 7, and 8.  Smaller 
aliquots of resting and activated T cells were lysed for mRNA sequencing and poly-A 
RNA was prepared for cloning after a Trizol extraction, oligo (dT)25 selection, and 
alkaline hydrolysis.  Both the RPFs and fragmented poly-A RNA from resting and 
activated T cells were run on a Urea Acrylamide gel.  Fragments of roughly 35 
nucleotides in length from the ribosomal fractions and poly-A RNA fragments of roughly 
35 to 55 nucleotides were isolated from the gel (Figure 7.6).   
The RNA fragments were polyadenylated to create an anchor for reverse transcription.  
The polyadenylated RNA was reverse transcribed using primers specific to the poly-A 
tail and containing sequences necessary for PCR amplification and high-throughput 
sequencing.  PCR was done in the presence of SYBR green and amplification was 
monitored on a real time PCR machine to bring the products to an optimal concentration 
for sequencing.   The products were purified and quantified for high-throughput 
sequencing (Figure 7.7).  We saw a distinct band at the size of the RPFs with the 
additional poly-A and primer sequences and a smear of the expected size from the 
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Figure 7.5 Sucrose Gradient Profile of Resting and CD3/CD28 Stimulated CD8+ T 
Cells.  (A) Cell-equivalent aliquots of resting or CD3/CD28 Stimulated normal human 
donor 1 CD8 T cells were micrococcal nuclease digested (1000U/ml) for 25 minutes at 
room temperature and applied to 10%–50% sucrose gradients. A254 traces of total RNA 
distribution are shown.  (B) 2µl aliquots of gradient fractions were dotted onto 
nitrocellulose and were analyzed by western blotting for RPL7 (with Rabbit polyclonal 
RPL7 specific ab72550) to determine the distribution of ribosomes. 
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Figure 7.6 Urea Acrylamide Gel of RPFs and PolyA RNA.  20% Urea-Acrylamide gel 
with separated RNA fragments is shown.  Isolated ribosomal protected fragments (RPFs) 
and poly-A mRNA (mRNA) from resting and CD3/CD28 activated CD8 T cells are 
indicated.  MicroRNA Marker (New England Biolabs, N2102S), Low Range ssRNA 
Ladder (New England Biolabs, N0364S), and RNA 32-mer oligonucleotides are shown 
with indicated sizes.   
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Figure 7.7 RPFs and mRNA PCR Products for High-Throughput Sequencing.  High 
sensitivity DNA assay bioanalyzer results for ribosomal protected fragments (RPFs) and 
poly-A mRNA (mRNA) for resting and CD3/CD28 activated T cells as indicated.  PCR 
cycle numbers for each sample are shown (#x). 
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hydrolyzed mRNA fragments.  We used different RT primer sequences for the mRNA 
and RPFs so that the two samples could be pooled for sequencing for the resting and 
activated samples. 
Ribosomal Profiling Read Statistics and Genomic Distribution of Binding 
The high-throughput sequencing produced over 200 million total reads for both the 
resting and the activated samples.  After filtering the raw data and collapsing it to contain 
only one copy of each sequence there were between 55 and a little over 70 million unique 
sequencing reads.  Next we stripped the reads of the linker sequences to distinguish 
whether the tags came from RPFs or mRNA.  We retrieved 6 to 10 times as many raw 
reads from the mRNA as from the RPF samples (Table 7.1).  This may be in part due to 
the differences in the amounts of starting material for each of these samples.  We started 
cloning from a greater amount of RNA as seen by the levels stained on the Urea 
Acrylamide gel in Figure 7.6, which led to the requirement for around 10 fewer PCR 
cycles to bring them to a concentration necessary for sequencing.  This would lead to 
many less duplicate reads being created during the amplification process, many of which 
were already eliminated in the proceeding step.  Furthermore, it is possible that the initial 
complexity of the RNA pools was different for the RPFs and the mRNA samples.  The 
poly-A samples should represent the mRNA in the cell whether or not it is being 
translated.  It also would include all regions of the molecule, while coding regions should 
predominate the translating population of RNA.  Therefore, the expected complexity of 
these samples would be very different. 
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!Table 7.1 RPFs and mRNA Sequencing Read Statistics. 
 
 
!
Resting Activated
Total Reads 220,007,550 215,585,970
After Quality Filtering 192,965,617 200,798,983
Exact Duplicates Collapsed 70,033,114 55,768,748
RPF mRNA RPF mRNA
Linker Stripped 8,537,955 51,405,429 4,646,999 43,333,499
CLIP Adaptor Removed 8,409,472 50,369,268 4,568,050 42,476,315
Poly-A Sequences Removed 8,290,118 49,351,320 4,486,767 41,310,320
hg18 Mapping 3,903,433 33,254,982 2,582,273 29,964,273
Not Mapped to rRNA 3,822,809 31,746,326 2,504,216 28,938,339
CDS Only 3,214,813 6,995,210 2,201,969 5,976,530
PCR Duplicates Collapsed 128,780 5,251,323 218,095 5,186,994
rRNA Mapping 347,403 4,212,912 177,901 2,974,432
PCR Duplicates Collapsed 23,666 1,085,502 21,479 1,144,789
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Next, the adapter and poly-A sequences were removed from the ends of the sequences 
and reads that contained only these sequences or had less than 5 nucleotides left after 
their clipping were removed from the dataset.  The resulting reads were mapped to the 
hg18 build of the human genome.  Between 2.5 million and 4 million RPF reads and 
around 30 million mRNA reads mapped to the genome per sample.  Next, reads that 
mapped to rRNA were subtracted from the samples to remove these contaminating 
sequences.  We then specified that the reads must map to coding sequence or untranslated 
region (UTR) exonic regions of the genome which only slightly reduced the number of 
RPF reads but reduced the reads from the mRNA dataset to between 20 and 22 percent of 
the mapped reads (Table 7.1).  This removed the potential for contamination from non-
mRNA species.  As seen in Figure 7.8, the great majority of RPF reads mapping to the 
human genome were either in the coding sequence or exonic regions of the 5’UTR and 
3’UTR of transcripts.  Still, 37 percent of the mapped RPF reads from resting T cells and 
17 percent of the mapped RPF reads from activated T cells fell in intronic regions of 
transcripts, deep intergenic regions of the genome or mapped to rRNA (Figure 7.8).  We 
removed these data from subsequent analyses from both the RPF and mRNA datasets so 
that they would accurately represent material likely to be present on ribosomes. 
Degenerate barcode sequences added to the RNA during the RT reaction allowed us to 
collapse for PCR duplicates in the same manner as with our CLIP data.  This allows us to 
reduce sequences to one copy that may have mismatches but map to the identical 
genomic locus and have the same barcode sequence.  This again was more impactful for 
the RPFs than the mRNAs because they required more PCR cycles of amplification and 
therefore many more replicates of uniquely cloned events.  These resulting collapsed 
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Figure 7.8 Mapped RPFs Read Genomic Distribution.  Distribution of human genome 
(hg18 build) mapped ribosomal protected fragments (RPFs) represented by pie chart for 
resting and CD3/CD28 activated CD8 lymphocytes. 
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reads served as the basis for subsequent analyses.  We were able to identify 130,000 
RPFs from resting CD8 T cells and 220,000 RPFs from activated CD8 T cells.  We also 
over 5 million mRNA reads for each sample (Table 7.1). 
Ribosomal Profiling Changes with T cell Activation 
With the RPF and mRNA reads aligned to the genome, we calculated an RPKM (reads 
per kilobase per million mapped reads) value for each transcript.  This allows us to 
compare a normalized value for RPF and mRNA for the resting and activated states.  By 
comparing the RPF RPKM value for each transcript to its mRNA RPKM we can examine 
the translational efficiency (TE) of the transcript (Ingolia et al., 2009).  Figure 7.9A 
compares the activated T cell TE with the resting T cell TE.  In this figure we 
demonstrate that the general tendency for most transcripts is that the TE does not shift 
dramatically between the resting and activated state because the plot seems to resemble 
the trend of y=x.  Still, for many transcripts the TE does change with activation.  We have 
highlighted in red transcripts that have the biggest increases in TE in the activated state 
and are robust 3’UTR targets of either HuR and/or Ago.  3’UTR CLIP targets are 
highlighted in blue that have decreased TE in the activated state.  These same transcript 
targets are highlighted in Figure 7.9B where the change in RPF between the activated and 
resting state is plotted against the change in mRNA tags for each transcript.  For most of 
the highlighted transcripts, we saw a greater change in RPF than mRNA with T cell 
activation, suggesting that while the steady state levels of these transcripts may be 
changing, the translational status is changing even more rapidly.   
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Figure 7.9 RPFs and mRNA Changes with T Cell Activation.  (A) Scatter plot of the 
activated T cell versus resting T cell Log2 ratio of ribosomal protected fragments (RPFs) reads per kilobase per million mapped reads (RPKM) to the mRNA RPKM (This ratio is 
called the translational efficiency: TE).  Line shown is y=x.  (B) Scatter plot of the Log2 
ratio of RPF RPKM in the activated to the resting state versus the Log2 ratio of mRNA 
RPKM in the activated to the resting state.  Line shown is y=x.  Highlighted in red are 
transcripts with the largest increases in TE in the activated state compared to the resting 
state with robust 3’UTR binding targets of Ago and/or HuR.  Highlighted in blue are 
transcripts with the largest decreases in TE in the activated state compared to the resting 
state with robust 3’UTR binding targets of Ago and/or HuR. 
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To examine this in more depth, we plotted the RPKM values of RPF versus the mRNA 
for both the resting and activated states for the red and blue highlighted transcripts from 
Figure 7.9 in Figure 7.10A.  This is further teased apart by highlighting the transcripts 
with increased TE with activation in Figure 7.10C and decreased TE with activation in 
Figure 7.10B.  In the background a gray point represents the mRNA and RPF data from 
the resting state and a purple point the data from the activated state.  A line connects the 
two points from each state for each transcript.  In this figure the highlighted data from the 
resting state is represented in the lighter color red or blue and the activated state in the 
darker color.  Looking at the highlighted data of the 3’UTR CLIP target transcripts with 
the most dynamic changes in TE, we found some targets that have large changes in 
mRNA abundance between the two states represented by connected points being 
dispersed laterally.  However, most of the large changes in TE are found from targets 
having dynamic changes in RPF between the resting and activated states, or are 
represented graphically by shifting vertically.  We hypothesize that changes in regulation 
and binding by HuR and Ago help mediate these changes in translation and occupancy by 
the ribosomes. 
Combining CLIP, Ribosomal Profiling and RNA Sequencing 
In Figure 7.11 we combined the dynamic changes seen in CLIP binding with the dynamic 
changes in ribosomal profiling graphically.  To do this, we plotted the Log2 ratio of 
activated to resting RPKM values of RPF compared to the ratio of activated to resting 
RPKM values of mRNA for transcripts containing an HuR binding site of biologic 
complexity of 3 and peak height of 5, but not containing an Ago CLIP cluster of that 
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Figure 7.10 T Cell RPFs and mRNA in the Resting and Activated State.  (A) Scatter 
plot of the Log2 ribosomal protected fragment reads per kilobase per million mapped reads (RPF RPKM) versus the Log2 mRNA RPKM.  In the background, gray points 
represent data from the resting state and purple points from the activated state.  A line 
connects the two points from each state for each transcript.  Highlighted in red are 
transcripts with the largest increases in translational efficiency (TE, RPF/mRNA) in the 
activated state compared to the resting state with robust 3’UTR binding targets of Ago 
and/or HuR (light red points represent data from the resting state and dark red points 
represent data from the activated state, a red line connects the two points from each state 
for each transcript).  Highlighted in blue are transcripts with the largest decreases in TE 
in the activated state compared to the resting state with robust 3’UTR binding targets of 
Ago and/or HuR (light blue points represent data from the resting state and dark blue 
points represent data from the activated state, a blue line connects the two points from 
each state for each transcript).  Line shown is y=x.  (B) Larger view highlighting 
transcripts with the largest decreases in TE in the activated state compared to the resting 
state with robust 3’UTR binding targets of Ago and/or HuR.  (C) Larger view 
highlighting transcripts with the largest increases in TE in the activated state compared to 
the resting state with robust 3’UTR binding targets of Ago and/or HuR. 
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Figure 7.11 Combining Ribosomal Profiling, mRNA Sequencing, and CLIP Data.  
Scatter plots of the Log2 ratio of ribosomal protected fragment reads per kilobase per million mapped reads (RPF RPKM) in the activated state to the resting state versus the 
Log2 ratio of mRNA RPKM in the activated state to the resting state.  (A) Transcripts 
with HuR clusters of biologic complexity of three (BC3) and peak height five (ph5) and 
no Ago clusters of those criteria.  Points are colored based upon the percentage of HuR 
CLIP tags in the cluster from each activation state.  The color scale gradient ranges from 
blue (100% of HuR tags in the resting state) to yellow (100% of HuR tags in the activated 
state).  (B) Transcripts with Ago clusters of BC3 and ph5 and no HuR clusters of those 
criteria.  Points are sized based upon the percentage of Ago CLIP tags in the cluster from 
each activation state.  The scale ranges from the smallest point (100% of Ago tags in the 
resting state) to the largest point (100% of Ago tags in the activated state).  (C) 
Transcripts with both Ago and HuR clusters of BC3 and ph5.  Points are colored based 
upon the percentage of HuR CLIP tags in the cluster from each activation state.  The 
color scale gradient ranges from blue (100% of HuR tags in the resting state) to yellow 
(100% of HuR tags in the activated state).  Points are sized based upon the percentage of 
Ago CLIP tags in the cluster from each activation state.  The scale ranges from the 
smallest point (100% of Ago tags in the resting state) to the largest point (100% of Ago 
tags in the activated state). 
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robustness.  To overlay the changes in HuR binding between the resting and activated 
states, the points were colored with a gradient of colors to represent the percentage of 
HuR binding in the resting state (in blue) or activated state (in yellow).  There are 
exceptions to the general pattern, but as described in earlier chapters, the changes in CLIP 
binding are most directly reflective of changes in mRNA expression levels between the 
two states.  Or more specifically, as transcripts are positioned from left to right on the x-
axis representing more mRNA in the resting state to more mRNA in the activated state, 
the colors of the points shift from dark blue to bright yellow representing a dominance in 
HuR binding in proportion to the levels of RNA.  The translational profile as represented 
on the y-axis seems to be more scattered without a clear pattern dictating the relationship 
between HuR binding with the RPF levels as they relate to mRNA expression (Figure 
7.11A).  This indicates that while HuR binding may impact changes in translational 
control, there is not an overall rule that governs these dynamics.  The role of HuR binding 
is part of a complex set of interactions with other regulatory RNA-binding proteins and 
may serve different functions depending on the target transcript. 
These same patterns are seen for targets of Ago alone in Figure 7.11B.  In this component 
of the figure, the amount of Ago CLIP binding is represented in the size of the data point 
on the graph for transcripts where there is a cluster of biologic complexity of at least 3 
and minimum peak height of 5 tags, without an HuR cluster at that level of binding on the 
transcript.  If all of the Ago binding is in the resting state, the point is of the smallest size, 
and would be the largest if the binding were exclusively in the activated state.  As seen in 
HuR binding, the amount of Ago binding in clusters in the activated state increases for 
transcripts that are more highly expressed in the activated state.  Graphically, this is seen 
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as an increase in the size of the plotted points as transcripts are positioned with increasing 
mRNA levels in the activated state from left to right.  Additionally, it is difficult to 
decipher a pattern of Ago regulation as it relates to the ribosomal profile of the transcripts 
with an hour of activation.  Similar to HuR, the consequences of Ago binding are often 
dictated by the sum of interactions of the transcript not solely with Ago but also with 
other RNA-binding proteins.  Thus, even without being able to determine a general rule 
relating Ago binding to translational status of its targets, it is important to consider the 
role of Ago on individual transcripts in the context of other regulatory factors.  
For transcripts that are robust targets of both HuR and Ago regulation, the correlations 
between binding and transcript expression are even more apparent.  The color gradient 
representing HuR binding levels in Figure 7.11C clearly shift from blue (resting) to 
yellow (activated) as transcript expression shifts from left to right representing more 
binding in the activated state.  The dot size representing Ago binding also shift from 
small to large in this direction showing a strong correlation between the binding proteins 
and transcript expression level.  Still, there are outliers from this pattern where large blue 
dots are seen or small yellow ones showing a shift in binding between the resting and 
activated state of the two proteins.  This is consistent with previously discussed results in 
Chapter 6.  While the majority of targets regulated by both proteins display binding 
patterns for each that match gene expression, there are exceptions where the binding 
patterns fluctuate in opposite directions with T cell stimulation.   
Additionally, while Ago and HuR binding patterns seem to mirror transcript expression 
as seen in their patterns with respect to the x-axis, there are many points that do not 
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follow a y=x trend.  In fact, it appears that there is a large density of transcripts that are 
represented vertically near the origin of the plot.  In this region, these vertical shifts 
indicate that while gene expression has not changed dramatically, that the TE has 
increased or decreased with T cell stimulation.  This indicates that Ago and HuR targets 
are being dynamical regulated with respect to translation without synchronous changes in 
transcript abundance. 
We narrowed this analysis to HuR and Ago binding in the 3’UTR region of target 
transcripts and the resulting plots are shown in Figure 7.12.  Generally, the same patterns 
noted above are still apparent, but with this smaller subset of target transcripts it is easier 
to visualize outliers.  For example, for 3’UTR targets of both proteins there are notable 
points in the upper right quadrant where the RPF and Ago binding is increased in the 
activated state, but HuR binding is decreased in the activated state as represented by large 
blue spots above the plotted y=x line (Figure 7.12C). These points represent transcripts 
where the transcript abundance and Ago binding is increasing with T cell activation, but 
the amount of HuR binding decreases.  These points seem to go against examples in the 
literature whereby increased Ago binding and decreased HuR binding would be expected 
to result in a decrease in ribosomal occupancy (Bazzini et al., 2012; Bhattacharyya, 
Habermacher, Martine, Closs, & Filipowicz, 2006a; 2006b; Guo et al., 2010).  It is 
possible that these transcripts represent breaks with this thought or they represent 
dynamic changes in RNA binding that will have the expected effects on RNA regulation 
at later time points. 
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Figure 7.12 3’UTR CLIP Targets: Combining Ribosomal Profiling, mRNA 
Sequencing, and CLIP Data.  Scatter plots of the Log2 ratio of ribosomal protected fragment reads per kilobase per million mapped reads (RPF RPKM) in the activated state 
to the resting state versus the Log2 ratio of mRNA RPKM in the activated state to the 
resting state.  (A) Transcripts with 3’ untranslated region (3’UTR) HuR clusters of 
biologic complexity of three (BC3) and peak height five (ph5) and no 3’UTR Ago 
clusters of those criteria.  Points are colored based upon the percentage of HuR CLIP tags 
in the cluster from each activation state.  The color scale gradient ranges from blue 
(100% of HuR tags in the resting state) to yellow (100% of HuR tags in the activated 
state).  (B) Transcripts with 3’UTR Ago clusters of BC3 and ph5 and no 3’UTR HuR 
clusters of those criteria.  Points are sized based upon the percentage of Ago CLIP tags in 
the cluster from each activation state.  The scale ranges from the smallest point (100% of 
Ago tags in the resting state) to the largest point (100% of Ago tags in the activated state).  
(C) Transcripts with both Ago and HuR 3’UTR clusters of BC3 and ph5.  Points are 
colored based upon the percentage of HuR CLIP tags in the cluster from each activation 
state.  The color scale gradient ranges from blue (100% of HuR tags in the resting state) 
to yellow (100% of HuR tags in the activated state).  Points are sized based upon the 
percentage of Ago CLIP tags in the cluster from each activation state.  The scale ranges 
from the smallest point (100% of Ago tags in the resting state) to the largest point (100% 
of Ago tags in the activated state). 
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Discussion 
In this section we explored the dynamic changes in translation that occur with T cell 
activation by comparing the deep sequencing of ribosome protected RNA fragments and 
mRNA.  By measuring the levels of transcripts protected by ribosomes, we were able to 
directly measure the amount of protein synthesis per transcript in the resting and 
activated states of a CD8 lymphocyte.  Comparing this information with the parallel RNA 
sequencing data generated from these same groups of cells, we intended to identify sites 
of translational regulation and to extract biologically meaningful insights into changes in 
HuR and Ago binding by overlaying their CLIP maps with the transcriptional and 
translational cellular states. 
One possible caveat to the ribosomal profiling dataset is that to date it only represents one 
biologic experiment.  To ensure that the dynamic changes we see in translation are 
reproducible, we will repeat this experiment with other normal donors and are currently 
recruiting donors to do so.  If possible, we will start with a larger number of cells to 
improve upon the complexity of the resulting cloned RPF dataset.  In these ways, we will 
define robust sites of translational changes with T cell activation.  Still, we believe these 
data represent biologically meaningful information and we plan to pursue interesting 
targets to validate our findings by other means such as by flow cytometry and performing 
quantitative western blot of resting and activated CD8 lymphocytes to investigate protein 
expression changes with different time points of T cell activation. 
The ribosomal profiling data combined with mRNA sequencing gives us insight into the 
rapid changes that occur with T cell activation both translationally and transcriptionally.  
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With only one hour stimulation with CD3/CD28 beads, it is remarkable how distinctly 
the global profiles of the cells change.  While many alterations in ribosomal occupancy 
correlate with changes in transcript expression, we were able to identify sites that did not 
match these variations in abundance and we believe these represent sites of translational 
control.  We were able to identify transcripts with robust HuR and Ago binding sites that 
had RPF values deviating from the patterns of transcript expression.   
Still, we did not uncover simple rules of translational regulation by the RNA binding 
proteins.  We can identify individual cases where protein binding increases or decreases 
correlating with both increases and decreases in RPF abundance.  This may represent the 
complex dynamics of multiple layers of combinatorial control that are necessary to 
dictate cellular function.  Even so, for individual candidate transcripts, we can learn much 
from this data about the dynamics of lymphocyte activation and the importance of tightly 
regulated transcriptional and translational control.  
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CHAPTER 8.  Studying T cell Regulation in HuR Deficient CD8 Lymphocytes 
Introduction 
In Chapter 6 we introduced the necessity for understanding the combinatorial control of 
Ago and HuR regulation of mRNA.  In summary, previous studies have indicated that 
(Argonaute) Ago and HuR may compete for regulatory function on target transcripts 
(Chang et al. 2012).  HuR binding may alleviate repression of microRNA-mediated 
inhibition of targets by altering a transcript’s subcellular localization and targeting it for 
translation upon the induction of stress (Bhattacharyya, Habermacher, Martine, Closs, 
and Filipowicz 2006a; 2006b).  Alternatively, HuR has been shown to work in concert 
with Ago to mediate repression of other mRNA (Glorian et al. 2011; Kim et al. 2009; 
Kundu et al. 2012). 
We have already described the impressive overlapping binding patterns of Ago and HuR 
in human cluster of differentiation eight (CD8) lymphocytes during T cell activation.  In 
order to further study the combinatorial control of HuR and Argonaute (Ago), we sought 
to investigate the binding patterns of Ago in T cells lacking HuR.  While HuR deficient 
mice are embryonic lethal, mice with HuR deficient T cells are viable throughout 
development.  HuR null lymphocytes, due to floxed excision of HuR exon 2 from Lck 
promoter driven Cre expression, have altered phenotypes in T cell maturation.  These T 
cells show decreased exiting of the thymus and reduced chemotaxis towards cytokines 
that alter the intracellular localization of HuR.  Single positive cells lacking HuR also 
have a reduced proliferative response after CD3/CD28 stimulation and show defects in 
intracellular signaling downstream of the T cell receptor.  HuR negative T cells also 
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avoided an apoptotic response when stimulated with CD3/CD28 as compared to HuR 
positive T cells.  The authors also found increased mRNA levels of Tnf with activation of 
HuR deficient cells as compared to HuR expressing T cells (Katsanou et al. 2009; 
Papadaki et al. 2009).  Thus, examining Ago binding maps upon CD3/CD28 activation of 
CD8 T cells with and without HuR provides a means to probe their possible synergistic 
and antagonistic regulatory functions in an important biological context.   
Results 
Lck-Cre+ HuRfl/fl CD8 Lymphocyte Characterization 
We characterized the levels of HuR in the T cells of conditional knock out (cKO) mice 
for potential use in CLIP, RNAseq, and ribosomal profiling experiments.  Three mice 
were chosen that were Lck-Cre+ and had both alleles of the second exon of HuR floxed 
and three mice that had a wild type HuR locus.  The PCR products confirming these 
genotypes are shown in Figure 8.1A.  For this experiment, splenic CD4 T cells were 
selected and their purity of nearly 99% was confirmed by flow cytometry (Figure 8.1B).  
Aliquots of the T cells were run on an SDS-PAGE gel and probed for HuR using the 3A2 
monoclonal antibody and also for Hsp90 as a loading control.  As seen in Figure 8.1C 
and quantified in Figure 8.1D, two of the three mice showed greatly reduced levels of 
HuR expression in their T cells, with expression levels around 5 percent of that of a wild 
type mouse.  However, in the third HuR cKO mouse, the expression of HuR was 
equivalent to that of a wild type mouse. 
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Fig 8.1 Lck-Cre HuRfl/fl Characterization.  (A) Genotyping PCR analysis of eight 
mice with determined genotypes as indicated for Lck-Cre+ HuRfl/+ (Het Cre+), Lck-Cre- 
HuRfl/+ (Het Cre-), Lck-Cre+ HuRfl/fl (KO), and Lck-Cre+ HuR+/+ (WT).  (B) T cell purity 
determined by CD3 and CD8 staining and flow cytometry.  Percentages of cells are noted 
in each quadrant.  (C) Mouse CD4 T cell lysate from the indicated number of cells was 
analyzed by western blotting for HuR (with monoclonal HuR specific 3A2) and HSP90 
(with monoclonal HSP90 specific BA86).  (D) Quantitation by phosphoimager analysis 
of HuR levels in (C) normalized against levels of HSP90.  Plotted are the averages of the 
three lanes for each mouse with standard deviations in error bars. 
100 101 102 103 104
FL2-H: CD3 PE
100
101
102
103
104
FL
3-
H:
 C
D4
 Pe
rC
P
0.5 98.7
0.140.66
C
D
4 
P
er
C
P
CD3 PE
HuR fl
HuR wt
Cre
Het
Cre+
Het
Cre-
KO
1
KO 
2
KO 
3
WT 
4
WT 
5
WT 
6
HuR fl
HuR wt
Cre
Het
Cre+
Het
Cre-
KO
1
KO 
2
KO 
3
WT 
4
WT 
5
WT 
6
0 
1 
2 
3 
4 
5 
6 
KO1 KO2 KO3 WT1 WT2 WT3 
Av
er
ag
e 
D
en
si
ty
 o
f H
uR
/H
sp
90
 
A B
C D
HuR
Hsp90
KO1 KO2 KO3 WT1 WT2 WT3
1 
x 
10
6
0.
25
 x
 1
06
0.
06
25
 x
 1
06
1 
x 
10
6
0.
25
 x
 1
06
0.
06
25
 x
 1
06
1 
x 
10
6
0.
25
 x
 1
06
0.
06
25
 x
 1
06
1 
x 
10
6
0.
25
 x
 1
06
0.
06
25
 x
 1
06
1 
x 
10
6
0.
25
 x
 1
06
0.
06
25
 x
 1
06
1 
x 
10
6
0.
25
 x
 1
06
0.
06
25
 x
 1
06
SP
213
To screen the mice in the colony, we evaluated the level of HuR expression in 
lymphocytes by intracellular staining for HuR and flow cytometry.  This allowed us to 
determine HuR expression in an ocular blood sample prior to sacrificing the animals for 
an experiment.  Briefly, mice were bled from the ocular vein and after red blood cell lysis, 
the cells were permeablized and intracellularly stained for HuR and analyzed by flow 
cytometry.  We found that the amount of HuR in Lck-Cre+ HuRfl/fl mouse T cells showed 
a continuous spectrum of expression levels.  These expression patterns varied for each 
individual mouse and ranged from levels at overlapping the isotype control, indicating 
virtually no HuR expression, to levels mimicking wild type protein expression (data not 
shown).   
To ensure that the levels of HuR identified by flow cytometry matched the levels detected 
by western blot, we sacrificed one wild type mouse and four animals that had been 
screened by HuR staining of blood cells to have HuR expression levels ranging from very 
low to wild type levels of protein.  T cells were isolated from these five mice and 
analyzed by both flow cytometry and western blot.  The intracellular HuR staining 
showed that the HuR expression patterns seen in peripheral blood were equivalent to 
those from splenic T cells ranging from low expression of HuR in KO1 to wild type 
expression in KO4 (Figure 8.2A).  These protein levels were confirmed by western blot 
(Figure 8.2B).  We concluded that the Lck-Cre+ HuRfl/fl mouse system was unreliable for 
consistently obtaining HuR deficient T cells, although it was possible to control for the 
phenotype of the mice by screening them by intracellular staining of T cells for HuR 
using flow cytometry.   
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Figure 8.2 HuR Intracellular Stain and Western Blot.  Analysis of CD4+ T cells from 
four Lck-Cre+ HuRfl/fl (KO) mice and one Lck-Cre+ HuR+/+ (WT) mouse.  (A) 
Intracellular stain for HuR (with monoclonal HuR specific 3A2) in colored lines and 
mouse IgG control antibody in gray shaded plot with secondary anti-mouse PE antibody 
as analyzed by flow cytometry.  Color of plotted lines match mice indicated in (B).  (B) 
Mouse CD4 T cell lysate was analyzed by western blotting for HuR (with monoclonal 
HuR specific 3A2) and HSP90 (with monoclonal HSP90 specific BA86).   
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CD4-Cre+ HuRfl/fl Mouse Characterization  
In order to have a more reliable system for studying T cells lacking the HuR protein, we 
began breeding the HuRfl/fl mice onto a CD4-Cre background.  All T cells express both 
CD4 and CD8 before they differentiate into single positive cells.  Therefore, CD4-driven 
Cre expression should delete HuR in all mature T cell subsets.  To screen the mice in the 
colony, we evaluated the level of HuR expression in the lymphocytes by flow cytometry 
as described above. The HuR profiles of these cells clearly segregated by genotype.  Both 
CD8 and CD4 lymphocytes from CD4-Cre+ HuRfl/fl showed consistently reduced levels of 
HuR as compared to wild type lymphocytes.  In the HuR cKO samples, there was a small 
peak of cells at expression levels comparable to the wild type mice (Figure 8.3A,B).  This 
signal was seen with irrelevant mouse IgG and secondary alone, so we do not believe that 
it is a population of HuR expressing T cells in the HuR cKO mice, but rather background 
staining in the assay.  When we gated on CD3 negative cells, which should not have Cre 
expression from the CD4 locus and therefore should retain full-length HuR even in 
HuRfl/fl cells, we did not see a difference in HuR expression between the HuR cKO and 
wild type mice (Figure 8.3C).  We concluded that HuR protein levels were robustly 
depleted in the HuR cKO mice and that the conditional excision of exon 2 of HuR was 
specific to T cells. 
Preparation of Mouse CD8 T cells for Ago CLIP  
We prepared wild type and HuR cKO T cells for analysis by Ago CLIP.  Originally, we 
intended to prepare both resting and activated cells to match the datasets collected for the 
human cells.  As in human cells, we observed that freshly isolated mouse T cells had 
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Figure 8.3 CD4-Cre HuRfl/fl Intracellular FACS from Blood.  Analysis of 
lymphocytes from CD4-Cre+ HuRfl/fl (cKO) mice or CD4-Cre+ HuR+/+ (WT) mice.  
Intracellular stain for HuR (with monoclonal HuR specific 3A2) with secondary anti-
mouse APC antibody as analyzed by flow cytometry.  (A) HuR stain of CD8+ T cells.  
(B) HuR stain of CD4+ T cells.  (C) HuR stain of CD3- cells. 
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elevated levels of Ifng mRNA, indicating that the isolation procedure caused low levels 
of activation. However, unlike with human cells, resting the mouse cells overnight in 
media did not permit recovery of healthy T cells the next day (data not shown).  
Therefore, we decided to utilize the T cells immediately after isolation by activating them 
in culture with CD3/CD28 beads.   
We processed three groups of four CD4-Cre+ HuRfl/fl mice, and three groups of four 
littermate wild type or CD4-Cre+ mice, to obtain six biologic samples for analysis.  These 
pooled T cells were determined to be more than 95% pure by flow cytometry (Figure 
8.4A).  The isolated T cells were stimulated for one hour in culture with CD3/CD28 
beads.  The activation states of the resulting lymphocytes were analyzed by isolation of 
total RNA from the cells.  The RNA was reverse transcribed into cDNA and the 
abundance of Ifng mRNA assayed by qPCR.  The delta Ct values for Ifng normalized to 
levels of GAPDH are plotted in Figure 8.4B in comparison to other mouse T cell sample 
qPCR data.  We saw very good stimulation of the T cells being prepared for CLIP 
regardless of genotype as compared to previously isolated samples.   
Furthermore, it was important to ensure that the levels of HuR in the T cell samples were 
significantly reduced in the CD4-Cre+ HuRfl/fl lymphocytes compared to the wild type T 
cells.  We ran lysate from an aliquot of the T cell samples on an SDS-PAGE gel and 
blotted for HuR and also for Hsp90 as a loading control.  We saw an average of roughly 
10 percent HuR expression in the HuR cKO T cells compared to matched littermate wild 
type cells.  In summary we were able to isolate a pure population of CD8 T cells from 
wild type and HuR cKO mice.  These cells had appropriate levels of HuR expression 
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Figure 8.4 Mouse CD8 T Cells: Characterization for Ago CLIP.  Analysis of 6 pools 
of purified mouse CD8+ T cells from CD4-Cre+ HuRfl/fl (cKO) mice (Pools A, C, E) or 
CD4-Cre+ HuR+/+ (WT) mice (Pools B, D, F).  (A) Representative T cell purity 
determined by CD8 staining and flow cytometry.  Percentages of CD8+ cells are noted in 
the box. (B) Ct values for Gapdh mRNA were subtracted from the Ct values for Ifng 
mRNA (dCt) for resting or CD3/CD28 stimulated CD8 T cells.  dCt values from each 
pool of mouse cells prepared for CLIP (A to F) is compared to previous resting and 
activated KO and WT mouse cells.  (C) Equivalent aliquots of mouse CD8 T cell lysate 
from the indicated samples were analyzed by western blotting for HuR (with monoclonal 
HuR specific 3A2) and HSP90 (with monoclonal HSP90 specific BA86).  (D) 
Quantitation by fluorescent signal analysis of HuR levels in (C). 
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corresponding to their genotype and were activated in vitro for one hour before 
crosslinking.  Both wild type and HuR cKO mouse CD8 T cells were applied in Ago 
CLIP analysis and high-throughput sequencing.  For these samples, we used the same 
crosslinking immunoprecipitation protocol as for human cells, but utilized a different 
cloning strategy of the CLIP tags with only one linker ligation step as described in 
Chapter 2. 
Tag Statistics 
We performed HITS-CLIP on CD8 lymphocytes of three biologic replicates of wild type 
and CD4-Cre+ HuRfl/fl mice stimulated for an hour with CD3/CD28 beads.  The final 
products were pooled together so that six samples were sequenced between two lanes.  
Each pooled Ago associated mRNA sample produced nearly 200 million sequencing 
reads.  Once we filtered and collapsed each pool so that each sequence was only 
represented once, we had between 20 and 25 million reads for each sample.  As 
mentioned previously, we think this dramatic decrease is due to over sequencing of the 
sample and also PCR duplication of CLIP tags.  We stripped the linker sequences from 
each read and segregated each sample from the pooled data, the four nucleotide indices 
are indicated in the table below each sample name.  Each sample contributed between 
close to 4 to 6 million reads, indicating that the samples were sequenced rather evenly.  
Each sample had roughly 1.5 to 4 million sequences that mapped to unique locations in 
the mm9 build of the mouse genome (Table 8.1). 
As with the other CLIP samples processed for the human dataset, the adapters contained 
a four nucleotide degenerative sequence.  Thus, when these randomly generated 
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!Table 8.1 Ago CLIP Tag Statistics from HuR cKO and WT Lymphocytes. 
 
 
 
cKO: 1,736,321
WT: 2,318,089 Pool 1 Pool 2
Total Reads 195,210,749 179,668,684
After Quality Filtering 143,705,912 141,577,140
Exact Duplicates 
Collapsed 20,777,570 23,331,600
A: cKO 
(GCAT) 23x
B: WT 
(GTCA) 24x
C: cKO 
(ACTG) 20x
D: WT 
(ACTG) 22x
E: cKO 
(AGCT) 21x
F: WT 
(TCGA) 19x
Linker Stripped 4,578,800 4,488,975 4,190,422 4,323,854 3,792,646 5,746,463
CLIP Adapter 
Removed
3,961,605 4,007,333 3,923,881 3,999,408 3,584,650 5,561,856
mm9 Mapping
(novoalign with trimming)
1,471,464 1,451,509 2,159,341 2,114,094 1,959,729 3,751,959
PCR Duplicates 
Collapsed
261,240 182,516 927,922 461,589 547,159 1,673,984
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oligonucleotides were ligated to the RNA they could be used to distinguish between 
independent Ago binding events at the same locus and PCR duplications of the same Ago 
interaction by comparing the four-nucleotide barcodes.  Thus, we collapsed sequences 
that had the same start and ending footprint on the genome that also had the same four-
nucleotide codes in the linker sequence.  In doing so, we can correct for some of the PCR 
amplification that reduces the true complexity of the sample.  The number of PCR cycles 
used for each sample are listed under the sample names and ranged between 19 and 24 
cycles.  After this computation, the samples were reduced to almost 200,000 to 2 million 
unique CLIP tags for each sample.  As with the human samples, the colors highlighting 
each sample correspond to the colors of the CLIP tags viewed on the genome browser 
(Table 8.1). 
Genomic Distribution of Ago Binding Sites 
To determine an overview of the Ago binding distributions in wild type and CD4-Cre+ 
HuRfl/fl cells, we examined the regions of transcripts that were targeted in the mouse T 
cells.  We clustered all of the tags together from both the wild type and HuR deficient 
lymphocytes, specifying that tags needed to overlap at least 5 nucleotides to be included 
in a cluster.  To demand that the clusters were reproducible, we only included clusters 
that contained CLIP reads from all three of the biologic samples in either the wild type 
and or the HuR deficient datasets.  We specified the cluster as wild type only if there 
were tags from all three wild type mouse samples and not more than one replicate 
represented from the HuR cKO data (Figure 8.5A), and the reciprocal for HuR cKO 
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Figure 8.5 Mouse Ago Clusters Genomic Distribution.  Distribution of Ago clusters 
comprised of at 3 biologic replicates exclusively in HuR wild-type mice (CD4-Cre+ 
HuR+/+, WT), HuR conditional knock out mice (CD4-Cre+ HuRfl/fl, cKO), or in both 
genotypes. 
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clusters (Figure 8.5B).  All six replicates needed to contribute tags to a cluster for it to be 
considered present in both biologic samples (Figure 8.5C). 
As we saw previously for the Ago and the HuR datasets, the largest pools of robust 
clusters mapped to intronic regions of target transcripts for all three groups.  The next 
most represented regions were the 3’ untranslated regions (UTRs) including the regions 
ten kilobases downstream of the annotated transcript, and then coding sequences.  
Interestingly, the proportion of intronic clusters decreased in the group of clusters present 
in both genotypes, while the percentages of clusters in 3’UTRs and coding sequence 
exons increased.  This may reflect the increased biologic complexity for these samples 
and possibly an even more robust distribution of binding.  Still, the proportion of deep 
intergenic clusters also increased in this set, while we might expect it to decrease with 
more stringent cutoffs, signaling that the differences in binding distribution may reflect 
differences in biology rather than in background signal for the samples.  
Ago Binds Egr3 and Ifng in Mouse T cells with or without HuR 
To begin our analysis of Ago binding in wild type and HuR cKO T cells, we examined 
the binding distribution of Ago on the Egr3 and Ifng transcripts.  These two transcripts 
were among the top targets with increased Ago and HuR binding following T cell 
activation in human lymphocytes.  Figure 8.6 shows the distribution of Ago binding to 
Egr3 in the mouse cells.  We included the region downstream of the annotated 3’UTR in 
the mouse that is homologous to the 3’UTR of the human transcript.  This unannotated 
mouse 3’UTR region includes the largest binding sites for Egr3 in the mouse.  It is clear 
from this binding map that HuR is not necessary for Ago to bind to this transcript with 
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Figure 8.6 Ago Binding on Mouse Egr3.  The position of individual Ago unique CLIP 
tags are plotted relative to their mapped position on the mouse Egr3 transcript.  From top 
to bottom: chromosomal location, Ago CLIP tags from activated HuR wild-type CD8 T 
cells (colors represent each donor sample as shown in Table 8.1), Ago CLIP tags from 
activated HuR cKO CD8 T cells, Gene diagram from RefSeq. 
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lymphocyte activation.  Interestingly, while the EGR3 binding map from human 
lymphocytes mostly excluded binding in intronic regions of the transcript, there are some 
clusters found in the intron in the mouse.  This may reflect slight differences in the 
regulatory function between species or may be an artifact of a slightly different time 
course of T cell activation biology in the mouse, even though one hour of stimulation was 
studied in both systems. 
Similarly, HuR was not necessary for Ago to bind to Ifng (Figure 8.7).  We found robust 
Ago binding sites in both wild type and HuR cKO activated T cells.  While we found 
robust intronic binding sites in the Egr3 transcript in mouse but not human, we saw no 
biologic complexity of three sites in intronic regions for Ifng in the mouse while we did 
in the human.  On the mouse transcript, we saw robust and reproducible binding in the 
coding sequence and UTRs, but not as much in introns.  Furthermore, it appears that the 
5’UTR binding in the mouse was limited to the HuR cKO T cells and increased in the 
coding region and 3’UTR in cells without HuR as well.  Therefore, we hypothesize that 
HuR may help recruit Ago to bind certain sites in Ifng, although this does not explain the 
differences in intronic binding between the biologic systems. 
Revisiting Dynamic Binding Changes from the Human Dataset: IRF9 and SATB1 
During the analysis of the human Ago and HuR CLIP data, we identified the IRF9 and 
SATB1 transcripts as being regulated in overlapping regions by the two RNA binding 
proteins.  We examined the binding patterns on these transcripts in particular, because the 
binding intensities changed dramatically in the opposite direction for Ago and HuR with 
T cell activation.  For the IRF9 transcript, although Ago binding increased with T cell 
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Figure 8.7 Ago Binding on Mouse Ifng.  The position of individual Ago unique CLIP 
tags are plotted relative to their mapped position on the mouse Ifng transcript.  From top 
to bottom: chromosomal location, Ago CLIP tags from activated HuR wild-type CD8 T 
cells (colors represent each donor sample as shown in Table 8.1), Ago CLIP tags from 
activated HuR cKO CD8 T cells, Gene diagram from RefSeq. 
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stimulation, HuR binding decreased (Figure 8.8A).  While there was robust binding in 
both activation states for both Ago and HuR, this binding pattern shift suggested that the 
proteins might be interacting antagonistically to exclude each other from this site.  
Interestingly, in examining the homologous region in the mouse, we found a robust 
binding site in the wild type activated T cells, matching the human activated state, but 
only scattered tags in the HuR cKO samples (Figure 8.8B).  This suggests that this 
binding site is conserved across species and that HuR may be necessary for robust Ago 
binding.  There is similarly scattered binding for both genotypes throughout the rest of 
the transcript, suggesting that there are comparable levels of this transcript available for 
potential regulation in both groups of mice (data not shown).  While Ago and HuR may 
compete for binding to this site, the mouse data suggests that HuR is necessary for Ago 
regulation.  
The human SATB1 binding map showed the opposite pattern for Ago and HuR in the 
human T cells.  With lymphocyte activation, Ago binding at this 3’UTR site was almost 
completely depleted, although HuR binding quantitatively increased (Figure 8.9A).  
Because of the low binding levels of Ago at this site in activated human T cells, it was 
interesting to find that the corresponding region in the mouse Satb1 3’UTR contains the 
largest region of Ago binding in both wild type and HuR cKO mice.  In fact, it appeared 
that the levels of Ago binding at this site were higher in the wild type mice (Figure 8.9B).  
Still, this is consistent with the IRF9 transcript, where we found that a possibly 
antagonistic site in the human transcript required HuR for binding in the mouse.  
Although the mouse Satb1 site clearly does not require HuR for Ago binding, as it is 
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Figure 8.8 Ago and HuR Binding in Human and Mouse: IRF9 3’UTR. (A) The 
position of individual Ago and HuR unique CLIP tags in biologic complexity two 
clusters plotted relative to their mapped position on the human IRF9 3’UTR.  The CLIP 
cluster showing dynamic reciprocal Ago and HuR binding changes is outlined in the 
3’UTR.  From top to bottom: chromosomal location, Ago CLIP tags from activated CD8 
T cells (colors represent each donor sample as shown in Table 6.1), Ago CLIP tags from 
resting CD8 T cells, HuR CLIP tags from activated CD8 T cells, HuR CLIP tags from 
resting CD8 T cells, Gene diagram from RefSeq.  (B) The position of individual Ago 
unique CLIP tags are plotted relative to their mapped position on the mouse Irf9 3’UTR.  
The homologous 3’UTR region showing dynamic reciprocal Ago and HuR binding 
changes on the human transcript is outlined.  From top to bottom: chromosomal location, 
Ago CLIP tags from activated HuR wild-type CD8 T cells (colors represent each donor 
sample as shown in Table 8.1), Ago CLIP tags from activated HuR cKO CD8 T cells, 
Gene diagram from RefSeq. 
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Figure 8.9 Ago and HuR Binding in Human and Mouse: SATB1 3’UTR.  (A) The 
position of individual Ago and HuR unique CLIP tags in biologic complexity two 
clusters plotted relative to their mapped position on the human SATB1 3’UTR.  The 
CLIP cluster showing dynamic reciprocal Ago and HuR binding changes is outlined in 
the 3’UTR.  From top to bottom: chromosomal location, Ago CLIP tags from activated 
CD8 T cells (colors represent each donor sample as shown in Table 6.1), Ago CLIP tags 
from resting CD8 T cells, HuR CLIP tags from activated CD8 T cells, HuR CLIP tags 
from resting CD8 T cells, Gene diagram from RefSeq.  (B) The position of individual 
Ago unique CLIP tags are plotted relative to their mapped position on the mouse Satb1 
3’UTR.  The homologous 3’UTR region showing dynamic reciprocal Ago and HuR 
binding changes on the human transcript is outlined.  From top to bottom: chromosomal 
location, Ago CLIP tags from activated HuR wild-type CD8 T cells (colors represent 
each donor sample as shown in Table 8.1), Ago CLIP tags from activated HuR cKO CD8 
T cells, Gene diagram from RefSeq. 
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robustly present in the HuR cKO cells, HuR does appear to enhance binding in the wild 
type cells despite the suggested competition in the human data. 
Exploring Ago Binding Changes between HuR Wild type and KO T cells 
Although it appeared that generally much of Ago binding was maintained in the HuR 
cKO cells, we identified sites of Ago regulation that were present only in wild type or 
HuR cKO cells.  We sorted the clusters by biologic complexity and then by tag numbers 
in each state.  The top coding region and 3’UTR binding sites changing between 
genotypes are listed in Figure 8.10.  Figure 8.10A represents binding sites where all three 
wild type replicate samples are represented in the cluster, but there is no robust binding 
site in the cells lacking HuR.  We suggest that these sites represent potential agonism in 
the binding of HuR and Ago because HuR would be necessary for Ago to be present at 
that regulatory site.   
Interestingly, the top target in this category was the Fyb transcript.  This 3’UTR cluster is 
in the homologous region as the binding changes discussed in the 3’UTR of the human 
FYB transcript in Chapter 6.  In the human 3’UTR, we saw overlapping binding of Ago 
and HuR.  While the binding for Ago was biologically complex in both states, actually 
increasing in biologic complexity with T cell activation, the number of tags represented 
in the Ago cluster decreased with T cell stimulation.  This contrasted with HuR, which 
had maximal biologic complexity in both states, but increased binding quantitatively with 
activation (Figure 8.11A).  In the mouse system, we see a robust binding site at this 
3’UTR location in the wild type animals, but no binding in the HuR cKO mice (Figure 
8.11B).  This suggests that Ago requires HuR at that site to bind.  There is binding of 
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Figure 8.10 Ago and HuR Combinatorial Control. All unique CLIP tags from both 
wild-type and HuR cKO mice were clustered together based on overlapping genomic 
positions of at least 5 nucleotides.  We sorted the clusters by biologic complexity and 
then by tag numbers in each state.  The top coding region and 3’UTR binding sites 
changing between genotypes are listed.  Each table lists the name of the transcript, the 
location of the cluster within the transcript, and the number of tags and biologic 
complexity (BC) of the cluster for each genotype. (A) Binding sites where all three wild-
type replicate samples are represented in the cluster, but there is no robust binding site in 
HuR cKO mouse T cells. (B) Binding sites where all three HuR cKO replicate samples 
are represented in the cluster, but there is no robust binding site in wild-type mouse T 
cells.  
HuR WT
HuR cKO
Ago and HuR: 
Antagonism
Location WT Tags (BC) KO Tags (BC)
Fyb 3‘UTR 11 (3) 0 (0)
Sdcbp CDS 9 (3) 0 (0)
Elf1 3‘UTR 5 (3) 0 (0)
Supt6h CDS 5 (3) 0 (0)
Usp7 3‘UTR 13 (3) 1 (1)
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Ago and HuR: 
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Location WT Tags (BC) KO Tags (BC)
Ppp1r15b CDS 0 (0) 6 (3)
Pdcd4 CDS 0 (0) 5 (3)
Gna13 3‘UTR 0 (0) 5 (3)
Cpeb4 3‘UTR 0 (0) 5 (3)
Ccnd2 3‘UTR 1 (1) 10 (3)
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Figure 8.11 Ago and HuR Binding in Human and Mouse: FYB 3’UTR.  (A) The 
position of individual Ago and HuR unique CLIP tags in biologic complexity two 
clusters plotted relative to their mapped position on the human FYB 3’UTR.  The CLIP 
cluster showing dynamic reciprocal Ago and HuR binding changes is outlined in the 
3’UTR.  From top to bottom: chromosomal location, Ago CLIP tags from activated CD8 
T cells (colors represent each donor sample as shown in Table 6.1), Ago CLIP tags from 
resting CD8 T cells, HuR CLIP tags from activated CD8 T cells, HuR CLIP tags from 
resting CD8 T cells, Gene diagram from RefSeq.  (B) The position of individual Ago 
unique CLIP tags are plotted relative to their mapped position on the mouse Fyb 3’UTR.  
The homologous 3’UTR region showing dynamic reciprocal Ago and HuR binding 
changes on the human transcript is outlined.  From top to bottom: chromosomal location, 
Ago CLIP tags from activated HuR wild-type CD8 T cells (colors represent each donor 
sample as shown in Table 8.1), Ago CLIP tags from activated HuR cKO CD8 T cells, 
Gene diagram from RefSeq. 
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Ago in other sites along the Fyb transcript in the HuR cKO mouse cells indicating that it 
is not a lack of the Fyb transcript in these animals that can explain the absence of binding 
at that site in the HuR cKO mice.  The mapped patterns in the human T cells are 
consistent with a model in which Ago and HuR compete quantitatively to bind in that site.  
Still, Ago and HuR both display robust binding patterns in both states.  Based on the 
mouse data, HuR binding appears to be necessary for Ago targeting to this 3’UTR region.  
We also examined sites of Ago regulation that were present in the HuR cKO mouse cells 
but not in the wild type lymphocytes.  We think these may represent sites of antagonism 
between HuR and Ago because Ago is only able to bind these RNA regions when HuR is 
not present in the cells.  The top ranked site in this category was in the Ppp1r15b 
transcript (Figure 8.10B).  The cluster was located in the first coding exon and although 
there were robust Ago binding sites in both genotypes upstream of this binding site, there 
were no tags seen in the wild type mice in that location (Figure 8.12B).  The human data 
supported this pattern, with a robust HuR binding site matching the same locus without a 
corresponding Ago site.  Upstream of the highlighted region in the exon there were a few 
small Ago clusters that matched the robust site in the HuR wild type mice.  Therefore, it 
appears that HuR may block Ago from binding to the highlighted site in the coding 
region of the Ppp1r15b transcript in both mice and human T cells. 
Another example of potential Ago and HuR antagonism was in a coding exon in the 
middle of the Pdcd4 transcript.  In this region, there was binding observed in the HuR 
cKO lymphocytes but not in the wild type cells (Figure 8.13B).  In concordance with this 
observation, there was HuR binding observed at this position in the human T cells 
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Figure 8.12 Ago and HuR Binding in Human and Mouse: Ppp1r15b Exon.  (A) The 
position of individual Ago and HuR unique CLIP tags in biologic complexity two 
clusters plotted relative to their mapped position on the human PPP1R15B 3’UTR.  The 
CLIP cluster showing dynamic reciprocal Ago and HuR binding changes is outlined in 
the 3’UTR.  From top to bottom: chromosomal location, Ago CLIP tags from activated 
CD8 T cells (colors represent each donor sample as shown in Table 6.1), Ago CLIP tags 
from resting CD8 T cells, HuR CLIP tags from activated CD8 T cells, HuR CLIP tags 
from resting CD8 T cells, Gene diagram from RefSeq.  (B) The position of individual 
Ago unique CLIP tags are plotted relative to their mapped position on the mouse 
Ppp1r15b 3’UTR.  The homologous 3’UTR region showing dynamic reciprocal Ago and 
HuR binding changes on the human transcript is outlined.  From top to bottom: 
chromosomal location, Ago CLIP tags from activated HuR wild-type CD8 T cells (colors 
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Figure 8.13 Ago and HuR Binding in Human and Mouse: Pdcd4 Exon.  (A) The 
position of individual Ago and HuR unique CLIP tags in biologic complexity two 
clusters plotted relative to their mapped position on the human PDCD4 3’UTR.  The 
CLIP cluster showing dynamic reciprocal Ago and HuR binding changes is outlined in 
the 3’UTR.  From top to bottom: chromosomal location, Ago CLIP tags from activated 
CD8 T cells (colors represent each donor sample as shown in Table 6.1), Ago CLIP tags 
from resting CD8 T cells, HuR CLIP tags from activated CD8 T cells, HuR CLIP tags 
from resting CD8 T cells, Gene diagram from RefSeq.  (B) The position of individual 
Ago unique CLIP tags are plotted relative to their mapped position on the mouse Pdcd4 
3’UTR.  The homologous 3’UTR region showing dynamic reciprocal Ago and HuR 
binding changes on the human transcript is outlined.  From top to bottom: chromosomal 
location, Ago CLIP tags from activated HuR wild-type CD8 T cells (colors represent 
each donor sample as shown in Table 8.1), Ago CLIP tags from activated HuR cKO CD8 
T cells, Gene diagram from RefSeq. 
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without binding of Ago, although there was an intronic cluster just downstream of this 
position in the resting state (Figure 8.13A).  Thus, these binding patterns suggest that 
HuR binding at this position in the Pdcd4 transcript precludes binding of Ago. 
Discussion 
In this chapter we examined the role of Ago in T cells lacking the normally ubiquitous 
HuR protein.  We first began by studying HuRfl/fl mice where the Lck promoter drove 
expression of Cre.  These mice had been previously described as having aberrant T cell 
maturation, migration, proliferative responses, and gene expression patterns (Papadaki et 
al. 2009).  We found that although the genotypes of Lck-Cre+ HuRfl/fl mice appeared to 
be identical, the down regulation of HuR in their lymphocytes was not.  Instead we 
observed that certain mice of this genotype maintained wild type levels of HuR while 
others showed highly reduced levels of HuR protein.  We were able to determine the 
levels of HuR in lymphocytes by screening the T cells by intracellular staining of HuR 
and flow cytometry and observed phenotypes in the mouse colony of HuR protein 
expression of around 5% to 100% of wild type HuR levels by western blot.  
In order to have a more phenotypically uniform population of mice with HuR deficient T 
cells, we bred the HuRfl/fl mice to those expressing Cre under control of the CD4 
promoter.  In contrast to the Lck-Cre mice, CD4-Cre+ HuRfl/fl mice showed reliable down 
regulation of HuR protein in their CD4 and CD8 T cells, which was not seen in CD3 
negative cells.  We therefore prepared CD8 T cells from pooled groups of CD4-Cre+ 
HuRfl/fl mice and littermate control wild type mice for Ago CLIP.  After isolating CD8 
lymphocytes, we activated the cells for one hour with CD3/CD28 beads and crosslinked 
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them.  We monitored the purity of the cells by flow cytometry, the activation state of the 
cells by qPCR for Ifng and did western blotting to confirm that the cells had the correct 
expression levels of HuR.  It is important to note that the isolated CD4-Cre HuR cKO 
mouse CD8 lymphocytes still maintained a low level of detectable HuR protein.  This 
may be due to contaminating cell populations or small numbers of T cells that escaped 
deletion of the second exon of HuR.  Still, the dramatic reduction in HuR protein 
expression in these samples provides a useful system for studying the reliance on HuR for 
Ago regulation in CD8 T cells. 
We performed Ago CLIP in the three biologic pools of wild type and HuR cKO CD8 
lymphocytes and were able to clone between 180,000 to almost 2 million unique Ago 
binding sites for each sample.  Similar to our human dataset, we found that clusters were 
most represented in intronic regions of target transcripts, followed by 3’UTRs and then 
coding sequences.  However, in the mouse data, 3’UTR regions were a larger percentage 
of the total than in the human dataset and there were almost twice the percentage of 
coding sequences represented here.  While these still do not resemble the previously 
published binding distributions for Ago in the brain or in regulatory CD4 T cells, they are 
more similar (Chi et al. 2009; Loeb et al. 2012).  Thus, in addition to the possibility of the 
patterns being specific to this cell subset, the differences may also reflect those between 
Ago regulation in humans and mice. 
For the majority of Ago binding sites, the patterns were not greatly altered without the 
presence of HuR in the T cells.  For example, the binding patterns looked very similar in 
wild type and HuR cKO lymphocytes for the Egr3 and Ifng transcripts.  For these two 
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targets we found that, contrasting in the human cells, Ago binding was apparent in the 
intronic region of Egr3 and not reproducibly in the introns of Ifng.  These may reflect 
differences in the biology of human and mouse lymphocytes in terms of the targets of 
Ago regulation or may be due to differences in the time course of the CD3/CD28 induced 
stimulatory cascades between the two species. 
Although we first identified the IRF9 and FYB transcripts in the human dataset as 
showing potential competitive regulation between Ago and HuR, the results from the 
mouse data suggest that these suggested quantitative changes in binding might not be as 
critical as the qualitative ones.  It therefore may be more important to examine the 
binding in the 3’UTR of this transcript as being robustly present for both Ago and HuR 
rather than trying to dissect quantitative changes in the binding patterns for the two 
proteins.  The cloning of bound RNA may not be reliably enumerative to that degree.  
Further examination of changes between wild type and HuR cKO Ago maps will provide 
a guide to interpret HuR dependent changes in Ago binding and will help define its 
regulatory role as it pertains to transcriptional and translational changes. 
This finding also emphasizes the previously discussed results in the human datasets, that 
the majority of Ago and HuR binding changes seen with activation are congruous.  While 
the two proteins may not always be dependent on each other, such as in the cases of the 
Egr3 and Ifng transcripts, the small percentage of overlapping clusters that represented 
possible antagonism between the proteins may only represent a small subset of the 
interactions between Ago and HuR.  Still, it appears that there are cases of Ago and HuR 
antagonism that are identifiable by studying Ago binding in the HuR cKO CD8 
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lymphocytes.  By overlaying RNAseq and Ribosomal Profiling data in these cells, we 
will learn more about the cooperative and antagonistic regulatory roles of Ago and HuR 
in the dynamics of T cell activation. 
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CHAPTER 9.  Exploring Tumor Immunity and Neurologic Autoimmunity in 
Paraneoplastic Neurologic Degeneration 
Introduction 
Paraneoplastic disorders are defined as symptoms resulting from damage caused by a 
malignant neoplasm at a site in the body remote from the tumor and can affect most 
organs and tissues.  This set of disorders can be caused by hormone and cytokine 
secretion by tumor cells or by an immune response against the tumor.  In some patients, 
tumor cells express proteins that are normally restricted to the brain, termed onconeural 
antigens.  The ectopic expression of onconeural antigens in tumors can elicit a strong 
immune response against the tumor.  It is thought that because the antigens are not 
normally presented in the body’s periphery, the immune system recognizes the antigens 
as foreign.  This can create a strong anti-tumor immune response yielding occult tumors 
in these patients and good outcomes with cancer treatment.  Unfortunately, this immune 
reaction can also lead to severe autoimmune disease in the brain leading to paraneoplastic 
neurologic degeneration (PND) (Figure 9.1).  This set of disorders represent some of the 
best-known cases of tumor immunity and are fairly unique in that the antigenic targets of 
the immune system have been characterized (R. B. Darnell, 1996; R. B. Darnell & Posner, 
2003a; 2003b; 2006).  
One such paraneoplastic disorder involves the onconeural antigen cerebellar 
degeneration-related protein 2 (cdr2).  While cdr2 is thought to normally be restricted to 
Purkinje neurons in the brain, this tumor rejection antigen is expressed in many breast 
and ovarian tumors, 25% and 60%, respectively.  In rare cases, an anti-tumor immune 
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Figure 9.1 Model of Paraneoplastic Neurologic Degeneration.  The presence of tumor 
cells in the periphery that expresses onconeural antigen (represented by green stars) 
results in an immune response to the onconeural protein that is able to respond to the 
tumor, resulting in tumor immunity.  Trafficking of this immune response to the nervous 
system targets onconeural antigen-expressing neurons, resulting in neuronal degeneration. 
blood-brain
barrierTumor Cell Neuron
*Tumor Immunity* *Autoimmune 
Neurologic 
Disease*
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response to this onconeural antigen breaks immune tolerance in the brain leading to 
severe neurodegeneration called paraneoplastic cerebellar degeneration (PCD).  
Frequently, PCD patients have limited oncologic disease when they are diagnosed with 
the disorder due to an impressive immunologic rejection of their gynecologic tumor 
(Albert & Darnell, 2004; Corradi, Yang, Darnell, Dalmau, & Darnell, 1997; J. C. Darnell, 
Albert, & Darnell, 2000; R. B. Darnell & Posner, 2003a; Peterson, Rosenblum, Kotanides, 
& Posner, 1992). 
A second paraneoplastic neurologic disorder, the Hu Syndrome arises from ectopic 
expression of the neuronal protein HuD in Small Cell Lung Cancer (SCLC) tumors.  It is 
thought that because HuD is typically restricted to the nervous system, an anti-
inflammatory and somewhat immune-privileged site, ectopic expression of HuD in a 
SCLC tumor stimulates tumor immunity as well as an autoimmune response in the 
nervous system.  Roughly one fifth of SCLC patients have a tumor immune response that 
breaks tolerance to this onconeural antigen, which is indicated by antibodies to Hu in 
patient sera.  In rare cases, the immune response results in severe autoimmunity in the 
form of PND called subacute sensory neuropathy and encephalomyelopathy (Figure 9.2).  
Patients with any HuD immunity display better outcomes with cancer treatment, 
suggesting that the HuD tumor immune response can be constructive and uncoupled from 
neuronal autoimmunity (Albert & Darnell, 2004; Dalmau, Furneaux, Gralla, Kris, & 
Posner, 1990; R. B. Darnell & Posner, 2003b; Rauer & Andreou, 2002).  
Although the presence of onconeural antibodies is useful in diagnosing patients with 
paraneoplastic neurologic degeneration, it is unclear what role they might play in disease 
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Figure 9.2 Hu Patient Schematic. 
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progression.  Typically, circulating antibodies mediate immune responses to extracellular 
antigens, while HuD and cdr2 are expressed intracellularly (Okano & Darnell, 1997).  
Furthermore, disease models utilizing autoantibodies recognizing onconeural antigens 
have failed to initiate disease (Sakai, Gofuku, Kitagawa, Ogasawara, & Hirose, 1995).  
Generally, intracellular proteins are presented as peptides extracellularly to the immune 
system in major histocompatibility complex (MHC) Class I molecule complexes.  Each T 
cell expresses a unique T cell receptor (TCR) that can bind a particular peptide-MHC 
complex.  In this way, T cells can initiate an immune response in an epitope and MHC 
restricted manner.   
Non-self proteins that indicate that a cell has been compromised, such as viral proteins, 
will be detected on the cell surface by cluster of differentiation eight (CD8) T cells and 
targeted for killing.  Because tumor cells often express unusual protein repertoires, CD8 
T cells are prime mediators of tumor immunity (Trombetta & Mellman, 2005).  In fact, 
activated T cells are often found in the cerebral spinal fluid of PND patients and members 
of the lab have identified cdr2 and HuD-specific CD8 T cells in PND patients (Albert, 
Austin, & Darnell, 2000; Albert et al., 1998; Roberts et al., 2009).  While CD8 T cells 
can mediate tumor immunity, their priming may rely on help from CD4 lymphocytes.  
CD4 T cells interact with antigen presenting cells and license the activation of CD8 T 
cells (Lanzavecchia, 1998; Ridge, Di Rosa, & Matzinger, 1998).  Additionally, CD4 
lymphocytes interact with B cells to induce the production of antibodies.  Thus it is 
important to consider the role of both CD4 and CD8 T cells to model PND syndromes. 
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To explore the possibility of using cdr2 as a potential target for immunotherapy of breast 
and ovarian cancer, the lab identified a peptide derived from human cdr2 (cdr2-290) that 
stably binds to MHC I molecule HLA-A2.1.  Additionally, cdr2-290 specific T cells were 
identified in HLA-A2.1+ PCD patients’ peripheral blood, but not normal HLA-A2.1+ 
donors, indicating that this epitope is part of the repertoire of the naturally occurring anti-
tumor response.  Using HLA-A2.1 expressing transgenic mice, high avidity cdr2-290 
cytotoxic T lymphocyte clones were isolated which are able to recognize and kill a 
number of human cancer cell lines that endogenously present cdr2.  One murine T cell 
clone shown to have a strong anti-tumor response against human tumor cell lines was 
chosen for subsequent analysis.  The alpha- and beta-T cell receptor (TCR) genes from 
the murine T cells were shown to recognize human cdr2-290 presented on HLA-A2.1 and 
were subsequently cloned.  Transfection of RNA derived from this alpha and beta-TCR 
into normal human donor CD8 T cells afforded the human T cells with the capability to 
lyse human tumor cell lines endogenously expressing cdr2 (Santomasso et al., 2007). 
In order to better understand the varying T cell responses in Hu patients, a murine system 
was used to study the immune response to HuD.  To study the CD8 T cell response to 
HuD in C57BL/6 mice, the dominant HuD epitope was defined as being peptide 321.  
The nature of the immune response to HuD in mice was explored by interrogating the 
difference between immune responses to the neuronal HuD, and the foreign antigen Beta-
galactosidase (β-gal).  To assay the CD8 T cell responses to these intracellular antigens, 
groups of mice were immunized with adenovirus expressing either HuD (AdV-HuD) or 
β-gal (AdV-β-gal).  After immunization with the virus and pertussis toxin, an agent 
which functions as an adjuvant and may help to disrupt the blood brain barrier, and again 
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with pertussis toxin two days later, CD8 T cells were harvested from the mouse spleens 
after thirteen days and were stimulated in culture with target cells presenting cognate 
antigen  (Figure 9.3A) (DeLuca, Blachère, Santomasso, & Darnell, 2009).   
After wild type C57Bl/6 mice were immunized with AdV-HuD, there was no CD8 T cell 
IFNG response seen directly ex vivo to HuD, but there was an antigen-specific response 
after in vitro T cell stimulation.  This suggests that there is peripheral tolerance to the 
neuronal HuD protein because the HuD-specific T cells are present in the immune 
repertoire, but they are not active directly ex vivo after antigen challenge.  In contrast, 
mice lacking HuD (HuD KO) and immunized with AdV-HuD did not display HuD 
tolerance.  HuD-specific T cells from HuD KO mice were active directly ex vivo and after 
in vitro stimulation, because HuD is a foreign antigen in the HuD KO.  Similarly, after 
immunizing wild type mice with AdV-β-gal, there was no immune tolerance observed to 
the foreign β-gal antigen; there was a detectable response directly ex vivo and after in 
vitro stimulation. (Figure 9.3B) (DeLuca et al., 2009).  This suggests that the expression 
of the neuronal HuD protein in a wild type host tolerizes the immune response to HuD 
epitopes.  However, the mechanism is unknown and the critical method by which this 
tolerance is broken in SCLC patients leading to tumor immunity and the Hu syndrome is 
not understood.  In the future, by mimicking the T cell phenotypes found in PND patients, 
we intend to model the neurologic degeneration central to these diseases in mice. 
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Figure 9.3 Mouse Adenovirus-HuD Immunizations.  (A) Cartoon of adenovirus 
immunization protocol.  Mice were immunized on day 0 (d0) with both adenovirus and 
pertussis toxin.  Two days later, they were given another dose of pertussis toxin.  The 
mice were sacrificed on day thirteen and half of the splenocytes were used directly in an 
ex vivo IFNG ELISPOT and the other half were incubated in flasks with peptide for in 
vitro stimulation (IVS).  On day 20, the in vitro stimulated splenocytes were harvested 
and used in an IFNG ELISPOT assay.  (B) Cartoon representing mouse immunization 
and ELISPOT results.  (Top) Wild-type (WT) mice were immunized with adenovirus-
HuD (AdV-HuD).  There was no IFNG response directly ex vivo, but there was a visible 
response after IVS.  (Middle) HuD knock out (HuD-/-) mice were immunized with AdV-
HuD.  There was a detectable IFNG response directly ex vivo and after IVS.  (Bottom) 
WT mice were immunized with adenovirus-βgal (AdV-βgal).  There was a detectable 
IFNG response directly ex vivo and after IVS. 
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Results 
Cdr2 T cell Receptor Optimization 
We sought to further characterize the cytotoxic capacity of mouse-derived, human cdr2-
reactive CD8 T cell clones in a human system.  For this purpose, we engineered the TCR 
genes from the high avidity cdr2-290 cytotoxic T lymphocyte clone described above 
(termed Clone 11/12) and from a second clone shown to have good tumor cell line 
reactivity (Clone 1) to improve the stability of the TCR RNA and increase the abundance 
of the receptor pair on the cell surface (Santomasso et al., 2007).  The TCR genes were 
originated and cloned from mouse cells but need to be expressed in human cells.  To 
maximize the translational efficiency of the TCRs, human codon-optimized versions of 
each of the alpha and beta chain genes were generated by de novo gene synthesis.  
Furthermore, it has been demonstrated that an additional cysteine residue in the constant 
region of each receptor chain helps proper TCR pairing by allowing for an added 
disulfide bond to form between the correctly paired alpha and beta-receptor chains 
(Cohen et al., 2007).  To enhance the ability of the electroporated cdr2-290 TCRs to pair 
correctly while competing with the endogenous TCRs in the human CD8 cells, a cysteine 
codon was incorporated into the constant region of each receptor chain during gene 
synthesis.  We cloned the synthetic TCR constructs into an expression vector for efficient 
RNA transcription of a polyadenylated mRNA, which was used for T cell 
electroporations (Figure 9.4) (vector kindly provided by Dr. Eli Gilboa). 
We electroporated human CD8 T cells with alpha and beta-chain TCR RNA from Clone 
1, Clone 11/12, or with no RNA in a mock electroporation.  After allowing the cells to 
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Figure 9.4 cdr2 TCR Optimization Schematic.!
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rest in culture, we screened the lymphocytes for TCR expression by tetramer staining 
with a cdr2-290 tetramer or a Flu-M1 tetramer as a negative control.  When we stained 
the electroporated cells with the Flu-M1 tetramer, we saw less than half a percentage of 
tetramer-positive CD8 cells.  This negative result was also seen for the cdr2-290 tetramer 
staining of mock electroporated cells and cdr2 TCR Clone 1 electroporated cells.  This 
negative result for Clone 1 was expected.  The inability of Clone 1 to bind tetramer was 
one of the main factors for it not being pursued previously, although we are uncertain 
why it fails to do so.  We did see a population of tetramer positive cells comprising ~7% 
of CD8 lymphocytes electroporated with cdr2 TCR Clone 11/12 (Figure 9.5).   
Characterization of Ovarian Cancer Patient Ascites Samples 
To study the potency of the electroporated T cells’ response to primary cancer tissue, we 
processed ovarian tumor cells from neurologically healthy oncologic patients’ ascites 
fluid for use in vitro.  The cancer cells would need to be both cdr2 positive and HLA-A2 
positive for the TCR clones to recognize cdr2-290 peptide presented on the cells.  To 
screen the haplotype of the cancer patients, we stained PBMC and analyzed the cells by 
flow cytometry.  We found that three patients were HLA-A2 negative and that five of the 
eight patients were HLA-A2 positive (Figure 9.6). 
In order to determine which tumor samples expressed cdr2, we immunoprecipitated cdr2 
from four ovarian ascites samples using sera from PCD patients.  Of the four patients 
tested, three expressed detectable cdr2 protein (data not shown).  Importantly, we 
identified the ascites from patients 4 and 6 as being cdr2 positive and HLA-A2 positive.  
Therefore, we would expect the cdr2 specific T cells to respond to these tumor cells.  The 
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Figure 9.5 cdr2 TCR Tetramer Stain of Electroporated Lymphocytes.  Flu-M1 (58-
66 peptide) or cdr2 (290-298 peptide) specific HLA-A2.1 tetramer staining of CD8 T 
cells electroporated with no RNA (Mock) or with the indicated cdr2 TCR Clone RNA 
(Clone1 or Clone 11/12).  The percentages of tetramer-positive cells are noted in the 
gated populations. 
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Figure 9.6 HLA-A2 Stain of Ovarian Cancer Patient PBMC.  Peripheral blood 
mononuclear cells (PBMC) from eight ovarian cancer patients were stained with FITC-
conjugated HLA-A2 antibody or Isotype Control (BD Biosciences).  Cells were washed 
and analyzed immediately by flow cytometry. 
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tumor from patient 3 was also cdr2 positive, but because this patient is HLA-A2 negative, 
the T cell clone should not be able to react to it.  Although patient 8 is HLA-A2 positive, 
the cdr2-290 specific T cells should not be able to engage these cells, as they are cdr2 
negative.  Thus, we identified tumor samples that should be targeted by the cdr2 specific 
T cells and also samples that will serve as important negative controls for future work. 
Flow Cytometry Based Killing Assay Development 
To determine the reactivity of the cdr2 specific lymphocytes against the primary tumor 
cells, we developed a flow cytometry based killing assay, schematized in Figure 9.7.  T 
cells electroporated with cdr2-290 TCRs or electroporated without RNA (mock) were co-
cultured overnight with target cells comprising cancer cell lines and primary ascites 
samples.  After the incubation, all of the cells were harvested from the well, stained with 
viability dye TO-PRO to designate dead cells and analyzed by flow cytometry.  A 
defined number of non-fluorescent beads were added to each sample as a means to 
normalize counts, and events were collected by flow cytometry until a set number of 
beads were captured.  In this manner, the number of target cells that had been killed and 
missing from the well could be distinguished between paired groups of cognate and 
irrelevant stimulators.  The total number of cells killed in the well by cognate T cells 
could then be calculated by taking the sum of TO-PRO positive dead cells and an 
estimate of the number of cells missing from the well.  Furthermore the percentage of 
killed target cells could be determined by comparing the killed cells to the number of 
collected target cells from paired co-cultures of T cells with irrelevant targets. 
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Figure 9.7 Tumor Killing Assay Schematic.  T cells electroporated with TCR RNA 
were co-cultured with target cells.  After an overnight incubation, the cells were 
harvested and stained with TO-PRO.  An equivalent aliquot of beads were added to each 
tube and events were collected on the flow cytometer until a set number of beads was 
collected.  The forward and side scatter distribution of the cells was used to gate on target 
cells as shown in the cartoon.  The number of TO-PRO positive cells indicates the dead 
target cells within the sample.  The number of killed target cells was estimated by adding 
the number of cells missing from the well as determined by the number of paired target 
cells collected from an incubation with irrelevant T cells and the number of TO-PRO 
positive cells.  From this number, the percentage of killed cells was calculated by 
comparing the number of killed cells to the total number of paired target cells co-cultured 
with irrelevant T cells. 
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Figure 9.8 shows representative data from one replicate of a killing assay set up with 
cdr2-290 Clone 11/12 TCR and mock electroporated T cells with different tumor cell 
lines and ascites samples.  T cells were co-cultured with T2 cells pulsed with irrelevant 
Flu-M1 peptide or cognate cdr2-290 peptide.  T2 cells are a human lymphoblast cell line 
deficient in TAP function containing abundant HLA-A2 molecules on the cell surface 
that can be loaded with exogenous peptide (Salter, Howell, & Cresswell, 1985).  The 
FACS plots in Figure 9.8A show the TO-PRO staining of these target cells.  We observed 
that mock electroporated T cells stimulated with T2 cells pulsed with either peptide gave 
a background of about 14% TO-PRO positive dead cells and nearly 20,000 total T2 cells 
were collected.  We saw the same results from Clone 11/12 TCR electroporated cells 
incubated with T2 cells pulsed with Flu-M1 peptide.  When cdr2-specific T cells were 
cultured with cognate T2 cells pulsed with cdr2-290 peptide, we were only able to collect 
about 5,000 target events and of those events 60% of the cells were dead.  Therefore we 
calculated that approximately 15,000 cells had been eliminated from the well and roughly 
3,000 additional cells were dead, but present in the well, leading us to determine that the 
cdr2-290 Clone 11/12 T cells had killed nearly 90% of the cognate T2 cells.   
We calculated the percentage of killed targets for each cell type and have displayed the 
results in Figure 9.8B.  Compared to mock electroporated T cells, cdr2-290 lymphocytes 
were able to kill ovarian cancer cell line COV413 cells that are both cdr2 and HLA-A2 
positive.  This killing was not enhanced by adding an irrelevant Flu-M1 peptide, but was 
greatly increased when the cells were pulsed with cdr2-290.  Treating the COV413 cells 
with IFNG to increase MHC Class I expression and processing of peptides did not 
increase the killing of these cells. 
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Figure 9.8 cdr2-Specific CD8 T Cell Tumor Killing Assay.  (A) Representative 
histograms of TO-PRO staining of target cells collected for the groups indicated.  The 
total number of targets and percentage of TO-PRO positive cells are indicated for each 
plot.  Targets included T2 cells pulsed with either Flu-M1 peptide or cdr2-290 peptide 
and the T cells included T cells electroporated without RNA (mock) or T cells 
electroporated with cdr2-290 specific T cell receptor RNA.  (B) Quantification of results 
from flow cytometry data as in (A).  Plotted is the percentage of killed Target cells for 
each sample (calculations described in Figure 9.7).  Targets included T2 cells: HLA-A2 
positive and cdr2 negative (T2), COV413: HLA-A2 positive and cdr2 positive (COV), 
and Ascites Sample 8: HLA-A2 positive and cdr2 negative (Asc8).  Some of the target 
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When we co-cultured lymphocytes with ascites cancer cells from patient 8, we did not 
see specific killing of tumor cells by the cdr2-290 TCR electroporated cells as compared 
to the background death of cells co-cultured with T cells that were mock electroporated.  
This was not surprising given that this tumor sample did not express detectable levels of 
cdr2 by IP-western blot.  Still, this patient was HLA-A2, and the cdr2-TCR 
electroporated cells were able to target ascites cells pulsed with cdr2-290 peptide.  This 
showed that primary cancer cells could present pre-processed peptide to CD8 
lymphocytes for killing.  IFNG treatment of the ascites cells increased the background 
level of dead target cells in the culture.  Nevertheless, increased MHC I expression on the 
cell surface enhanced the killing potential of the cdr2-290 specific T cells in response to 
the ascites.  With IFNG treatment and pulsed with cdr2 peptide, the ascites served as 
comparable targets to the HLA-A2 cell lines (Figure 9.8B).  This suggests that 
endogenously, the primary tumor cells may display decreased presentation of peptides to 
help shield them from the surveying immune system.  This could serve as a potential 
problem for T cell therapy although it could potentially be overcome with cytokine 
treatment.  Nevertheless, we were able to see specific targeting of a peptide-pulsed 
primary ascites tumor sample by cdr2-TCR electroporated lymphocytes.  This assay 
provides the potential to quantify the ability of cytotoxic T cells to kill target cells in vitro.   
Cdr2-specific CD8 T cell Responses to Primary Human Cancer Cells  
In addition to the flow cytometry based killing assay, we examined the responsiveness of 
the electroporated T cells to target cells in an IFNG ELISPOT assay.  Human CD8 T 
cells were electroporated with either cdr2-290 Clone 1 TCRs, Clone 11/12 TCRs, or GFP 
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RNA as a negative control.  The T cells were co-cultured with target cells in ELISPOT 
plate wells coated with anti-IFNG antibody to capture the released cytokines from 
activated T cells.  After twenty hours, the cells were washed from the wells and bound 
IFNG was used to develop spots on the membranes in each well.  In this way the number 
of spot-forming lymphocytes could be counted per million plated T cells. 
We found that Clone 1 and Clone 11/12 cdr2-290 TCR electroporated cells were able to 
respond to both high and low concentrations of cdr2-290 peptide pulsed T2 cells but not 
to T2 cells pulsed with the irrelevant Flu-M1 peptide.  Both were also able to kill 
humanized mouse kidney epithelial cells infected with adenovirus expressing human cdr2 
(AdV-hcdr2).  Neither of the T cell clones responded to adenovirus driven expression of 
mouse cdr2 (AdV-mcdr2) in these cells, showing specificity to the human cdr2-290 
peptide (Figure 9.9A).  Clone 11/12 had a higher number of spot forming cells than 
Clone 1 at both concentrations of peptide pulsed T2 cells and with the adenovirus 
infected cells signaling that it may be a higher avidity T cell clone.  The reactivity to the 
AdV-hcdr2 infected cells is important because it shows that the T cell clones were able to 
respond to endogenously processed and presented cdr2 peptides, not just cells pulsed 
with peptide on their cell surfaces. 
We also used tumor cell lines and patient ascites cells as targets in the ELISPOT.  We 
found that both cdr2-290 clones were able to respond to COV413 ovarian cancer cells 
that are HLA-A2 positive and express cdr2.  The clones could not respond to the cdr2 
expressing HeLa cells that are not HLA-A2 positive, demonstrating that the immune 
response is HLA restricted.  Unfortunately, we did not see any significant response to 
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Figure 9.9 cdr2-Specific CD8 T Cell IFNG ELISPOT.  To test for recognition of 
endogenous cdr2 tumors by the electroporated cdr2 specific T cells, cdr2 T cell receptor 
RNA electroporated T cells (Clone 1 or Clone 11/12) or control GFP RNA electroporated 
T cells were co-cultured with target cells in a twenty-hour IFNG ELISPOT assay.  Values, 
representing spot forming cells per million CD8 T cells, are the average of triplicate 
wells; error bars indicate standard deviation.  (A) T cells co-cultured with: T2 cells 
(HLA-A2 positive and cdr2 negative) pulsed with Flu-M1 peptide (+M1) or cdr2-290 
peptide (cdr2) at low [lo] or high [hi] concentrations, humanized kidney epithelial cells 
(KECS) (HLA-A2 positive and endogenously cdr2 negative) infected with adenoviruses 
driving expression of either human cdr2 or mouse cdr2.  (B) T cells co-cultured with: 
COV413 tumor cells (HLA-A2 positive and cdr2 positive), HeLa tumor cells (HLA-A2 
negative and cdr2 positive), ascites sample 3: HLA-A2 negative and cdr2 positive (Asc3), 
ascites sample 4: HLA-A2 positive and cdr2 positive (Asc4), ascites sample 6: HLA-A2 
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cdr2 expressing primary ascites samples whether they were HLA-A2 negative (Ascites 3) 
or HLA-A2 positive (Ascites 4 and 6) with or without IFNG treatment (Figure 9.9B).  It 
is possible that the cdr2 expression in these cells is below the detection of the T cell 
clones or that the presentation of cdr2-290 on the surfaces of the cells is not efficient.  
In order to screen for the effector potential of T cells that were in contact with cognate 
targets, we stained cdr2-290 TCR electroporated cells for CD107a and TNF following 
co-culture with target cells as in the ELISPOT assay.  Following TCR engagement, the 
secretion of lytic granules from activated CD8 T cells should lead to the presence of 
CD107a on the cell surface of the lymphocytes.  CD107a that is normally present on the 
lytic granule membrane will fuse with the cell membrane to release its contents and 
interrogate the target cell (Betts et al., 2003).  After co-culture with T2 cells pulsed with 
cognate peptide, we saw a dramatic increase in the CD107a expression on the surface of 
CD8 T cells electroporated with Clone 1 or Clone 11/12 TCRs, but not mock 
electroporated cells.  The expression of TNF also increased in these cells as seen by a 
shift upward in the scatter plot (Figure 9.10).  Interestingly, the percentage of activated 
cells in this assay greatly exceeds the percentage of tetramer positive cells indicating that 
tetramer staining may be an underestimate of functional cdr2 specific TCR expressing T 
cells (Figure 9.5).  
In parallel with the results from the IFNG ELISPOT assay, we saw a strong shift in both 
TNF and CD107a in cdr2-specific T cells in response to humanized KECs infected with 
AdV-hcdr2 but not AdV-mcdr2 and no response from the mock electroporated T cells.  
While we did not observe a significant response to the HLA-A2 positive cdr2 positive 
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Figure 9.10 cdr2-specific CD8 T Cell CD107a and TNF Assay.  FACS analysis for the 
degranulation marker protein CD107a and TNF was performed after co-culture T cells 
electroporated without RNA (mock) or T cells electroporated with cdr2-290 specific T 
cell receptor RNA (Clone 1 or Clone 11/12) with target cells: T2 cells (HLA-A2 positive 
and cdr2 negative) pulsed with Flu-M1 peptide (+M1) or cdr2-290 peptide (cdr2), 
humanized kidney epithelial cells (KECs) (HLA-A2 positive and endogenously cdr2 
negative) infected with adenoviruses driving expression of either human cdr2 or mouse 
cdr2, ascites sample 3: HLA-A2 negative and cdr2 positive (Asc3), ascites sample 4: 
HLA-A2 positive and cdr2 positive (Asc4), ascites sample 6: HLA-A2 positive and cdr2 
positive (Asc6).  Gating was performed on live lymphocytes based on forward and side 
scatter characteristics. The percentages of cells staining for CD107a were as indicated. 
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ascites tumor cells in the ELISPOT assay (Ascites 4 and 6), we did see a slight but 
detectable increase in CD107a expression on the surface of cdr2-specific T cells in 
response to the tumors that was not present in response to the HLA-A2 negative cdr2 
positive cells (Ascites 3) (Figure 9.10).  Although small, this was the first example of a 
cdr2-specific TCR electroporated lymphocyte response directed against primary human 
cancer cells.   
HuD Specific CD8 T cell Clone Characterization 
To isolate a CD8 T cell clone specific for HuD peptide 321, a wild type mouse was 
immunized with AdV-HuD and pertussis toxin as described previously.  Isolated T cells 
were in vitro stimulated with peptide 321 and a bulk line of HuD peptide 321 CD8 T cells 
was established.  The line was plated in limiting dilutions and the clonal T cells were then 
continually re-stimulated with peptide 321 while being characterized.  We chose a 
peptide 321 HuD clone that proliferated well in culture, was able to specifically recognize 
targets pulsed with minimal peptide 321 (Figure 9.11A,B), could respond to cells 
endogenously presenting HuD (Figure 9.11C), was able to specifically kill targets pulsed 
with peptide 321 (Figure 9.11D), and stained completely with MHC HuD-p321 tetramer 
as analyzed by flow cytometry (Figure 9.11E).   
We isolated RNA from the HuD peptide 321 CD8 T cell clone of interest and amplified 
cDNA for the alpha- and beta-TCRs using the 5’ RACE PCR technique and known TCR 
constant region sequences.  Using gene specific primers, we cloned the entire TCR genes.  
Isolated HuD peptide 321 TCR genes could now be sub-cloned into a cassette vector and 
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Figure 9.11 HuD peptide 321 CD8 T Cell Clone Characterization.  (A) Cloned HuD 
peptide 321 (p321) T cells specifically recognize peptide 321 pulsed targets.  T cells were 
co-cultured with EL4 cells (HuD negative) alone or with HuD p321 in a low 
concentration [low] or high concentration [high] in a twenty-hour IFNG ELISPOT assay.  
Values, representing spot forming cells per million CD8 T cells, are the average of 
triplicate wells; error bars indicate standard deviation.  (B) Cloned HuD p321 T cells 
respond to targets pulsed with less peptide 321 than the bulk line of T cells.  Cloned T 
cells or bulk HuD T cell line were co-cultured with EL4 cells (HuD negative) with 
irrelevant peptide (EL4+irr) or with HuD p321 at the µM concentrations indicated in a 
twenty-hour IFNG ELISPOT assay.  Values, representing spot forming cells per 5,000 
CD8 T cells, are the average of triplicate wells; error bars indicate standard deviation.  
(C) Cloned HuD p321 specific T cells respond to cells presenting endogenously 
processed HuD.  T cells were co-cultured with kidney epithelial cells (KECs) alone or 
infected with irrelevant (AdV-Irrel.) or HuD expressing adenovirus (AdV-HuD) in a 
twenty-hour IFNG ELISPOT assay.  Values, representing spot forming cells per 5,000 
CD8 T cells, are the average of triplicate wells; error bars indicate standard deviation.  
(D) Cloned HuD p321 specific T cells specifically kill targets pulsed with p321.  T cells 
were plated with chromium labeled peptide-pulsed EL4 cells at the indicated T cell to 
EL4 cell ratios.  Values represent the percentage of chromium released from the target 
cells.  (E) Cloned HuD p321 specific T cells were all MHC HuD-p321 tetramer positive.  
T cells were stained with CD8 antibody and MHC-tetramer specific for cognate HuD 
peptide or irrelevant peptide.  The percentages of tetramer-positive cells are noted in the 
gated populations. 
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injected into embryonic cells to create a transgenic mouse where the majority of T cells 
will have the same HuD-specific TCR (Kouskoff, Signorelli, Benoist, & Mathis, 1995).  
Attempts at HuD Specific CD4 T cell Epitope Discovery 
To determine the dominant epitope for the CD4 T cell response to HuD, we used an 
algorithm to predict potential MHC Class II epitopes.  To ascertain whether there were 
HuD T cells specific for any of the predicted peptides in the C57Bl/6 repertoire, we 
immunized mice with each potential peptide emulsified in the Titermax adjuvant.  After 
seven days, the draining lymph nodes were harvested and CD4 T cells were isolated.  The 
T cells were then plated in a forty-hour IFNG ELISPOT assay with targets pulsed with 
the cognate peptide or an irrelevant Class II peptide as a negative control.  Three out of 
the six predicted peptides were present in the mouse T cell repertoire (Figure 9.12).  
Although possible epitopes have now been identified, it is important to characterize the T 
cell responses to all of these HuD peptides to determine if any of them are naturally 
processed and presented, and which is optimal.  This has proven difficult due to the 
strong response of CD4 T cells to sera used to grow AdV-HuD for injection into the mice 
and the dependence on sera to grow the resulting mouse cells in culture.  
Exploring Tolerance to HuD Using Wild Type and HuD KO Mouse Bone Marrow 
Chimeras  
To determine whether the expression of HuD in bone marrow derived cells plays a role in 
the tolerance to HuD, we transferred bone marrow from wild type and HuD KO mice into 
sub-lethally irradiated wild type and HuD KO hosts.  After bone marrow transplantation, 
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Figure 9.12 IFNG CD4 T Cell HuD Peptide Titermax Experiment.  C57BL/6 mice 
were immunized with individual peptides as indicated in Titermax adjuvant.  7 days later, 
draining lymph node CD8 T cells were co-cultured in a forty-hour IFNG ELISPOT assay 
with targets pulsed with cognate or irrelevant peptide.  Values, representing spot forming 
cells per million CD8 T cells, are the average of triplicate wells; error bars indicate 
standard deviation.   
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the mice were rested for two months to allow for the new bone marrow to fully 
reconstitute the host immune system.  The mice were then immunized with AdV-HuD 
and pertussis toxin as previously described (Figure 9.13).  We expected that the T cell 
responses in each mouse would behave like their host.  For example, we hypothesized 
that even with wild type bone marrow the T cells would not be peripherally tolerized in 
the HuD KO host due to a lack of neuronal HuD expression.  Therefore, we expected that 
the isolated T cells from HuD KO hosts would respond to antigen-specific targets directly 
ex vivo and expanded by in vitro stimulation with or without HuD being present in the 
bone marrow.  The T cells from wild type bone marrow or HuD KO bone marrow 
transferred into wild type hosts were expected to only respond to antigen-specific targets 
after in vitro stimulation because we hypothesized that HuD expression in the host 
neuronal system would be sufficient to tolerize HuD specific T cell responses regardless 
of the genotype of the bone marrow derived cells.  
The collated results from IFNG ELISPOT assays from two different immunization 
experiments are summarized in Figure 9.13.  In HuD KO hosts reconstituted with 
transferred HuD KO bone marrow, we were able to recapitulate the HuD KO phenotype 
in seeing a response to HuD peptide 321 directly ex vivo and after in vitro stimulation.  In 
contrast, peripheral tolerance to HuD was maintained in wild type hosts reconstituted 
with either the wild type or HuD KO bone marrow, as these mice maintain expression of 
HuD in the neuronal system.  The peripheral tolerance to HuD was maintained as in a 
fully wild type mouse and antigen specific responses to HuD peptide 321 were not seen 
directly ex vivo.  The T cells from both groups continued to mimic wild type mouse 
responses and showed antigen-specific activation to HuD peptide 321 after in vitro 
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Figure 9.13 HuD Tolerance Bone Marrow Chimera Experiment Summary.  Cartoon 
representing bone marrow chimera genotypes, mouse immunizations, and ELISPOT 
results.  Bone marrow from HuD knock out (green colored animals: HuD-/-) or wild-type 
mice (purple colored animals: WT) were transferred into sub-lethally irradiated hosts that 
were either HuD-/- or WT.  Control WT mice that were not chimeric are indicated in the 
bottom two rows.  After allowing for bone marrow reconstitution, mice were immunized 
with adenovirus-HuD (AdV-HuD) and pertussis toxin on day 0 (d0) and again with 
pertussis toxin on d2, except for control mice represented in the bottom row of the figure 
as indicated.  The mice were sacrificed on d13 and half of the splenocytes were evaluated 
directly in an ex vivo IFNG ELISPOT and the other half were incubated in flasks with 
peptide for in vitro stimulation (IVS).  On day 20, the in vitro stimulated splenocytes 
were harvested and analyzed in an IFNG ELISPOT assay.  The results of individual mice 
from two different experiments are enumerated as a ratio of the number of responsive 
mice to HuD peptide 321 out of the total number of mice assayed between the two 
experiments.  A blue check mark indicates a positive response of the group and a red “X” 
indicates no HuD p321 response. 
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stimulation indicating that even the HuD KO derived T cells were able to be tolerized in 
the wild type host and were not centrally deleted in either case.  More specifically, in 
bone marrow chimeras in wild type hosts, we did not see a response to HuD-specific 
targets directly ex vivo, but did observe T cell expansion and a an HuD-specific response 
after an in vitro stimulation with the HuD 321 peptide.  Importantly, we did not see HuD-
specific responses after in vitro stimulation with HuD peptide of T cells from wild type 
mice that were not immunized with AdV-HuD indicating that the in vitro stimulated 
response was specific to viral immunization (Figure 9.13). 
In addition, to explore the role of neuronal antigen absence or expression on the induction 
of tolerance in bone marrow derived cells from wild type mice, we transferred bone 
marrow from wild type mice into sub-lethally irradiated HuD KO hosts.  Remarkably, the 
mice also displayed a wild type phenotype.  The CD8 T cells did not respond to HuD 
peptide 321 directly ex vivo, but did display an antigen-specific response after in vitro 
stimulation (Figure 9.13).  This suggests that even in an HuD KO mouse that does not 
express the neuronal HuD, the presence of bone marrow derived cells containing a 
functional HuD gene is enough to tolerize emerging HuD-specific T cells.  This implies 
that the presence of HuD in neurons is not necessary to induce tolerance in T cells to 
HuD, and that bone marrow derived cells may be sufficient to tolerize CD8 T cells to a 
neuronal antigen.   
Development of Tools to Study Tolerance to HuD 
Experiments transferring T cells or bone marrow from wild type or HuD KO mice into 
different hosts have begun to address whether HuD reactive T cells are being tolerized 
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and/or deleted in the periphery.  One difficulty with these experiments was that we 
needed to challenge mice with AdV-β-gal in parallel to the mice challenged with AdV-
HuD as a positive control for an antigen specific response upon virus challenge.  While 
this helped to control for adenovirus immunization, it was not a control within the same 
animal and also doubled the number of mice needed for each experiment.  A new strategy 
was tested and adopted to intradermally immunize with both AdV-HuD and AdV-β-gal 
on opposite sides of the same mouse.  In these experiments, we observed a response to β-
gal directly ex vivo while we were still unable to detect an HuD-specific response at this 
time.  We were able to recover a response to HuD after in vitro stimulation (Figure 9.14).  
The magnitudes of the response to both antigens after the double adenovirus 
immunization were comparable to the responses to that antigen in a singly immunized 
mouse.  With this new approach, we can recapitulate the phenotypes we observe with 
single immunizations in a mouse immunized with both viruses.  This strategy internally 
controls for natural variability or abnormalities in the immune response in a mouse 
specific manner. 
In parallel, an approach for double immunization with Titermax emulsified peptides was 
also explored.  We observed that a mouse immunized with different Titermax emulsified 
peptides in each of the back footpads mounts a detectable antigen-specific response in the 
corresponding draining popliteal and inguinal lymph nodes.  Interestingly, we only see 
the response in the draining lymph nodes from each footpad and not on the opposite side 
of the same doubly immunized mouse.  Furthermore, the response to each peptide in the 
double immunized mouse is of the same magnitude of a singly immunized mouse (Figure 
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Figure 9.14 Tools to Study Tolerance to HuD: Double Adenovirus Immunization.  
Two mice were immunized with adenovirus-β-Gal (AdV-β-Gal), adenovirus-HuD (AdV-
HuD) or both adenoviruses with pertussis toxin on day 0 (d0) and again with pertussis 
toxin on d2.  The mice were sacrificed on d13 and half of the splenocytes were evaluated 
directly in an ex vivo ELISPOT and the other half were split into two flasks and incubated 
with HuD peptide 321 (p321), β-Gal peptide 96 (p96), or β-Gal peptide 297 (p297) for in 
vitro stimulation (IVS).  On day 20, the in vitro stimulated splenocytes were harvested 
analyzed in an ELISPOT assay.  In the twenty-hour IFNG ELISPOT assays, T cells were 
co-cultured with EL4 cells (HuD and β-Gal negative) with HuD p321, β-Gal p96, β-Gal 
p497, irrelevant Ova peptide 257, or alone.  Values, representing spot forming cells per 
million CD8 T cells, are the average of triplicate wells; error bars indicate standard 
deviation.  (A) Ex vivo IFNG ELISPOT Results from each immunized mouse are shown.  
(B) IVS IFNG ELISPOT results from each immunized mouse stimulated in two flasks 
each with either β-Gal peptide (AdV-β-Gal immunized mice), replicate stimulations of 
HuD p321 (AdV-HuD immunized mice), or β-Gal p96 and HuD p321 (AdV-β-Gal and 
AdV-HuD immunized mice) as indicated. 
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Figure 9.15 Tools to Study Tolerance to HuD: Double Peptide-Titermax 
Immunization.  C57BL/6 mice were immunized with individual peptides into one 
footpad with β-Gal peptide 497 (p497) or HuD peptide 321 (p321), or with individual 
peptides (p497 and p321) in either back footpads in Titermax adjuvant as indicated.  7 
days later, draining lymph node CD8 T cells were co-cultured in a twenty-hour IFNG 
ELISPOT assay with EL4 cells (HuD and β-Gal negative) with β-Gal p497, HuD p321, 
irrelevant Ova peptide 257, or alone.  Values, representing spot forming cells per million 
CD8 T cells, are the average of triplicate wells; error bars indicate standard deviation.  
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9.15).  With this internal control, we have a better way to monitor the effectiveness of our 
bone marrow or T cell transfers and for abnormal responses in an animal specific control. 
Discussion 
In this chapter we examined the immune responses to onconeural antigens.  We were able 
to deliver cdr2-specific T cell receptors to human CD8 T cells by electroporation of TCR 
alpha- and beta-chain RNA.  Using optimized TCR genes for two different mouse-
derived human cdr2-specific clones, we were able to confer cdr2-290 peptide immunity 
to normal human donor cells.  Although the majority of cells showed cdr2 reactivity in 
functional assays, it is unclear why such small percentages of cells were stained by cdr2-
290 tetramer.  If we increased the TCR expression further, it is possible that the T cells 
could confer an even more promising functional outcome. 
We demonstrated specific targeting of HLA-A2 cdr2-expressing tumor cell lines by both 
TCR clones.  Furthermore, working with primary tumor cells collected from ovarian 
cancer patient ascites samples, we were able to show reactivity to primary samples that 
were HLA-A2 positive and expressed cdr2.  Still, the magnitude of this immune reaction 
would need to be improved to consider the possibility of cancer treatment.  We also need 
to repeat the flow cytometry based killing assays with both cdr2-specific TCR Clone 1 
and Clone 11/12 with HLA-A2 and cdr2 positive primary ascites samples.  By exploring 
the ability of the electroporated lymphocytes to recognize and attack primary tumor cells 
endogenously expressing cdr2, these future experiments would explore the potential of 
using adoptively transferred cdr2-290 TCR T cells in clinical therapy for breast and 
ovarian cancer. 
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We have previously described the dominant CD8 T cell epitope of HuD in C57BL/6 mice, 
peptide 321 (p321) (DeLuca et al., 2009). Here we described establishing clonal HuD-
specific CD8 T cells and characterizing their responses to targets expressing HuD.  
Although potential CD4 T cell epitopes have been established, future work is needed to 
identify the CD4 T cell dominant HuD epitope.   We have cloned the TCR genes from 
optimal CD8 T cell clones and this could be repeated for the CD4 T cell epitope.  The 
identified TCR genes could be used to make transgenic mice expressing HuD-specific 
CD4 or CD8 TCRs.   
There is currently no animal model for the Hu syndrome.  The laboratory’s discovery of 
two different kinds of CD8 T cells in Hu patients suggests that generating HuD-specific 
transgenic T cells may allow us to learn how to skew HuD-specific CD8 T cells to 
different phenotypes and monitor the functional consequences (Roberts et al., 2009).  
Also, nothing is known about CD4 T cell responses in the Hu syndrome.  We believe that 
a critical component in determining whether patients are tolerant of their tumor or react to 
it may be related to the presence or absence of effective CD4 T cell responses.  Therefore, 
both proposed HuD TCR transgenic mice would be critical tools for understanding the 
immune response to HuD.  
In future work, we propose to characterize the persistence of TCR transgenic CD4 and 
CD8 T cells in WT and HuD KO hosts.  It is possible that the transgenic lymphocytes 
would be deleted due to their recognition of native antigen, but as in a WT mouse, we 
expect the HuD-specific T cells would persist, even if in small quantities.  Therefore, it 
will be important to study the transgenic T cells’ migration patterns in the thymus and 
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throughout the mice and to study their proliferation patterns.  We would also study the 
presence of the lymphocytes in the nervous system and whether they cause damage to 
neurons expressing HuD.  We would expect the transgenic cells to be tolerized to HuD 
and therefore not cause damage to neurons in a resting state.  We hypothesize that by 
challenging mice with a peripheral tumor expressing HuD and providing disruptions to 
the blood brain barrier, using agents such as pertussis toxin, we may be able to uncover a 
link to promote an escape from tolerance and possibly lead to neuronal degeneration. 
By making bone marrow chimeras of wild type and HuD KO mice, we were able to 
further study the peripheral tolerance to HuD.  As expected, we recapitulated the HuD 
KO mouse phenotype when transferring HuD KO bone marrow into a KO host.  In these 
animals, we were able to detect an active immune response to HuD peptide 321 directly 
ex vivo following immunization with AdV-HuD and pertussis toxin.  This immunity was 
also seen after in vitro stimulation of splenocytes with the HuD peptide.  Also as 
anticipated, having either HuD KO or wild type bone marrow in a wild type host 
produced tolerance to HuD in the peripheral T cells.  For these mice, no immune 
response to HuD was seen directly ex vivo after immunization, but was recovered after in 
vitro stimulation.  We consider this response to be a case of tolerance because although 
the HuD specific T cells were present in the mice, we were not able to detect their 
activity until they were propagated in culture.  Interestingly, we saw this same wild type 
phenotype in HuD KO mice with transferred wild type bone marrow.  We did not expect 
to see the presence of a functional HuD gene in bone marrow derived cells be able to 
confer tolerance in an otherwise HuD deficient animal, when HuD is thought to be 
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restricted to the nervous system.  Further work is needed to explore the source of HuD 
expression in bone marrow derived cells and its role in tolerance in a normal mouse. 
With transgenic T cells, we could challenge the mice to mimic possible Hu syndrome 
initiating events and follow the migration of the HuD-specific cells in the mouse, 
including the CNS.  By conducting transfer experiments using the transgenic TCR mice 
in combination with wild type and HuD KO littermates, we aim to elucidate the 
mechanism mediating the anergy of HuD-specific T cells and understand how this 
tolerance is broken in Hu syndrome patients.  Understanding the tumor immune response 
and the autoimmune neurologic disease for both PCD and the Hu Syndrome are of major 
clinical importance and could lead to new interventions for disease. 
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CHAPTER 10.  General Discussion 
Summary 
The careful control of the adaptive immune response allows for the host to respond to 
rapid changes in its homeostasis and protect against the invasion of pathogens and other 
systemic injury.  While the processes mediating these important retaliations have been 
studied in extensive detail, the acute molecular processes of regulatory control in T cell 
activation have still not been completely elucidated.  Lymphocytes have the ability to 
react quickly to confront the presence of cognate antigen within their host.  They initiate 
and terminate cytotoxic and inflammatory pathways abruptly to contain the damage of 
the invading offense and simultaneously protect the surrounding environment from their 
own dangerous defense mechanisms.  The induction of new transcription is important to 
shaping these responses.  Nonetheless, the rapid control of translation post-
transcriptionally is also critical to the immediate function of these cells.   
RNA-binding proteins, such as Ago and HuR, have previously been shown to mediate 
both the proper development of lymphocytes and the regulation of their translational 
responses.  Though there is a vast literature analyzing the targets of Ago and HuR control, 
the majority of work has been done in non-physiologic in vitro systems and little is 
known about the dynamics of their regulation in vivo.  The results presented here 
represent the determination of Argonaute (Ago) and HuR RNA-binding maps in ex vivo 
normal healthy donor cluster of differentiation eight (CD8) lymphocytes before and after 
T cell stimulation.  By overlaying the transcriptional and translational status of these 
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dynamically changing lymphocytes, we provide a system to functionally decipher the 
roles of these regulatory proteins and their impacts on the inflammatory response.   
Overlapping RNA-Binding of Ago and HuR 
We observed that 40% of Ago clusters and 14% of HuR clusters overlap each other, 
within 64-nucleotides up or downstream of their peak binding positions.  Interestingly, 
not only do many Ago and HuR clusters overlap within a small distance, but also their 
peak positions are highly superimposable.  This implies that in a large proportion of their 
binding sites, the two proteins are found in the same position.  While CLIP data 
represents the binding specificities of a population of cells and not necessarily a map of a 
single RNA molecule, this propensity of two such distinct proteins to preferentially bind 
the same loci is remarkable.  These binding similarities were not limited to one T cell 
stimulation state and quantitative differences in binding for both proteins were often 
similarly reflective of the transcriptional levels of the targets.  This suggests that Ago and 
HuR may bind these sites cooperatively or in a step-wise fashion to instigate regulatory 
control.  In this way the two proteins could work together or antagonistically to regulate 
function.  
Because the majority of Ago binding was preserved in the HuR cKO mice, it is unlikely 
that Ago is dependent on HuR as a rule.  Still we were able to observe clusters that were 
present in either one of the mouse genotypes and not in the other, so HuR may be 
necessary for the binding of Ago to some regulatory sites and may preclude Ago binding 
in others.  We propose that while the binding of these proteins to the same message may 
in some cases be independent, that their regulatory capacities are still intertwined.  
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Rapid Changes in RNA-Binding with CD8 T cell Activation 
Ago and HuR display rapid changes in binding patterns with CD3/CD28 stimulation of 
CD8 lymphocytes.  While viewing the distributions of binding at one hour represents an 
early point in the T cell activation regulatory cascade, it is clear that we could learn much 
from the regulatory states of these cells at both even earlier and later time points.  For 
example, assessing Ago and HuR de novo binding to a transcript at early time points after 
stimulation may allow a determination of whether there is an ordered hierarchy of 
binding between these two proteins.  Repeating a time course in HuR cKO T cells would 
complement such studies.   
One model to address the binding of Ago and HuR to the same RNA sequence domains is 
that Ago and HuR do not bind simultaneously to their joint targets.  In this model, if 
binding of one protein proceeds the other in binding pre-processed RNA, then the ratios 
of binding events in the intronic regions of transcripts to the exonic regions, that will 
remain in the final mature mRNA, may be indicative of a time line of regulation.  For 
example, in the activated lymphocyte Ago CLIP map of IFNG (Figure 6.2), the larger 
binding sites in the 3’UTR as compared to intronic regions may indicate that Ago is 
binding later in the life cycle of the mRNA than HuR.  HuR is bound more evenly in its 
introns and exons, even though it too shows some preference for 3’UTR binding.  It is 
possible that HuR is important in the immediate processing of the IFNG transcript in the 
nucleus and that the large induction of transcription needs to be tempered by Ago after 
processing to mediate translational control as time progresses in the stimulatory cascade.  
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Assaying the timing and efficiency of mRNA processing in the wild type and HuR cKO 
T cells could help define this regulation. 
Studying the transcriptional and translational statuses of T cells at later time points may 
also help resolve the functional outcome of Ago and HuR binding events.  Because both 
proteins often displayed correlative changes in binding with transcript levels, it is 
possible that the large changes in transcript abundance with T cell activation may be 
occluding our ability to identify the regulatory consequences of these binding events.  
While we have largely focused in our examples on messages that had increased binding 
and message levels with activation, it is important to note that we also see the reverse as 
well.  Understanding the rapid changes in RNA-protein interactions may give us clues to 
the eventual stability and translational control of the message, and the interactions 
between both Ago and HuR may dictate these fates.   
For example, within one hour of activation, the levels of IFNG transcript can increase by 
a factor of 102-103.  Since Ago and HuR robustly bind this message, it is not surprising 
that their interactions with IFNG would increase in this time period.  Still, the eventual 
effect of Ago binding, for example, is most likely to help degrade this message in a 
pattern common to the decreases seen in many early activation genes quickly increased 
after transcription.  While HuR may be functioning synergistically with Ago, it is more 
likely from previous work that it is helping to stabilize or steer copies of the message to 
translational machinery to balance this repressive Ago response.  This kind of balanced 
regulation could be critical for IFNG so that too much cytokine is not produced after T 
cell stimulation, which could be detrimental to healthy cells in the immediate 
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environment of the lymphocyte.  While Ago may be necessary to dampen IFNG 
expression for host safety, rapid translational increases in IFNG protein mediated by HuR 
stabilization may be just as critical to the inflammatory response.  With considerable 
increased message being made at one hour, even if Ago were mediating degradation of 
IFNG, we would still observe this as an overall rise in transcript levels.  Therefore, it may 
be informative to look at later times for transcription level responses of targets, when the 
immediate escalation of the activation has quelled, to determine the functional outcomes 
of these early binding events.  Looking at IFNG levels over time in the HuR KO mice 
could also help assess this. 
Analysis of CLIP Data in the Context of Translational Status 
With both proteins changing binding patterns congruently with the dynamic variations in 
transcript expression, it appears that the large changes in message levels may be 
obscuring Ago and HuR mediated dynamic changes in transcript stability, or that these 
proteins often work together to modify transcript abundance.  This differs from the results 
of the ribosomal profiling work.  While it is hard to define a single general rule for shifts 
in ribosomal occupancy of Ago and HuR targets with T cell activation, it is clear that 
these messages do not automatically enter the translational machinery in proportion to 
their levels.   
In the analysis of Ago and HuR 3’UTR targets, we see that the binding patterns of the 
proteins correlate well with the patterns in gene expression changes of the messages.  For 
example, in Figure 7.12A, as the ratio of message levels between the resting and 
activated state shifts from left to right on the axis, signifying transcripts with more RNA 
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in the resting state on the left or more RNA in the activated state on the right, HuR 
binding patterns also shift from having more binding in the resting state to more in the 
activated state shown by points changing in color from blue to yellow.  If this pattern 
were reflected in the translational state of each message, the plotted points would 
resemble the y=x line.  Instead, we see a scattering of points mainly around the origin of 
the graph.  This pattern suggests that for many HuR targets, the translational changes 
(vertical shifts, up or down) are greater than transcriptional changes (horizontal shifts, left 
or right).  These rapid changes suggest that HuR is part of a critical and complex network 
of translational regulation shortly after lymphocyte stimulation.  Differences in the 
translational responses of individual transcripts with activation may reflect the 
interactions of HuR, or analogously Ago, with other factors such as other RNA-binding 
proteins or subcellular localization changes to mediate translational control.  
We have reported multiple examples of dynamic reciprocal changes in Ago and HuR 
binding patterns in overlapping sites throughout this work.  For messages such as FYB 
and SATB1, we described shifts where the binding levels for HuR increased with 
activation and Ago decreased with activation, although both represented biologically 
reproducible binding in both states.  This corresponded to CLIP binding maps in the 
mouse data, where dynamically changing but robust binding of Ago and HuR in the 
human reflected a preference for binding in wild type cells as compared to HuR cKO.  
We propose that these may be examples where robust binding in both states in the human 
is more salient than quantitative differences observed in CLIP tag numbers with 
activation for predicting the necessity of coincident binding for Ago and HuR in the 
mouse.  As shown in Table 10.1, while we saw subtle shifts in the transcript levels of 
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!Table 10.1 Dynamic Changes in Ago and HuR binding and Translational Efficiency. 
 
 
 
Human
Ago
Human
HuR
Resting
RPF 
(RPKM)
Resting
mRNA
(RPKM)
Resting
TE
Activated
RPF
(RPKM)
Activated
mRNA
(RPKM)
Activated
TE
EGR3 Act Act --- --- --- 1533 1418 1.08
IFNG Act Act --- --- --- 22,375 6871 3.26
IRF9 Act Rest 51
*8 cloned tags
72 0.70 67
*18 cloned tags
60 1.11
SATB1 Rest Act 187 273 0.69 134 199 0.67
FYB Rest Act 500 496 1.01 364 384 0.95
RPF/mRNA RPF/mRNA
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these genes in human T cells, which both decreased with activation, we did not see 
dynamic shifts in the translational efficiency.  The binding patterns of Ago and HuR are 
similar in these sites and may suggest that the decrease with Ago binding of these 
transcripts with activation is linked to the reduction in message, while HuR maintains the 
correlative translational status of these targets. 
In the case of the IRF9 transcript, we saw the opposite binding pattern changes for Ago 
and HuR in the human T cells with activation.  Ago binding increased with T cell 
activation, while HuR binding decreased.  Again, both binding sites were still 
reproducible in both states even though their levels shifted in opposite directions.  
Analyzing the homologous site in the mouse suggests that HuR is supportive of Ago 
binding because there was more binding seen in the wild type mice than in the HuR cKO.  
Interestingly, we did see a shift in translational efficiency for the IRF9 mRNA in human 
T cells with activation.  In the resting state, there was less ribosomal occupancy than 
message, but the opposite was true after T cell activation (Table 10.1).  Although these 
changes represent differences in relatively small numbers of cloned tags and therefore 
need to be independently validated, including with additional human samples and in the 
mouse, these results suggest that HuR may help recruit Ago binding to IRF9 and that 
with T cell activation this translates into increased ribosomal occupancy.    
Generally, we have observed large dynamic shifts in translational status acutely with T 
cell activation that are often not mediated by similar transcriptional changes.  Still, there 
does not appear to be a single universal rule governing all of the effects of Ago and HuR 
binding on target transcripts.  This is likely due to the complexity of the regulatory 
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systems in which these proteins interact, and suggest that individual transcripts have 
evolved to be differentially regulated by the same Ago and HuR proteins.  There are 
many possibilities for how this might happen, such as via the action of additional factors, 
by the timing of their binding events, or due to the effects of Ago and HuR binding 
different regions within the transcript such as the coding sequence versus the 3’UTR or 
even more subtle differences in the precise binding positions of Ago compared to HuR.  
With more replicates and analysis of translational profiles in the HuR cKO mouse system, 
it will be interesting to try to define patterns in these changes and to determine pathways 
of regulation by these proteins that can be separated out from the massive changes in 
cellular states. 
Genomic Distribution of Ago and HuR Regulation in CD8 Lymphocytes 
Previous work on Ago and HuR regulatory control of target mRNA has largely focused 
on their binding interactions with 3’ untranslated regions (3’UTRs).  However, the 
analysis described here indicates the first role for Ago and HuR interaction in intronic 
regions of transcripts.  While the rapid increase in transcription with T cell stimulation 
might indicate a large pool of newly synthesized RNA available for RNA-binding, these 
patterns are maintained in both the resting and the activated states.  Additionally, the 
predominance of intronic mapping of Ago CLIP tag clusters in the HuR cKO T cells 
indicates that Ago binding in these regions is not dependent on the presence of HuR.  The 
data suggest that these proteins are deposited on transcripts either co-transcriptionally or 
soon after transcription. 
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In the mouse brain, Hu proteins most frequently bind to 3’UTRs, but also bind to intronic 
sequences and can mediate alternative splicing of neuronal transcripts (Ince-Dunn et al. 
2012).  HuR has also been shown to bind intronic sequences in human cell lines and its 
potential role in splicing and the possible link between pre-mRNA processing and 
transcript stability inferred.  The stability of RNA targets was more greatly impacted in 
HuR knockdown experiments if the RNA contained HuR binding sites in both the 3’UTR 
and the intron than either of the two alone (Lebedeva et al. 2011; Mukherjee et al. 2011).  
Still, the interaction of HuR and Ago in these intronic regions has not been previously 
explored.  We propose that the formerly described effects of HuR on pre-mRNA 
processing and mRNA stability involve interactions with Ago.  HuR and Ago may 
interact with target transcripts in the nucleus to direct splicing events, although it is 
currently unclear whether they function cooperatively or antagonistically in this process 
to control the mature message.  It is possible that the binding of HuR or Ago could not 
only direct the sites of splicing, but could also regulate the timing of splicing events by 
interfering with splicing machinery and other RNA-binding proteins.  Their binding 
could help mediate processing or sequester the RNA, similar to their roles in the 
cytoplasm.  Analysis of Ago target transcripts in the HuR cKO mice might help elucidate 
a clearer model of control.  
Furthermore, the role of immediate binding of HuR and Ago to nascent RNA may serve 
an even more important role in the regulation of immune function than in previously 
studied systems.  As previously described, the abundant initiation of transcription with 
the induction of an immune reaction needs to be carefully titrated to secure that cytotoxic 
and inflammatory signals are directed properly.  Binding of RNA by both HuR and Ago 
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in the nucleus may ensure that when being shuttled into the cytoplasm, that the messages 
are already being directed for the appropriate fate.  They could be directed by HuR 
directly to active polysomes, or filtered by Ago into cytoplasmic foci such as P-bodies 
and stress granules for quick interactions with other RNA-binding proteins, or simply 
degraded. 
It would be interesting to consider the binding positions of HuR and Ago on transcripts at 
further time points after T cell activation.  We propose that if HuR and Ago are deposited 
co-transcriptionally on pre-processed RNA, that after the message has been spliced and 
shuttled to the cytoplasm, that we may observe the resolution of these intronic sites in an 
increase in binding in the 3’UTRs more similar to what is seen in the steady state of the 
brain.  Still, the binding events in the intronic regions appear to be sequence specific and 
present in the resting state as well.  Thus, the regulation of the timing and sites of splicing 
by HuR and Ago may represent another level of post-transcriptional control, whereby 
target mRNAs could have different availabilities for maturation and processing in the 
nucleus due to their interrogation by Ago and HuR.  The quick shuttling of HuR out of 
the nucleus with T cell activation could therefore represent the transportation of targets to 
the cytoplasm or also the release of nuclear targets for the availability of processing.  
Ago and HuR and microRNA Regulation 
The regulation of RNA processing by Ago and HuR is not only restricted to mRNA.  We 
observed robust binding sites for both proteins in primary microRNA transcript loci.  In 
the example of the microRNA-17-92 locus, we see binding of Ago to microRNA stem 
loop regions that are greater in length than mature microRNA sequences.  This binding is 
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robust in both the resting and the activated states, indicating that microRNA processing is 
active in both groups of cells.  Ago has been shown to aid Dicer in microRNA processing, 
or in the case of miR-451, microRNA can be processed by Ago without Dicer 
involvement (Cheloufi et al. 2010; Cifuentes et al. 2010; Diederichs and Haber 2007).  
Our data reveals that in vivo, Ago associates with microRNA before they are mature 
species.  Interestingly, there is an increase in binding of Ago to regions between stem 
loops with stimulation induced transcript level induction, indicating that Ago may bind to 
microRNA transcripts in the nucleus with T cell activation.  This may indicate a new role 
for Ago in the processing of microRNA and may have been previously missed due to the 
predominant analyses of steady state biology.  
We also see an impressive increase in binding in the miR-17-92 region by HuR, 
mirroring the increase in transcript levels with lymphocyte activation.  Thus, HuR may 
play a role in regulating the dynamics of processing immediately following transcription 
of microRNA message.  Furthermore, the HuR binding pattern is distinct from Ago.   
Most notably, unlike Ago, the predominant binding sites appear to match sequences 
between the microRNA stem loops and not as frequently in sites that will eventually 
make up the mature microRNA 22-mers.  We therefore propose that HuR is involved in 
the processing of microRNAs in the nucleus and would expect to see differences in the 
levels of mature microRNA bound to Ago in the HuR cKO T cells. 
Interestingly, the levels of Ago binding in the mouse miR-17-92 cluster vary in some 
regions between the wild type and HuR cKO T cells.  Although some of these CLIP tags 
are 22-nucleotides in length and represent mature microRNA, we did not specifically 
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clone the microRNA population and so our analysis is limited mostly to mRNA binding 
sites.  While there are robust Ago binding events in both animals, even though there are 
less total unique reads in the HuR cKO dataset, there are quantitatively more binding 
sites specifically on what will be the mature miR-92a and miR-20a transcripts. The rest 
of the microRNAs have similar binding patterns in both mice (Figure 10.1).  
There is little Ago or HuR binding to or around miR-92a in the human dataset, so it is 
hard to infer a conclusion about this change in the mouse system.  However, miR-20a had 
a unique pattern of HuR binding in human T cells among this cluster of microRNA.  HuR 
displayed binding sites covering the stem loop region instead of being restricted to only 
up or downstream of the mature microRNA site.  Thus, it is very interesting that Ago 
binding would be increased preferentially for this microRNA in the HuR cKO cells.  This 
suggests that HuR binding to miR-20a impedes efficient binding of Ago and may explain 
why their binding patterns are almost exclusive of each other in other parts of this region 
in the human dataset.  We hypothesize that because HuR binding mostly excludes mature 
microRNA message, HuR plays a role in loading microRNAs into Ago and that binding 
of HuR to eventual mature sequences would inhibit Ago association in those sites.   
Intriguingly, most of the top 7-mers represented in Ago clusters that overlap HuR were 
microRNAs that were cloned in low frequencies in Ago CLIP.  And conversely, the seed 
matches from the most highly represented microRNA from Ago CLIP, miR-142-3p, was 
preferentially not found in these sites, but rather in sites where Ago binding did not 
overlap HuR.  This suggests that HuR binding together with Ago may enrich for target 
sites utilizing more rare microRNAs in T cells.  Furthermore, it supports our model that 
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Figure 10.1 Ago and HuR Binding in Human and Mouse: microRNA-17-92 Locus.  
(A) The position of individual Ago and HuR unique CLIP tags in biologic complexity 
two clusters plotted relative to their mapped position on the human microRNA-17-92 
locus.  From top to bottom: chromosomal location, Ago CLIP tags from activated CD8 T 
cells (colors represent each donor sample as shown in Table 6.1), Ago CLIP tags from 
resting CD8 T cells, HuR CLIP tags from activated CD8 T cells, HuR CLIP tags from 
resting CD8 T cells, Gene diagram from RefSeq.  (B) The position of individual Ago 
unique CLIP tags are plotted relative to their mapped position on the mouse microRNA-
17-92 locus, with microRNA-20a highlighted.  From top to bottom: chromosomal 
location, Ago CLIP tags from activated HuR wild-type CD8 T cells (colors represent 
each donor sample as shown in Table 8.1), Ago CLIP tags from activated HuR cKO CD8 
T cells, Gene diagram from RefSeq. 
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B
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HuR could be a chaperone for loading Ago with microRNAs or for Ago message 
targeting and it is possible that without this interaction, Ago would not show a binding 
preference for these rare microRNA seed sites.  This might not be necessary for highly 
abundant microRNAs such as miR-142-3p.  Additional analysis of Ago-microRNA 
association in the HuR cKO animals is needed to further explore this model. 
Conclusion 
The results presented in this thesis represent the identification and careful 
characterization of Ago and HuR RNA-binding in the activation of CD8 lymphocytes.  
Studying normal healthy donor CD8 T cells, we have characterized a system to 
investigate lymphocyte stimulation ex vivo to probe the regulation of this important 
immune function.  These studies also serve as a useful surrogate system for 
understanding larger issues of dynamic control of RNA regulation in other cellular stress 
conditions.  We demonstrated the reproducibility of our methods to robustly identify Ago 
and HuR RNA-binding events in human biologic samples representing two cellular states.  
Furthermore, we identified the transcriptional and translational status of each lymphocyte 
activation state using ribosomal profiling and RNA sequencing, providing a means to 
functionally interpret the Ago and HuR binding maps.  Moreover, by studying the 
binding maps for Ago in mouse CD8 T cells with or without HuR, we establish a system 
for investigating the dependence of Ago on HuR for its target specificities in the mouse, 
and for focusing on regions in which Ago and HuR binding is likely to be interdependent 
following the stimulation of human T cells. 
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